false
--12-31
Q3
0001591165
0001591165
2023-01-01
2023-09-30
0001591165
2023-11-10
0001591165
2023-09-30
0001591165
2022-12-31
0001591165
us-gaap:RelatedPartyMember
2023-09-30
0001591165
us-gaap:RelatedPartyMember
2022-12-31
0001591165
us-gaap:NonrelatedPartyMember
2023-09-30
0001591165
us-gaap:NonrelatedPartyMember
2022-12-31
0001591165
us-gaap:SeriesAPreferredStockMember
2023-09-30
0001591165
us-gaap:SeriesAPreferredStockMember
2022-12-31
0001591165
2023-07-01
2023-09-30
0001591165
2022-07-01
2022-09-30
0001591165
2022-01-01
2022-09-30
0001591165
us-gaap:SeriesAPreferredStockMember
us-gaap:PreferredStockMember
2022-06-30
0001591165
us-gaap:CommonStockMember
2022-06-30
0001591165
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001591165
us-gaap:RetainedEarningsMember
2022-06-30
0001591165
2022-06-30
0001591165
us-gaap:SeriesAPreferredStockMember
us-gaap:PreferredStockMember
2023-06-30
0001591165
us-gaap:CommonStockMember
2023-06-30
0001591165
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001591165
us-gaap:RetainedEarningsMember
2023-06-30
0001591165
2023-06-30
0001591165
us-gaap:SeriesAPreferredStockMember
us-gaap:PreferredStockMember
2021-12-31
0001591165
us-gaap:CommonStockMember
2021-12-31
0001591165
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001591165
us-gaap:RetainedEarningsMember
2021-12-31
0001591165
2021-12-31
0001591165
us-gaap:SeriesAPreferredStockMember
us-gaap:PreferredStockMember
2022-12-31
0001591165
us-gaap:CommonStockMember
2022-12-31
0001591165
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001591165
us-gaap:RetainedEarningsMember
2022-12-31
0001591165
us-gaap:SeriesAPreferredStockMember
us-gaap:PreferredStockMember
2022-07-01
2022-09-30
0001591165
us-gaap:CommonStockMember
2022-07-01
2022-09-30
0001591165
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2022-09-30
0001591165
us-gaap:RetainedEarningsMember
2022-07-01
2022-09-30
0001591165
us-gaap:SeriesAPreferredStockMember
us-gaap:PreferredStockMember
2023-07-01
2023-09-30
0001591165
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001591165
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001591165
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001591165
us-gaap:SeriesAPreferredStockMember
us-gaap:PreferredStockMember
2022-01-01
2022-09-30
0001591165
us-gaap:CommonStockMember
2022-01-01
2022-09-30
0001591165
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-09-30
0001591165
us-gaap:RetainedEarningsMember
2022-01-01
2022-09-30
0001591165
us-gaap:SeriesAPreferredStockMember
us-gaap:PreferredStockMember
2023-01-01
2023-09-30
0001591165
us-gaap:CommonStockMember
2023-01-01
2023-09-30
0001591165
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-09-30
0001591165
us-gaap:RetainedEarningsMember
2023-01-01
2023-09-30
0001591165
us-gaap:SeriesAPreferredStockMember
us-gaap:PreferredStockMember
2022-09-30
0001591165
us-gaap:CommonStockMember
2022-09-30
0001591165
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0001591165
us-gaap:RetainedEarningsMember
2022-09-30
0001591165
2022-09-30
0001591165
us-gaap:SeriesAPreferredStockMember
us-gaap:PreferredStockMember
2023-09-30
0001591165
us-gaap:CommonStockMember
2023-09-30
0001591165
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001591165
us-gaap:RetainedEarningsMember
2023-09-30
0001591165
2022-06-10
0001591165
us-gaap:SeriesAPreferredStockMember
2022-09-10
0001591165
2022-06-05
2022-06-10
0001591165
IVRN:LimitedLiabilityCompanyAgreementMember
2023-09-21
2023-09-21
0001591165
IVRN:RedemptionAgreementMember
2023-09-21
2023-09-21
0001591165
IVRN:RedemptionAgreementMember
2023-01-01
2023-09-30
0001591165
2023-11-09
0001591165
IVRN:SecuritiesPurchaseAgreementMember
2023-02-24
0001591165
IVRN:SecuritiesPurchaseAgreementMember
2023-02-23
2023-02-24
0001591165
IVRN:SecuritiesPurchaseAgreementMember
2023-02-24
2023-02-24
0001591165
IVRN:SecuritiesPurchaseAgreementMember
2023-02-26
2023-02-28
0001591165
IVRN:SecuritiesPurchaseAgreementMember
2023-03-27
0001591165
IVRN:SecuritiesPurchaseAgreementMember
2023-04-12
0001591165
IVRN:SecuritiesPurchaseAgreementMember
2023-03-26
2023-03-27
0001591165
2023-03-27
2023-03-27
0001591165
us-gaap:FairValueInputsLevel1Member
2023-09-30
0001591165
us-gaap:FairValueInputsLevel2Member
2023-09-30
0001591165
us-gaap:FairValueInputsLevel3Member
2023-09-30
0001591165
us-gaap:FairValueInputsLevel3Member
2022-12-31
0001591165
us-gaap:FairValueInputsLevel3Member
2023-01-01
2023-09-30
0001591165
IVRN:RaymondMonteleoneMember
2021-01-10
2021-01-12
0001591165
IVRN:RaymondMonteleoneMember
2021-12-30
2022-07-02
0001591165
IVRN:RaymondMonteleoneMember
2023-07-01
2023-09-30
0001591165
IVRN:RaymondMonteleoneMember
2023-01-01
2023-09-30
0001591165
IVRN:RaymondMonteleoneMember
2022-07-01
2022-09-30
0001591165
IVRN:RaymondMonteleoneMember
2022-01-01
2022-09-30
0001591165
IVRN:RaymondMonteleoneMember
2023-09-30
0001591165
IVRN:WilliamHorneMember
IVRN:OralAgreementMember
2021-01-10
2021-01-12
0001591165
IVRN:WilliamHorneMember
IVRN:OralAgreementMember
2021-06-29
2022-07-02
0001591165
IVRN:OralAgreementMember
IVRN:WilliamHorneMember
2023-07-01
2023-09-30
0001591165
IVRN:OralAgreementMember
IVRN:WilliamHorneMember
2023-01-01
2023-09-30
0001591165
IVRN:OralAgreementMember
IVRN:WilliamHorneMember
2022-07-01
2022-09-30
0001591165
IVRN:OralAgreementMember
IVRN:WilliamHorneMember
2022-01-01
2022-09-30
0001591165
IVRN:OralAgreementMember
IVRN:WilliamHorneMember
2023-09-30
0001591165
IVRN:RichardRosenblumMember
IVRN:OralAgreementMember
2022-01-15
2022-01-17
0001591165
IVRN:RichardRosenblumMember
IVRN:OralAgreementMember
2021-06-29
2022-07-02
0001591165
IVRN:OralAgreementMember
IVRN:RichardRosenblumMember
2023-07-01
2023-09-30
0001591165
IVRN:OralAgreementMember
IVRN:RichardRosenblumMember
2023-01-01
2023-09-30
0001591165
IVRN:OralAgreementMember
IVRN:RichardRosenblumMember
2022-07-01
2022-09-30
0001591165
IVRN:OralAgreementMember
IVRN:RichardRosenblumMember
2022-01-01
2022-09-30
0001591165
IVRN:OralAgreementMember
IVRN:RichardRosenblumMember
2023-09-30
0001591165
IVRN:MatthewAndererMember
IVRN:OralAgreementMember
2022-01-15
2022-01-17
0001591165
IVRN:MatthewAndererMember
IVRN:OralAgreementMember
2021-06-29
2022-07-02
0001591165
IVRN:OralAgreementMember
IVRN:MatthewAndererMember
2023-07-01
2023-09-30
0001591165
IVRN:OralAgreementMember
IVRN:MatthewAndererMember
2023-01-01
2023-09-30
0001591165
IVRN:OralAgreementMember
IVRN:MatthewAndererMember
2022-07-01
2022-09-30
0001591165
IVRN:OralAgreementMember
IVRN:MatthewAndererMember
2022-01-01
2022-09-30
0001591165
IVRN:OralAgreementMember
IVRN:MatthewAndererMember
2023-09-30
0001591165
IVRN:SecuredConvertibleNoteAgreementMember
us-gaap:InvestorMember
2021-04-02
0001591165
IVRN:SecuredConvertibleNoteAgreementMember
us-gaap:InvestorMember
2021-03-30
2021-04-02
0001591165
IVRN:SecuredConvertibleNoteAgreementMember
us-gaap:CommonStockMember
2021-04-02
0001591165
IVRN:SecuredConvertibleNoteAgreementMember
IVRN:FWHCBridgeLLCMember
2021-03-30
2021-04-02
0001591165
IVRN:SecuredConvertibleNoteAgreementMember
IVRN:FWHCBridgeLLCMember
us-gaap:InvestorMember
2021-03-30
2021-04-02
0001591165
IVRN:SecondClosingBringDownAgreementMember
2021-10-14
0001591165
IVRN:SecondClosingBringDownAgreementMember
2021-10-13
2021-10-14
0001591165
IVRN:SecondClosingBringDownAgreementMember
IVRN:FWHCBridgeLLCMember
us-gaap:InvestorMember
2021-10-13
2021-10-14
0001591165
IVRN:DebtConversionAgreementMember
2022-02-22
0001591165
IVRN:DebtConversionAgreementMember
us-gaap:ShareBasedCompensationAwardTrancheOneMember
2022-02-21
2022-02-22
0001591165
IVRN:DebtConversionAgreementMember
2022-02-21
2022-02-22
0001591165
IVRN:DebtConversionAgreementMember
srt:MinimumMember
2022-02-21
2022-02-22
0001591165
IVRN:DebtConversionAgreementMember
srt:MaximumMember
2022-02-21
2022-02-22
0001591165
IVRN:NoteConversionAgreementMember
IVRN:NewNotesMember
2022-04-28
2022-04-29
0001591165
IVRN:NoteConversionAgreementMember
IVRN:NewNotesMember
2022-04-29
0001591165
IVRN:NoteConversionAgreementMember
2022-04-29
0001591165
2022-01-01
2022-12-31
0001591165
IVRN:NoteConversionAgreementMember
2022-04-28
2022-04-29
0001591165
IVRN:NoteConversionAgreementMember
2022-01-01
2022-12-31
0001591165
IVRN:SecuritiesPurchaseAgreementMember
us-gaap:InvestorMember
2023-01-01
2023-09-30
0001591165
IVRN:SecuritiesPurchaseAgreementMember
us-gaap:InvestorMember
2023-09-30
0001591165
us-gaap:InvestorMember
IVRN:SecuritiesPurchaseAgreementMember
2023-03-27
0001591165
us-gaap:InvestorMember
IVRN:SecuritiesPurchaseAgreementMember
2023-04-12
0001591165
us-gaap:InvestorMember
IVRN:SecuritiesPurchaseAgreementMember
2023-04-11
2023-04-12
0001591165
2023-03-26
2023-03-27
0001591165
IVRN:SecuritiesPurchaseAgreementMember
us-gaap:InvestorMember
2023-03-26
2023-03-27
0001591165
srt:ChiefExecutiveOfficerMember
2022-01-01
2022-12-31
0001591165
srt:ChiefExecutiveOfficerMember
2023-01-01
2023-09-30
0001591165
IVRN:WarrantHoldersMember
2022-03-31
0001591165
IVRN:WarrantHoldersMember
2022-12-31
0001591165
IVRN:WarrantHoldersMember
2022-01-01
2022-12-31
0001591165
us-gaap:CommonStockMember
IVRN:PurchaseAgreementMember
2022-09-27
2022-09-29
0001591165
us-gaap:WarrantMember
IVRN:PurchaseAgreementMember
2022-09-29
0001591165
IVRN:PurchaseAgreementMember
2022-09-29
0001591165
IVRN:PurchaseAgreementMember
2022-09-27
2022-09-29
0001591165
us-gaap:CommonStockMember
IVRN:PurchaseAgreementMember
2022-11-12
2022-11-14
0001591165
us-gaap:WarrantMember
IVRN:PurchaseAgreementMember
2022-11-14
0001591165
IVRN:PurchaseAgreementMember
2022-11-14
0001591165
IVRN:PurchaseAgreementMember
2022-11-12
2022-11-14
0001591165
us-gaap:CommonStockMember
2023-03-16
2023-03-17
0001591165
us-gaap:CommonStockMember
2023-05-22
2023-05-23
0001591165
us-gaap:CommonStockMember
2023-06-08
2023-06-08
0001591165
us-gaap:CommonStockMember
2023-07-09
2023-07-10
0001591165
us-gaap:CommonStockMember
2023-07-19
2023-07-20
0001591165
us-gaap:SeriesAPreferredStockMember
2023-01-01
2023-09-30
0001591165
IVRN:DirectorsAndOfficersMember
2021-03-30
2021-04-02
0001591165
IVRN:WarrantsMember
2023-01-01
2023-09-30
0001591165
IVRN:StockOptionsMember
2023-01-01
2023-09-30
0001591165
IVRN:WarrantsMember
2022-01-01
2022-09-30
0001591165
IVRN:StockOptionsMember
2022-01-01
2022-09-30
0001591165
us-gaap:SeriesAPreferredStockMember
IVRN:ReverseStockSplitMember
2023-09-30
0001591165
IVRN:ReverseStockSplitMember
2023-01-01
2023-09-30
0001591165
IVRN:OneForOneThousandReverseStockSplitMember
2023-09-30
0001591165
IVRN:OneForOneThousandReverseStockSplitMember
2022-12-31
0001591165
us-gaap:SeriesAPreferredStockMember
IVRN:OneForOneThousandReverseStockSplitMember
2023-09-30
0001591165
us-gaap:SeriesAPreferredStockMember
IVRN:OneForOneThousandReverseStockSplitMember
2022-12-31
0001591165
srt:MinimumMember
IVRN:TwoThousandTwentyOneGrantsMember
2023-09-30
0001591165
srt:MaximumMember
IVRN:TwoThousandTwentyOneGrantsMember
2023-09-30
0001591165
srt:MinimumMember
IVRN:TwoThousandTwentyOneGrantsMember
2023-01-01
2023-09-30
0001591165
srt:MaximumMember
IVRN:TwoThousandTwentyOneGrantsMember
2023-01-01
2023-09-30
0001591165
IVRN:WarrantsToPurchaseCommonStockMember
2023-01-01
2023-09-30
0001591165
IVRN:WarrantsToPurchaseCommonStockMember
2022-01-01
2022-09-30
0001591165
IVRN:SeriesAPreferredStockConvertibleToCommonStockMember
2023-01-01
2023-09-30
0001591165
IVRN:SeriesAPreferredStockConvertibleToCommonStockMember
2022-01-01
2022-09-30
0001591165
IVRN:EmploymentAgreementMember
srt:ChiefExecutiveOfficerMember
IVRN:YurkowskyMember
2021-12-22
2021-12-23
0001591165
2021-12-22
2021-12-23
0001591165
IVRN:EquityAwardMember
srt:ChiefExecutiveOfficerMember
srt:MinimumMember
2021-12-22
2021-12-23
0001591165
IVRN:EquityAwardMember
srt:ChiefExecutiveOfficerMember
srt:MaximumMember
2021-12-22
2021-12-23
0001591165
IVRN:EquityAwardMember
2021-12-22
2021-12-23
0001591165
IVRN:ConsultingAgreementMember
IVRN:TanyaRhodesOfRhodesAndAssociatesIncMember
2020-06-10
2020-06-15
0001591165
IVRN:ConsultingAgreementMember
IVRN:TanyaRhodesOfRhodesAndAssociatesIncMember
2020-06-15
0001591165
2021-01-01
2021-01-02
0001591165
IVRN:ConsultingAgreementMember
IVRN:TanyaRhodesOfRhodesAndAssociatesIncMember
2023-09-30
0001591165
IVRN:SinclairBroadcastGroupIncMember
2023-01-01
2023-09-30
0001591165
IVRN:ITNNetworkLLCMember
2023-01-01
2023-09-30
0001591165
IVRN:NotesPayableMember
2023-01-01
2023-09-30
0001591165
IVRN:NotesPayableMember
2023-09-30
0001591165
IVRN:NotesPayableMember
IVRN:MergerMember
2023-01-01
2023-09-30
0001591165
IVRN:PromissoryNoteMember
2023-09-30
0001591165
IVRN:PromissoryNoteMember
2022-12-31
0001591165
IVRN:NotesPayableMember
srt:MaximumMember
2023-09-30
0001591165
IVRN:NotesPayableMember
srt:MinimumMember
2023-09-30
0001591165
IVRN:TwoAccreditedInvestorsMember
IVRN:SecuritiesPurchaseAgreementMember
2022-06-09
0001591165
IVRN:AccreditedInvestorsMember
IVRN:SecuritiesPurchaseAgreementMember
2022-06-07
2022-06-09
0001591165
IVRN:AccreditedInvestorsMember
IVRN:SecuritiesPurchaseAgreementMember
2022-06-09
0001591165
IVRN:AccreditedInvestorsMember
IVRN:SecuritiesPurchaseAgreementMember
2022-06-08
2022-06-09
0001591165
IVRN:AccreditedInvestorMember
IVRN:SecuritiesPurchaseAgreementMember
2022-08-08
0001591165
IVRN:AccreditedInvestorMember
IVRN:SecuritiesPurchaseAgreementMember
2022-08-07
2022-08-08
0001591165
IVRN:AccreditedInvestorMember
IVRN:SecuritiesPurchaseAgreementMember
2023-02-28
0001591165
IVRN:AccreditedInvestorMember
IVRN:SecuritiesPurchaseAgreementMember
2023-02-02
0001591165
IVRN:AccreditedInvestorMember
IVRN:SecuritiesPurchaseAgreementMember
2023-02-27
2023-02-28
0001591165
IVRN:JantibodyLLCMember
2022-09-07
0001591165
IVRN:JantibodyAgreementMember
us-gaap:CommonStockMember
2022-09-07
2022-09-07
0001591165
2022-09-07
0001591165
2022-09-07
2022-09-07
0001591165
us-gaap:CommonStockMember
2022-09-07
2022-09-07
0001591165
IVRN:AntiDilutionSharesMember
2022-01-01
2022-12-31
0001591165
IVRN:ScionAgreementMember
2022-12-22
0001591165
IVRN:ScionSolutionsLLCMember
2023-09-30
0001591165
IVRN:ScionAgreementMember
2022-12-22
2022-12-22
0001591165
IVRN:JantibodyLLCMember
2023-01-01
2023-09-30
0001591165
IVRN:ScionAgreementMember
2023-01-01
2023-09-30
0001591165
us-gaap:IntellectualPropertyMember
2022-09-07
0001591165
IVRN:ScionAgreementMember
IVRN:QualifiedFundingOrUpliftingMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
IVRN:AnniversaryOfUpliftingYearOneMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
IVRN:AnniversaryOfUpliftingYearTwoMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
IVRN:InitiationOfSkinDiscStudyMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
IVRN:ReceiptOfApprovalClearanceThatAllowSkinDiscToGoToMarketMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
IVRN:SubmissionForSpecificAndIndividualReimbursementCodesRelatingToSkindiscMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
IVRN:ReceiptOfSpecificAndIndividualReimbursementCodesRelatingToSkindiscMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
IVRN:CompletionOfSkindiscStudyMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
IVRN:LaunchOfAnyAdditionalSkindiscProductLineExtensionMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
us-gaap:SalesMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
IVRN:SalesFromSkinDiscOneMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
IVRN:SalesFromSkinDiscTwoMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
IVRN:SalesFromSkinDiscThreeMember
2022-12-22
2022-12-22
0001591165
IVRN:ScionAgreementMember
IVRN:SalesFromSkinDiscFourMember
2022-12-22
2022-12-22
0001591165
us-gaap:IntellectualPropertyMember
2022-12-22
0001591165
IVRN:GrantedForInducementAgreementMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementOneMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementOneMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementOneMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementOneMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementTwoMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementTwoMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementTwoMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementTwoMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementThreeMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementThreeMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementThreeMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementThreeMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementFourMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementFourMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementFourMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementFourMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementFiveMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementFiveMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementFiveMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementFiveMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementSixMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementSixMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementSixMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementSixMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementSevenMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementSevenMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementSevenMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementSevenMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForServicesProvidedMember
2023-09-30
0001591165
IVRN:GrantedForServicesProvidedMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForServicesProvidedMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForServicesProvidedMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementEightMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementEightMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementEightMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementEightMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementNineMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementNineMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementNineMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementNineMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementTenMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementTenMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementTenMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForInducementAgreementTenMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForSecuritiesPurchaseAgreementMember
2023-09-30
0001591165
IVRN:GrantedForSecuritiesPurchaseAgreementMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForSecuritiesPurchaseAgreementMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForSecuritiesPurchaseAgreementMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForSecuritiesPurchaseAgreementOneMember
2023-09-30
0001591165
IVRN:GrantedForSecuritiesPurchaseAgreementOneMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForSecuritiesPurchaseAgreementOneMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForSecuritiesPurchaseAgreementOneMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementMember
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementOneMember
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementOneMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementOneMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementOneMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementTwoMember
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementTwoMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementTwoMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementTwoMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementThreeMember
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementThreeMember
2023-01-01
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementThreeMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001591165
IVRN:GrantedForConvertibleNoteAgreementThreeMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
(Mark
One)
☒ |
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended September 30, 2023
or
☐ |
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the transition period from ___________ to ____________
Commission
file number: 001-36763
INNOVEREN
SCIENTIFIC, INC
(Exact
name of registrant as specified in its charter)
Nevada |
|
46-3312262 |
(State
or other jurisdiction of |
|
(IRS
Employer |
incorporation
or organization) |
|
Identification
No.) |
2202
N. West Shore Blvd. Ste 200 |
|
|
Tampa,
Florida |
|
33607 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(844)
633-6839
(Registrant’s
Telephone Number, Including Area Code)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Ticker
symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
IVRN |
|
OTC
Capital Markets |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
☒
Yes ☐ No
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files.)
☒
Yes ☐ No
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”
and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer ☐ |
Accelerated
filer ☐ |
Non-accelerated
filer ☒ |
Smaller
Reporting Company ☒ |
|
Emerging
Growth Company ☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
☐
Yes ☒ No
As
of November 10, 2023, 712,710 shares of the registrant’s common stock were outstanding.
INNOVEREN
SCIENTIFIC, INC AND SUBSIDIARIES
TABLE
OF CONTENTS
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
Quarterly Report on Form 10-Q contains “forward-looking statements” as defined under United States federal securities laws.
These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results,
performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by
the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:
|
● |
the
Company’s ability to market, commercialize, and achieve broader market acceptance for its products; |
|
|
|
|
● |
the
Company’s ability to successfully expand and achieve full productivity from its sales, clinical support, and marketing capabilities; |
|
|
|
|
● |
the
Company’s ability to successfully complete the development of, and obtain regulatory clearance or approval for its products;
and |
|
|
|
|
● |
the
estimates regarding the sufficiency of the Company’s cash resources, the ability to obtain additional capital, or the ability
to maintain or grow sources of revenue. |
In
some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,”
“estimates,” “expects,” “intends,” “may,” “plans,” “potential,”
“predicts,” “projects,” “should,” “will,” “would,” and similar expressions
intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although the Company
believes that it has a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that these
statements are based on a combination of facts and factors currently known by the Company and its projections of the future, about which
it cannot be certain. As a result of these factors, the Company cannot assure you that the forward-looking statements in this Quarterly
Report will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation
or warranty by the Company, or any other person, that it will achieve its objectives and plans in any specified time frame, or at all.
The Company does not undertake to update any of the forward-looking statements after the date of this Quarterly Report, except to the
extent required by applicable securities laws.
Item
1. Financial Statements
INNOVEREN
SCIENTIFIC, INC AND SUBSIDIARIES
CONSOLIDATED
BALANCE SHEETS
| |
| | |
| |
| |
(Unaudited) | | |
| |
| |
September 30, 2023 | | |
December 31, 2022 | |
Assets | |
| | | |
| | |
| |
| | | |
| | |
Current Assets | |
| | | |
| | |
Cash | |
$ | 543,882 | | |
$ | - | |
Patient financing receivable, current portion | |
| 9,933 | | |
| 29,464 | |
Other receivable | |
| 55,751 | | |
| - | |
Prepaid expenses | |
| 139,920 | | |
| 54,381 | |
Total Current Assets | |
| 749,486 | | |
| 83,845 | |
| |
| | | |
| | |
Property and equipment, net | |
| 15,525 | | |
| 20,394 | |
Patient financing receivable, net of current portion | |
| 5,893 | | |
| 14,436 | |
Other assets | |
| 18,412 | | |
| 18,682 | |
Total assets | |
$ | 789,316 | | |
$ | 137,357 | |
| |
| | | |
| | |
Liabilities and Stockholders’ Deficit | |
| | | |
| | |
| |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Accounts payable | |
$ | 1,259,050 | | |
$ | 971,492 | |
Accrued liabilities | |
| 1,507,859 | | |
| 1,418,368 | |
Other current liabilities | |
| 229,166 | | |
| 139,330 | |
Notes payable, current portion | |
| 110,471 | | |
| 104,468 | |
Convertible notes payable, related parties | |
| 3,325,000 | | |
| 3,325,000 | |
Convertible notes payable | |
| 406,395 | | |
| 430,095 | |
Convertible notes payable carried at fair value, related parties | |
| 426,255 | | |
| - | |
Convertible notes payable carried at fair value | |
| 157,483 | | |
| - | |
Lease liability, current portion | |
| 12,772 | | |
| 63,291 | |
Anti-dilution share contingent consideration liability | |
| 501,531 | | |
| 501,531 | |
Deferred gain on redemption of equity method investment | |
| 869,249 | | |
| - | |
Deferred gain on sale of IP | |
| 55,751 | | |
| - | |
Interest payable, related parties | |
| 563,990 | | |
| 400,042 | |
Interest payable | |
| 236,064 | | |
| 123,276 | |
Total Current Liabilities | |
| 9,661,036 | | |
| 7,476,893 | |
| |
| | | |
| | |
Long-term Liabilities | |
| | | |
| | |
Royalty liability | |
| 1,697,000 | | |
| 1,697,000 | |
Milestone payment contingent consideration liability | |
| 320,850 | | |
| 320,850 | |
Total Long-term Liabilities | |
| 2,017,850 | | |
| 2,017,850 | |
| |
| | | |
| | |
Total Liabilities | |
| 11,678,886 | | |
| 9,494,743 | |
| |
| | | |
| | |
Stockholders’ Equity (Deficit) | |
| | | |
| | |
Preferred Stock - $.001 par value: 1,000,000,000 shares authorized;
Series A Preferred Stock - $.001 par value: 800,000,000 shares authorized, 438,776,170 shares issued and outstanding at
September 30, 2023 and December 31, 2022, respectively. | |
| 438,773 | | |
| 438,773 | |
Common stock - $.001 par value: 500,000,000 shares authorized, 712,170 and 618,506 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively. | |
| 714 | | |
| 618 | |
Additional paid-in capital | |
| 49,764,451 | | |
| 49,531,216 | |
Accumulated deficit | |
| (61,093,508 | ) | |
| (59,327,993 | ) |
Total Stockholders’ Deficit | |
| (10,889,570 | ) | |
| (9,357,386 | ) |
| |
| | | |
| | |
Total Liabilities and Stockholders’ Deficit | |
$ | 789,316 | | |
$ | 137,357 | |
See
accompanying notes to the consolidated financial statements
INNOVEREN
SCIENTIFIC, INC AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF OPERATIONS
(Unaudited)
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three months ended
September 30, | | |
Nine months ended
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenues | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | 453,460 | |
Cost of Sales | |
| - | | |
| - | | |
| - | | |
| (116,602 | ) |
Gross Profit | |
| - | | |
| - | | |
| - | | |
| 336,858 | |
| |
| | | |
| | | |
| | | |
| | |
Operating Expenses | |
| | | |
| | | |
| | | |
| | |
Salaries and related costs | |
| 105,534 | | |
| 221,304 | | |
| 432,510 | | |
| 848,036 | |
Share based compensation | |
| 26,232 | | |
| 120,448 | | |
| 100,759 | | |
| 535,481 | |
Loss on disposal of property and equipment | |
| - | | |
| - | | |
| - | | |
| 9,610 | |
Acquired in process research and development | |
| - | | |
| 1,245,948 | | |
| - | | |
| 1,245,948 | |
Other general and administrative | |
| 289,504 | | |
| 268,076 | | |
| 717,518 | | |
| 1,172,738 | |
Total Operating Expenses | |
| 421,270 | | |
| 1,855,776 | | |
| 1,250,787 | | |
| 3,811,813 | |
| |
| | | |
| | | |
| | | |
| | |
Operating Loss | |
| (421,270 | ) | |
| (1,855,776 | ) | |
| (1,250,787 | ) | |
| (3,474,955 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other Income (Expense) | |
| | | |
| | | |
| | | |
| | |
Warrant expense | |
| - | | |
| (334,238 | ) | |
| - | | |
| (334,238 | ) |
Inducement expense | |
| - | | |
| - | | |
| - | | |
| (3,024,872 | ) |
Day one loss on convertible notes carried at fair value | |
| - | | |
| - | | |
| (1,527,239 | ) | |
| - | |
Gain on convertible notes carried at fair value | |
| 14,792 | | |
| - | | |
| 1,329,629 | | |
| - | |
Loss on extinguishment of convertible notes payable | |
| - | | |
| - | | |
| - | | |
| (2,196,100 | ) |
Interest income | |
| 446 | | |
| 1,756 | | |
| 1,941 | | |
| 506,795 | |
Interest expense | |
| (99,587 | ) | |
| (91,186 | ) | |
| (348,447 | ) | |
| (278,665 | ) |
Other income (expense) | |
| 9,844 | | |
| - | | |
| 29,388 | | |
| (4,457 | ) |
Total Other Income (Expense) | |
| (74,505 | ) | |
| (423,668 | ) | |
| (514,728 | ) | |
| (5,331,537 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net (Loss) | |
$ | (495,775 | ) | |
$ | (2,279,444 | ) | |
$ | (1,765,515 | ) | |
$ | (8,806,492 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net (Loss) attributable to common stockholders | |
$ | (495,775 | ) | |
$ | (2,279,444 | ) | |
$ | (1,765,515 | ) | |
$ | (8,806,492 | ) |
| |
| | | |
| | | |
| | | |
| | |
(Loss) per share – basic and diluted | |
$ | (0.73 | ) | |
$ | (8.04 | ) | |
$ | (2.69 | ) | |
$ | (34.07 | ) |
Weighted average outstanding shares - basic | |
| 682,209 | | |
| 283,579 | | |
| 655,783 | | |
| 258,483 | |
See
accompanying notes to the consolidated financial statements
INNOVEREN
SCIENTIFIC AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF STOCKHOLDERS’ DEFICIT
For
the three months and nine months ended September 30, 2023 and 2022
(Unaudited)
| |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Three months ended | |
Preferred Series
A Stock | | |
Common Stock | | |
Additional
Paid-in | | |
Accumulated | | |
Stockholders’ | |
September 30, 2022 and 2023 | |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
Balances - June 30, 2022 | |
| 494,579,119 | | |
$ | 494,578 | | |
| 257,282 | | |
$ | 257 | | |
$ | 48,481,350 | | |
$ | (55,555,461 | ) | |
$ | (6,579,276 | ) |
Conversion of Series A Preferred Stock to Common Stock | |
| (55,802,949 | ) | |
| (55,805 | ) | |
| 55,805 | | |
| 55 | | |
| 55,750 | | |
| - | | |
| - | |
Issuance of Common Stock pursuant to securities purchase agreement | |
| - | | |
| - | | |
| 112,500 | | |
| 113 | | |
| 224,888 | | |
| - | | |
| 225,001 | |
Issuance of Common Stock pursuant to Jantibody acquisistion | |
| - | | |
| - | | |
| 52,023 | | |
| 52 | | |
| 29,505 | | |
| - | | |
| 29,557 | |
Warrant expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 334,238 | | |
| - | | |
| 334,238 | |
Share based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| 120,448 | | |
| - | | |
| 120,448 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (2,279,444 | ) | |
| (2,279,444 | ) |
Balances - September 30, 2022 | |
| 438,776,170 | | |
$ | 438,773 | | |
| 477,610 | | |
$ | 477 | | |
$ | 49,246,179 | | |
$ | (57,834,905 | ) | |
$ | (8,149,476 | ) |
| |
Preferred Series
A Stock | | |
Common Stock | | |
Additional
Paid-in | | |
Accumulated | | |
Stockholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
Balances - June 30, 2023 | |
| 438,776,170 | | |
$ | 438,773 | | |
| 661,345 | | |
$ | 662 | | |
$ | 49,723,571 | | |
$ | (60,597,733 | ) | |
$ | (10,434,727 | ) |
Conversion of convertible notes payable to Common Stock | |
| - | | |
| - | | |
| 51,365 | | |
| 52 | | |
| 14,648 | | |
| - | | |
| 14,700 | |
Share based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| 26,232 | | |
| - | | |
| 26,232 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (495,775 | ) | |
| (495,775 | ) |
Balances - September 30, 2023 | |
| 438,776,170 | | |
$ | 438,773 | | |
| 712,710 | | |
$ | 714 | | |
$ | 49,764,451 | | |
$ | (61,093,508 | ) | |
$ | (10,889,570 | ) |
Nine months ended | |
Preferred Series
A Stock | | |
Common Stock | | |
Additional
Paid-in | | |
Accumulated | | |
Stockholders’ | |
September 30, 2022 and 2023 | |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
Balances - December 31, 2021 | |
| 501,887,534 | | |
$ | 501,887 | | |
| 166,394 | | |
$ | 164,199 | | |
$ | 43,700,084 | | |
$ | (49,028,413 | ) | |
$ | (4,662,243 | ) |
Conversion of Series A Preferred Stock to Common Stock | |
| (63,111,364 | ) | |
| (63,114 | ) | |
| 63,114 | | |
| 7,364 | | |
| 55,750 | | |
| - | | |
| - | |
Adjustment for 1-for-1,000 reverse
stock split | |
| - | | |
| - | | |
| - | | |
| (254,831 | ) | |
| 254,831 | | |
| - | | |
| - | |
Issuance of Common Stock pursuant to securities purchase agreement | |
| - | | |
| - | | |
| 112,500 | | |
| 113 | | |
| 224,888 | | |
| - | | |
| 225,001 | |
Issuance of Common Stock pursuant to Jantibody acquisistion | |
| - | | |
| - | | |
| 52,023 | | |
| 52 | | |
| 29,505 | | |
| - | | |
| 29,557 | |
Inducement expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 3,024,872 | | |
| - | | |
| 3,024,872 | |
Warrant expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 334,238 | | |
| - | | |
| 334,238 | |
Conversion of warrants to Common Stock | |
| - | | |
| - | | |
| 83,579 | | |
| 83,580 | | |
| 1,086,530 | | |
| - | | |
| 1,170,110 | |
Share based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| 535,481 | | |
| - | | |
| 535,481 | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (8,806,492 | ) | |
| (8,806,492 | ) |
Balances - September 30, 2022 | |
| 438,776,170 | | |
$ | 438,773 | | |
| 477,610 | | |
$ | 477 | | |
$ | 49,246,179 | | |
$ | (57,834,905 | ) | |
$ | (8,149,476 | ) |
| |
Preferred Series
A Stock | | |
Common Stock | | |
Additional
Paid-in | | |
Accumulated | | |
Stockholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
Balances - December 31, 2022 | |
| 438,776,170 | | |
$ | 438,773 | | |
| 618,506 | | |
$ | 618 | | |
$ | 49,531,216 | | |
$ | (59,327,993 | ) | |
$ | (9,357,386 | ) |
Balance | |
| 438,776,170 | | |
$ | 438,773 | | |
| 618,506 | | |
$ | 618 | | |
$ | 49,531,216 | | |
$ | (59,327,993 | ) | |
$ | (9,357,386 | ) |
Issuance of warrants pursuant to convertible notes payable | |
| - | | |
| - | | |
| - | | |
| - | | |
| 73,872 | | |
| - | | |
| 73,872 | |
Conversion of convertible notes payable to Common Stock | |
| - | | |
| - | | |
| 94,204 | | |
| 96 | | |
| 58,604 | | |
| - | | |
| 58,700 | |
Share based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| 100,759 | | |
| - | | |
| 100,759 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (1,765,515 | ) | |
| (1,765,515 | ) |
Balances - September 30, 2023 | |
| 438,776,170 | | |
$ | 438,773 | | |
| 712,710 | | |
$ | 714 | | |
$ | 49,764,451 | | |
$ | (61,093,508 | ) | |
$ | (10,889,570 | ) |
Balance | |
| 438,776,170 | | |
$ | 438,773 | | |
| 712,710 | | |
$ | 714 | | |
$ | 49,764,451 | | |
$ | (61,093,508 | ) | |
$ | (10,889,570 | ) |
See
accompanying notes to the consolidated financial statements
INNOVEREN
SCIENTIFIC, INC AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(Unaudited)
| |
2023 | | |
2022 | |
| |
For the nine months ended September 30, | |
| |
2023 | | |
2022 | |
Cash Flows from Operating Activities | |
| | | |
| | |
Net loss | |
$ | (1,765,515 | ) | |
$ | (8,806,492 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 4,869 | | |
| 10,086 | |
Amortization of debt premium | |
| - | | |
| (499,100 | ) |
Inducement expense | |
| - | | |
| 3,024,872 | |
Share based compensation expense | |
| 100,759 | | |
| 535,481 | |
Loss on debt extinguishment | |
| - | | |
| 2,196,100 | |
Warrant expense | |
| - | | |
| 334,238 | |
Bad debt expense | |
| 20,301 | | |
| 59,820 | |
Loss on disposal of property and equipment | |
| - | | |
| 9,610 | |
Expense of acquired IP, R&D | |
| - | | |
| 1,245,948 | |
Day one loss on derivative liabilities | |
| 1,527,239 | | |
| - | |
Gain on convertible notes payable carried at fair value | |
| (1,329,629 | ) | |
| - | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| - | | |
| (46,320 | ) |
Patient financing receivable, current portion | |
| 3,659 | | |
| 11,789 | |
Patient financing receivable, net of current portion | |
| 4,383 | | |
| 41,037 | |
Other assets | |
| - | | |
| (2,981 | ) |
Prepaid expenses and other assets | |
| (85,539 | ) | |
| (57,304 | ) |
Interest payable | |
| 112,788 | | |
| 120,677 | |
Interest payable, related parties | |
| 163,948 | | |
| 144,593 | |
Accounts payable | |
| 287,558 | | |
| 235,876 | |
Accrued liabilities | |
| 89,491 | | |
| 58,830 | |
Other current liabilities | |
| 39,317 | | |
| (24,739 | ) |
Deferred revenue | |
| - | | |
| (414,025 | ) |
Net Cash Used in Operating Activities | |
| (826,371 | ) | |
| (1,822,004 | ) |
| |
| | | |
| | |
Cash Flows from Investing Activities | |
| | | |
| | |
Proceeds from redemption of equity method investment | |
| 869,249 | | |
| - | |
Cash acquired in asset acquisition | |
| - | | |
| 469 | |
Net Cash Provided By Investing Activities | |
| 869,249 | | |
| 469 | |
| |
| | | |
| | |
Cash Flows from Financing Activities | |
| | | |
| | |
Proceeds from notes payable | |
| 18,004 | | |
| 67,500 | |
Proceeds from convertible notes payable | |
| 150,000 | | |
| 437,500 | |
Payment on PPP Loan | |
| - | | |
| (66,275 | ) |
Payment on note payable | |
| (12,000 | ) | |
| (57,500 | ) |
Proceeds from warrants exercised | |
| - | | |
| 1,170,110 | |
Proceeds from issuance of common stock | |
| - | | |
| 225,001 | |
Payment on debt financing costs | |
| - | | |
| (13,250 | ) |
Payments on convertible notes | |
| (115,000 | ) | |
| - | |
Proceeds from convertible notes carried at fair value, related parties | |
| 275,000 | | |
| - | |
Proceeds from convertible notes carried at fair value | |
| 185,000 | | |
| - | |
Net Cash Provided by Financing Activities | |
| 501,004 | | |
| 1,763,086 | |
| |
| | | |
| | |
Net Change in Cash | |
| 543,882 | | |
| (58,449 | ) |
| |
| | | |
| | |
Cash - Beginning of period | |
| - | | |
| 95,172 | |
| |
| | | |
| | |
Cash - End of period | |
$ | 543,882 | | |
$ | 36,723 | |
| |
| | | |
| | |
Supplementary Cash Flow Information | |
| | | |
| | |
Cash paid for interest | |
$ | 80,710 | | |
$ | 9,916 | |
| |
| | | |
| | |
Non Cash Investing & Financing Activity | |
| | | |
| | |
Conversion of Series A Preferred Stock to Common Stock | |
$ | - | | |
$ | 63,114 | |
Issuance of warrants pursuant to inducement agreements | |
$ | - | | |
$ | 2,993,872 | |
Issuance of warrants for services rendered | |
$ | - | | |
$ | 31,000 | |
Issuance of warrants pursuant to securities purchase agreement | |
$ | - | | |
$ | 334,238 | |
Issuance of Common Stock pursuant to SkinDisc acquisition | |
$ | - | | |
$ | 29,557 | |
Conversion of convertible notes payable to Common Stock | |
$ | 58,700 | | |
$ | - | |
Issuance of warrants pursuant to convertible notes payable - related parties | |
$ | 44,255 | | |
$ | - | |
Issuance of warrants pursuant to convertible notes payable | |
$ | 29,617 | | |
$ | - | |
See
accompanying notes to the consolidated financial statements
INNOVEREN
SCIENTIFIC, INC
NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
Note
1 - Description of the Company
DESCRIPTION
OF THE COMPANY
On
July 5, 2023, Innoveren Scientific, Inc. (the “Company formerly known as H-Cyte, Inc.”) filed with the Secretary of State
of the State of Nevada a Certificate of Amendment to Second Amended and Restated Article of Incorporation to change the corporate name
from H-Cyte, Inc. to Innoveren Scientific, Inc. The name change and Company’s new symbol, IVRN, became effective with FINRA on
July 10, 2023.
Innoveren
Scientific, Inc (“the Company”) has evolved from focusing on treating chronic lung conditions after the closure of its lung
treatment clinics due to COVID-19. The Company is currently focusing on acquiring and developing early-stage companies or their technologies
in the areas of therapeutics, medical devices, and diagnostics. The goal is to develop these companies and incubate their technologies
to meaningful clinical inflection points.
On
June 3, 2022, the Company closed its clinic in Scottsdale, Arizona. The Company has closed all of its clinical operations in the autologous
infusion therapy business which delivered treatments for patients with chronic respiratory and pulmonary disorders. The Company will
continue to pursue Food and Drug Administration (“FDA”) approval of the device that was utilized in the treatment provided
at the clinics. The
Company has implemented the transition into a biologics and therapeutic device incubator company to bring new technologies to market.
The
consolidated results for Innoveren Scientific, Inc include the following wholly-owned subsidiaries: H-CYTE Management, LLC, Medovex Corp,
Cognitive Health Institute, LLC, and Lung Institute Tampa, LLC and the results include Lung Institute Dallas, LLC (“LI Dallas”),
Lung Institute Nashville, LLC (“LI Nashville”), Lung Institute Pittsburgh, LLC (“LI Pittsburgh”), and Lung Institute
Scottsdale, LLC (“LI Scottsdale”), as Variable Interest Entities (“VIEs”). Additionally, H-CYTE Management, LLC
was the operator and manager of the various Lung Health Institute (LHI) clinics: LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale.
The LI Dallas and LI Pittsburgh clinics did not reopen in 2020 after the temporary closure of all LI clinics due to COVID-19. During
the first quarter of 2022, the Company closed the LI Tampa and LI Nashville clinics. During the second quarter of 2022, the Company closed
the LI Scottsdale clinic. All LHI clinics are closed as of September 30, 2023. The Company leases a shared office space for its corporate
address as the Company’s employees continue to work remotely.
On
June 10, 2022, the Company amended (the “Amendment”) its Articles of Incorporation to effectuate a one-for-one thousand reverse
stock split (the “Reverse Split”) of its common stock. The Reverse Split was approved by FINRA on June 10, 2022 and effectuated
on June 13, 2022. Pursuant to the Amendment, the Company also reduced the authorized shares of common stock to 500,000,000. As a result
of the Reverse Split, as of September 30, 2023, the Company has 712,710 shares of common stock outstanding and 438,776,170 shares of Series
A Preferred Stock outstanding. As a result of the Reverse Stock Split, the Series A Preferred Stock conversion ratio is now one thousand
shares of Series A Preferred Stock converts into one share of common stock. Accordingly, the 438,776,170 outstanding shares of Series
A Preferred Stock are now convertible into an aggregate of 438,776 shares of common stock.
On
September 7, 2022, the Company acquired all of the membership interests, with common stock, of Jantibody LLC (“Jantibody”),
a Nevada limited liability company. Jantibody is focused on the development of novel proprietary immunotherapies targeted towards ovarian
cancer, pancreatic cancer, and mesothelioma (see Note 9).
On
December 22, 2022, the Company acquired all the membership interests, with common stock, in Scion Solutions, LLC (“Scion”).
Scion is a life sciences company that has developed a new technology in regenerative medicine specifically for limb salvage. Their proprietary
product SkinDisc (patent pending) is a combination of stem cells and several other molecular components that stimulate tissue regeneration
(see Note 9).
Effective
September 21, 2023, Corp (as “Seller”) entered into a Membership Interest and LLCA Rights Redemption Agreement (“Redemption
Agreement”) with JV for the redemption (purchase) by JV of all of Corp’s membership interests outstanding with the JV, as
well as the purchase all of the rights of Corp under the Amended and Restated Limited Liability Company Agreement (“LLCA”)
dated April 2, 2021 (the “LLCA Rights”), for a purchase price of approximately $869,000. In addition, Corp and JV have agreed
in principle for the assignment and transfer of the DenerveX IP (the “2023 IP Agreement”) by Corp to JV for the rights to
IP under the DenerveX device and technology and all trade names, patents, trademarks, and other IP under the Medovex and Medovex Corp
names, for a purchase price of approximately $56,000. The Company and Corp will no longer be a party to any rights or obligations associated
with the DenerveX IP or associated assets.
The
sale of membership interests in the JV and the IP under the DenerveX device and technology was recorded as deferral on gain on
redemption of equity method investment of approximately $869,000
and deferral on gain on sale of IP of approximately $56,000,
for the three and nine months ended September 30, 2023, on the accompanying consolidated statements of operations.
Note
2 – Basis of presentation
BASIS
OF PRESENTATION
The
accompanying interim consolidated financial statements have been prepared based upon U.S. Securities and Exchange Commission rules that
permit reduced disclosure for interim periods. Therefore, they do not include all information and footnote disclosures necessary for
a complete presentation of the Company’s financial position, results of operations and cash flows, in conformity with generally
accepted accounting principles. The Company filed audited consolidated financial statements as of and for the fiscal years ended December
31, 2022 and 2021, which included all information and notes necessary for such complete presentation in conjunction with its 2022 Annual
Report on Form 10-K.
Certain
prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on
the reported results of operations.
The
results of operations for the interim period ended September 30, 2023, are not necessarily indicative of the results to be expected for
any future period or the entire fiscal year. These interim consolidated financial statements should be read in conjunction with the audited
consolidated financial statements for the year ended December 31, 2022, which are contained in the Company’s 2022 Annual Report
on Form 10-K. For further discussion refer to Note 2 – “Basis Of Presentation And Summary of Significant Accounting Policies”
to the consolidated financial statements and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations – Critical Accounting Policies and Estimates” in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2022.
Note
3 – Liquidity, Going Concern and Sources of Liquidity
LIQUIDITY,
GOING CONCERN AND SOURCES OF LIQUIDITY
The
Company incurred net losses of approximately $496,000
and $1,766,000 for
the three and nine months ended September 30, 2023. The Company has historically incurred losses from operations and expects to continue
to generate negative cash flows as it implements its plan around acquiring and developing early-stage companies or their technologies
in the areas of therapeutics, medical devices, and diagnostics. The consolidated financial statements are prepared using accounting principles
generally accepted in the United States (“U.S. GAAP”) as applicable to a going concern.
The
Company had cash on hand of approximately $544,000 as of September 30, 2023 and approximately $150,000, as of November 9, 2023. The Company’s
cash is insufficient to fund its operations over the next year and the Company is currently working to obtain additional debt or equity
financing to help support short-term working capital needs.
There
can be no assurance that the Company will be able to raise additional funds or that the terms and conditions of any future financings
will be workable or acceptable to the Company or its shareholders. If the Company is unable to fund its operations from existing cash
on hand, operating cash flows, additional borrowings, or raising equity capital, the Company may be forced to cease operations. The consolidated
financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
On
February 24, 2023, the Company and certain investors entered into Securities Purchase Agreements (the “SPA”), whereby the
Company sold and issued to the certain investors an aggregate of three hundred thousand dollars ($300,000) of the Company’s convertible
promissory notes (the “Note” or “Notes”), which are convertible into the Company’s Common Stock, $0.001
par value (“Common Stock”). In connection with the aforementioned Notes, the Company also issued to the investors a warrant
to purchase (the “Purchase Warrant”) a certain number of shares of Common Stock, which are equal to 20% of the shares of
Common Stock issuable upon conversion of the Note, based on a price of $2.00 per share. These warrants have a term of five (5) years,
with an exercise price of $2.00 per share. Unless the Company chooses to terminate earlier, the offering and the sale of the Notes shall
terminate on the sooner of the sale of the maximum offering amount or April 30, 2023. However, the Company extended this offering to June 30, 2023, per terms of agreement.
The
Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering. Interest on
the Note shall accrue on the unpaid principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated
on an actual/365-day basis. In the event that the Company moves forward with a qualified offering, as referenced in the SPA, the Holder
may convert the unpaid and outstanding principal plus any accrued and unpaid interest into shares of the Company’s Common Stock
at a conversion price equal to a 20% discount to the offering price.
Further,
in connection with the SPA, the Company also issued Common Stock Purchase Warrants to certain investors, which are exercisable on or
prior to the close of business on the five (5) year anniversary of the initial issue date, to purchase up to a certain amount of shares
of Common Stock, with 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory Note purchased by the
Holder, pursuant to the SPA between the Holder and the Company, dated February 24, 2023. The Company issued Warrants to purchase an aggregate
of 30,000 shares of Common Stock. The exercise price per share of the Common Stock under these Warrants is $2.00.
On
February 28, 2023, the Company entered into a securities purchase agreement for a total of $150,000 with an accredited investor. The
note issued is convertible into common stock at a 65% discount to the lowest trading price in the 20-day period prior to conversion.
The note bears interest at 10% and is due one year from issuance. For the first six months, the Company has the right to prepay the note
at a premium of between 25% and 40% depending on when it is repaid.
On
March 27, 2023, the Company and three related party investors entered into Securities Purchase Agreements (the “SPA”), whereby,
the Company sold and issued to the certain investors, an aggregate of one hundred twenty five thousand dollars ($125,000) of the Company’s
convertible promissory notes (the “Note” or “Notes”), which are convertible into the Company’s Common Stock,
$0.001 par value (“Common Stock”). On April 12, 2023, the Company and an additional investor entered into the SPA, whereby,
the Company sold and issued an aggregate of thirty five thousand dollars ($35,000) of the Company’s Notes. In connection with the
aforementioned Notes, the Company also issued to the investors a warrant to purchase (the “Purchase Warrant”) a certain number
of shares of Common Stock, which are equal to 20% of the shares of Common Stock issuable upon conversion of the Note, based on a price
of $2.00 per share. These warrants have a term of five (5) years, with an exercise price of $2.00 per share. Unless the Company chooses
to terminate earlier, the offering and the sale of the Notes shall terminate on the sooner of the sale of the maximum offering amount
or April 30, 2023. However, the Company extended this offering to June 30, 2023, per terms of agreement.
The
March 27, 2023 Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified
offering. The April 12, 2023 Note has a maturity date 60 days from issuance. Interest on the Note shall accrue on the unpaid
principal balance of this Note at the rate of eight percent (8%) per annum and will be calculated on an actual/365-day basis. The
Company defaulted on this note on June 12, 2023 which triggered an increase in interest from 8% to 12%. In the event that the
Company moves forward with a qualified offering, as referenced in the SPA, the Holder may convert the unpaid and outstanding
principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock at a conversion price equal to a 20%
discount to the offering price.
Further,
in connection with the SPA, the Company also issued Common Stock Purchase Warrants to certain investors, which are exercisable on or
prior to the close of business on the five (5) year anniversary of the initial issue date, to purchase up to a certain amount of shares
of Common Stock, with 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory Note purchased by the
Holder, pursuant to the SPA between the Holder and the Company. The Company issued Warrants to purchase an aggregate of 12,500 shares
of Common Stock. The exercise price per share of the Common Stock under these Warrants is $2.00.
Note
4 – Fair Value of Financial Instruments
FAIR VALUE OF FINANCIAL INSTRUMENTS
The
Company measures certain financial instruments and certain financial instruments with related parties at fair value on a recurring basis.
The Company elected the fair value option of accounting for certain debt instruments. Under the fair value option, the financial instrument
is initially measured at its issue date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis
each reporting period with the resulting fair value adjustment recognized as other income (expense) in the consolidated statement of
operations. As of September 30, 2023, the fair value of these instruments was as follows:
SCHEDULE OF FAIR VALUE INSTRUMENT
| |
Total | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
| |
| | |
| | |
| | |
| |
Assets: | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Liabilities: | |
| | | |
| | | |
| | | |
| | |
Convertible Notes at fair value | |
$ | 583,738 | | |
$ | - | | |
$ | - | | |
$ | 583,738 | |
The
following is a reconciliation of the beginning and ending balances for the Convertible Notes measured at fair value on a recurring basis
using significant unobservable inputs (Level 3) during the nine months ended September 30, 2023:
SCHEDULE OF CONVERTIBLE NOTE MEASURED AT FAIR VALUE
| |
| | |
Balance at December 31, 2022 | |
$ | — | |
Fair value of Convertible Notes issued | |
| (1,913,367 | ) |
Gain on change in fair value of Convertible Notes | |
| 1,329,629 | |
| |
| | |
Balance at September 30, 2023 | |
$ | (583,738 | ) |
The
estimated fair values reported utilize the Company’s common stock price along with certain Level 3 inputs, as discussed below,
in the development of Monte Carlo simulation models. The estimated fair values are subjective and are affected by changes in inputs to
the valuation models /analyses, including the Company’s common stock price, the Company’s dividend yield, risk-free rates
based on U.S. Treasury security yields, and certain other Level-3 inputs including, assumptions regarding the estimated volatility in
the value of the Company’s common stock price, the probability of a Qualified Offering, the estimated price of a Qualified Offering,
and credit-risk adjusted discount rates. Changes in these assumptions can materially affect the estimated fair values.
Note
5 – Related Party Transactions
RELATED
PARTY TRANSACTIONS
Officers
and Board Members and Related Expenses
On
January 12, 2021, Mr. Raymond Monteleone was appointed as Chairman of the Board, Audit Committee Chair, and Compensation Committee Chair.
There are understandings between the Company and Mr. Monteleone for him to receive $7,500 per month to serve on the Board of Directors
and an additional $2,500 per quarter to serve as Chairman of the Board, Audit Committee Chair, and Compensation Committee Chair. Effective
July 1, 2022, due to lack of working capital, Mr. Monteleone receives $3,750 per month to serve on the Board of Directors and to serve
as Chairman of the Board, Audit Committee Chair, and Compensation Committee Chair. For the three months and nine months ended September
30, 2023 the Company expensed $11,250 and $33,750, respectively, for board of director fees to Mr. Monteleone. For the three months and
nine months ended September 30, 2022 the Company expensed $13,750 and $63,750, respectively, for board of director fees to Mr. Monteleone.
Due to lack of financial resources, the Company has been unable to pay Mr. Monteleone for his services totaling $57,500, which is included
in accounts payable as of September 30, 2023.
On
January 12, 2021, Mr. William Horne stepped down as Chairman of the Board. Mr. Horne will remain a member of the Board. Mr. Horne agreed
to continue to defer the $108,000 in base salary deferred by him in 2018 until such time as there is a positive cash flow to meet the
Company’s financial obligations and then the Company and Mr. Horne will work together in good faith to negotiate a payment plan
for such deferred salary. Effective December 1, 2021, Mr. Horne will receive $5,000 per month to serve on the Board of Directors. Effective
July 1, 2022, due to lack of working capital, Mr. Horne receives $2,500 per month to serve on the Board of Directors. For the three months
and nine months ended September 30, 2023, the Company expensed approximately $7,500 and $22,500, respectively, in compensation and board
of director fees to Mr. Horne. For the three months and nine months ended September 30, 2022 the Company expensed $7,500 and $42,500
respectively, for board of director fees to Mr. Horne. Due to lack of financial resources, the Company has been unable to pay Mr. Horne
for his services totaling $37,500, which is included in accounts payable as of September 30, 2023.
Mr.
Richard Rosenblum entered into an oral agreement with the Company effective January 17, 2022, in which Mr. Rosenblum will receive $5,000
per month to serve on the Board of Directors. Effective July 1, 2022, due to lack of working capital, Mr. Rosenblum receives $2,500 per
month to serve on the Board of Directors. For the three and nine months ended September 30, 2023 the Company expensed $7,500 and $22,500,
for board of director fees to Mr. Rosenblum. For the three months and nine months ended September 30, 2022 the Company expensed $7,500
and $35,000, respectively, for board of director fees to Mr. Rosenblum. Due to lack of financial resources, the Company has been unable
to pay Mr. Rosenblum for his services totaling $37,500, which is included in accounts payable as of September 30, 2023.
Mr.
Matthew Anderer entered into an oral agreement with the Company effective January 17, 2022, in which Mr. Anderer will receive $5,000
per month to serve on the Board of Directors. Effective July 1, 2022, due to lack of working capital, Mr. Anderer receives $2,500 per
month to serve on the Board of Directors. For the three month and nine months ended September 30, 2023 the Company expensed $7,500 and
$22,500, respectively, for board of director fees to Mr. Anderer. For the three months and nine months ended September 30, 2022 the Company
expensed $7,500 and $35,000, respectively, for board of director fees to Mr. Anderer. Due to lack of financial resources, the Company
has been unable to pay Mr. Anderer for his services totaling $37,500, which is included in accounts payable as of September 30, 2023.
Debt
and Other Obligations
Convertible
Notes Payable
On
April 1, 2021, the Company, entered into a Secured Convertible Note Purchase Agreement (the “April 2021 Note Purchase
Agreement”) with five (5) related party investors (the “Holders”). Pursuant to the terms of the April 2021 Note
Purchase Agreement, the Company sold promissory notes in the aggregate principal amount of $2,575,000 maturing
on June
17, 2022 with an annual interest rate of 8%.
The Notes are convertible into shares of Common Stock at a discount of 20%
to the price paid for such New Securities in the next round of financing that meets the definition of Qualified Financing as defined
in the April 2021 Note Purchase Agreement. The Notes are secured by the assets of the Company under a security agreement with the
Holders. The lead investor of the April 2021 Note Purchase Agreement, FWHC Bridge, LLC, advanced $1,500,000 of
the total amount to the Company. FWHC Bridge, LLC is an affiliated entity of FWHC, LLC, which is a principal stockholder and related
party of the Company. An additional affiliate of FWHC, LLC provided an additional $25,000 as
part of the April 2021 Note Purchase Agreement. The Company entered into an agreement with the noteholders to extend the
maturity of the outstanding notes until July 31, 2024.
On
October 14, 2021, the Company entered into the Second Closing Bring Down Agreement (the “October 2021 Note Purchase Agreement”)
whereby the five (5) related party investors who had entered into the April 2021 Note Purchase Agreement purchased new notes in the Company
in the aggregate principal amount of $750,000. The Notes are due and payable on June 17, 2022 and bear interest at an annual rate of
8%. The Notes are convertible into shares of Common Stock at a discount of 20% to the price paid for such New Securities in the next
financing that meets the definition of a Qualified Financing as defined in the Note Purchase Agreement. The Notes are secured by all
of the assets of the Company under a security agreement with the Holders. The lead investor of the October 2021 Note Purchase Agreement,
FWHC Bridge, LLC, advanced $437,000 of the total amount to the Company. FWHC Bridge, LLC is an affiliated entity of FWHC, LLC, which
is a principal stockholder and related party of the Company. An additional affiliate of FWHC, LLC provided an additional $7,000 as part
of the October 2021 Note Purchase Agreement. The Company entered into an agreement with the noteholders to extend the maturity of the outstanding notes until
July 31, 2024.
On
February 22, 2022, the Company entered into a Debt Conversion Agreement (the “Amendment Agreement”) which i) provided for
an additional round of convertible debt financing (“Tranche 2 Notes”) of up to $500,000 and ii) amended the conversion price
on the convertible notes issued April 1, 2021 and October 8, 2021 (“Tranche 1 Notes”) from 80% of the price paid in a Qualified
Financing (proceeds of at least $15 million), to the lesser of (x) $0.002 and (y) the price paid in a Qualified Financing (proceeds of
at least $10 million). The Amendment Agreement also provides the following Milestone Payments:
|
1) |
$1,000,000
after filing a premarket notification pursuant to Section 510(k) of the Food, Drug and Cosmetic Act, of its intent to market its
PRP cellular therapy |
|
2) |
Following
the closing of a Qualified Financing, 25% of all proceeds raised in excess of $10 million (not to exceed $1 million) |
The
Milestone Payments are not to exceed $2 million, and the Amendment Agreement also specifies that a Qualified Financing will not occur
prior to the closing of the acquisition of Jantibody, LLC.
The
Company evaluated the Amendment Agreement under ASC 470-50, “Debt – Modification and Extinguishment”, and concluded
that probability of having to pay a Milestone payment was minimal and the change in the fair value of the conversion feature was not
material. The Amendment did not cause a material change in cash flows so extinguishment accounting was not applicable.
On
April 29, 2022, the Company entered into an Amended and Restated Note Conversion Agreement (the “Note Conversion Agreement”)
with certain holders of its Tranche 1 Notes (i) providing for a conversion price equal to the lesser of (x) $0.002 per share (pre-split)
and (y) the price per share paid by the investors in a Qualified Financing for such New Securities purchased for cash and not through
conversion of Notes (as such terms are defined in the Note Conversion Agreement), in each case subject to appropriate adjustment in the
event of any stock dividend, stock split, combination or other similar recapitalization, (ii) automatic conversion upon the occurrence
of a Qualified Financing, and (iii) amendment of the maturity date from March 31, 2022 to June 17, 2022 (the “New Notes”).
Upon the effective date of the Company’s 1,000-1 reverse split, the conversion price adjusted to the lesser of (a) the price in
the Qualified Financing or (b) $2.00 per share. The New Notes also provided the investors with Royalty Payments equal to 15% of all net
sales generated by the Company with respect to the sale of products or services associated with the 510(k) Notification related to the
Company’s autologous cellular therapy (PRP-PBMC) to treat chronic lung disorder. The Royalty Payments are in lieu of the Milestone
Payments but are perpetual and there is no limit to the aggregate amount of Royalty Payments that may be paid. It is the intent of the Company to pay the royalty payments even though the required conditions were not met. The
Company entered into an agreement with the noteholders to extend the maturity of the outstanding notes until July 31, 2024.
Due
to changes in key provisions of the Tranche 1 Notes, the Company analyzed the before and after cash flows between the (i) fair value
of the New Notes and (ii) reacquisition price of the Tranche 1 Notes prior to the (A) change in the maturity date from March 31, 2022
to June 17, 2022, (B) change in the conversion price to the lesser of (x) $2.00 and (y) the price paid in a Qualified Financing, and
(C) the fair value of the potential Royalty Payments, to determine whether these changes resulted in a modification or extinguishment
of the Tranche 1 Notes. The Company entered into an agreement with the noteholders to extend the maturity of the outstanding notes until
July 31, 2024
The
Company used a discounted cash flow method with Monte Carlo Simulation to value the Royalty Payments. Future Royalty Payments were estimated
based on management’s best estimate of future cash flows under various scenarios which were discounted to present value using a
risk-adjusted rate of 70%.
Based
on the before and after cash flows of each note, the change was considered significantly different. Consequently, the New Notes were
accounted for as a debt extinguishment of the Tranche 1 Notes and a new debt issuance of the New Notes. The Company recorded a $2.2 million
loss upon extinguishment of debt in the year ended December 31, 2022, which was comprised of the following:
SCHEDULE OF LOSS UPON EXTINGUISHMENT
|
|
|
|
|
Carrying
value of Tranche 1 Notes |
|
$ |
3,580,738 |
|
Less:
Fair value of New Notes |
|
|
(4,079,838 |
) |
Less:
Fair value of Royalty Payments |
|
|
(1,697,000 |
) |
Loss
on Extinguishment |
|
$ |
(2,196,100 |
) |
The
Note Conversion Agreement also provided for the consummation of a Tranche 2 Financing (the “Tranche 2 Notes”) subject to
(i) the aggregate principal amount of indebtedness represented by the Tranche 2 Notes being capped at $500,000 and (ii) Tranche 2 Notes’
being an unsecured obligation of the Company and expressly subordinate in all respects to all indebtedness of the Company under the Notes
and including language in which the holders of such Tranche 2 Notes acknowledge, confirm and agree to the foregoing subordination terms.
Pursuant to the terms of the Note Conversion Agreement, the Investors have agreed not to sell any capital stock of the Company for a
period of 12 months following the Qualified Financing. For the year ended December 31, 2022, approximately $499,000 of amortization of
the debt premium is included in interest income. The Company entered into an agreement with the noteholders to extend the maturity of
the outstanding notes until July 31, 2024.
On
February 24, 2023, the Company and certain investors entered into Securities Purchase Agreements (the “SPA”), whereby the
Company sold and issued to the certain investors an aggregate of three hundred thousand dollars ($300,000) of the Company’s convertible
promissory notes (the “Note” or “Notes”), which are convertible into the Company’s Common Stock, $0.001
par value (“Common Stock”). In connection with the aforementioned Notes, the Company also issued to the investors a warrant
to purchase (the “Purchase Warrant”) a certain number of shares of Common Stock, which are equal to 20% of the shares of
Common Stock issuable upon conversion of the Note, based on a price of $2.00 per share. These warrants have a term of five (5) years,
with an exercise price of $2.00 per share. Unless the Company chooses to terminate earlier, the offering and the sale of the Notes shall
terminate on the sooner of the sale of the maximum offering amount or April 30, 2023. However, the Company extended this offering to June 30, 2023 per terms of agreement.
The
Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering. Interest on
the Note shall accrue on the unpaid principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated
on an actual/365-day basis. In the event that the Company moves forward with a qualified offering, as referenced in the SPA, the Holder
may convert the unpaid and outstanding principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock
at a conversion price equal to a 20% discount to the offering price.
Further,
in connection with the February 2023 SPA, the Company also issued Common Stock Purchase Warrants to certain investors, which are exercisable
on or prior to the close of business on the five (5) year anniversary of the initial issue date, to purchase up to a certain amount of
shares of Common Stock, with 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory Note purchased
by the Holder, pursuant to the SPA between the Holder and the Company, dated February 24, 2023. The Company issued Warrants to purchase
an aggregate of 30,000 shares of Common Stock. The exercise price per share of the Common Stock under these Warrants is $2.00.
On
March 27, 2023, the Company and three related party investors entered into Securities Purchase Agreements (the “SPA”), whereby,
the Company sold and issued to the certain investors, an aggregate of one hundred twenty five thousand dollars ($125,000) of the Company’s
convertible promissory notes (the “Note” or “Notes”), which are convertible into the Company’s Common Stock,
$0.001 par value (“Common Stock”).
On
April 12, 2023, the Company and an additional investor entered into the SPA, whereby the Company sold and issued thirty five thousand
dollars ($35,000) of the Company’s Notes. In connection with the aforementioned Notes, the Company also issued to the investors
a warrant to purchase (the “Purchase Warrant”) a certain number of shares of Common Stock, which are equal to 20% of the
shares of Common Stock issuable upon conversion of the Note, based on a price of $2.00 per share. These warrants have a term of five
(5) years, with an exercise price of $2.00 per share. Unless the Company chooses to terminate earlier, the offering and the sale of the
Notes shall terminate on the sooner of the sale of the maximum offering amount or April 30, 2023. However, the Company extended this
offering to June 30, 2023 per terms of the agreement.
The
March 27, 2023, Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified
offering. The April 12, 2023, Note has a maturity date 60 days from issuance. Interest on the Note shall accrue on the unpaid
principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated on an actual/365-day basis. The
Company defaulted on this note on June 12, 2023 which triggered an increase in interest from 8% to 12%. In the event that the
Company moves forward with a qualified offering, as referenced in the SPA, the Holder may convert the unpaid and outstanding
principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock at a conversion price equal to a 20%
discount to the offering price.
Further,
in connection with the March 2023 and April 2023 SPA, the Company also issued Common Stock Purchase Warrants to certain investors, which
are exercisable on or prior to the close of business on the five (5) year anniversary of the initial issue date, to purchase up to a
certain amount of shares of Common Stock, with 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory
Note purchased by the Holder, pursuant to the SPA between the Holder and the Company. The Company issued Warrants to purchase an aggregate
of 12,500 shares of Common Stock. The exercise price per share of the Common Stock under these Warrants is $2.00.
We
evaluated the February 2023, March 2023, and April 2023 SPA in accordance with ASC Topic 815, Derivatives and Hedging, and determined
that they contained a variable share settlement feature tied to the price of a future financing which functions as a redemption option.
FASB ASC 825-10-25 allows the Company to elect the fair value option for recording financial instruments when they are initially recognized
or if there is an event that requires re-measurement of the instruments at fair value, such as a significant modification of the debt.
The Company elected to initially and subsequently measure the Convertible Notes in their entirety at fair value, with changes in fair
value recognized in earnings. Management believes the fair value option best reflects the underlying economics of these Convertible Notes.
Because
these Convertible Notes are carried in their entirety at fair value, the value of the contingent conversion feature is embodied in that
fair value. The Company estimates the fair value based on a probability weighted analysis which considers the present value of the cash
flows using a credit risk adjusted rate enhanced by the conversion feature valued using a Monte Carlo model. This method was considered
by management to be the most appropriate method of encompassing the credit risk and exercise behavior that a market participant would
consider when valuing a hybrid financial instrument. Inputs used to value the Convertible Notes as of September 30, 2023 included, (i)
present value of future cash flows using a credit risk adjusted rate of 20.0%, (ii) remaining term of approximately five months, (iii)
volatility of 322%, (iv) closing stock price on the valuation date, and (v) the conversion price based on the estimated price of a Qualified
Offering, less a 20% discount, in accordance with the terms of the Note. Changes due to instrument-specific credit risk are recorded
in Other Comprehensive Income with all other changes in value being recorded in net income.
At
inception, the fair value of the Convertible Notes using the fair value option was $1,913,367, and the fair value of the related Warrants
issued was approximately $73,872. Because the fair value of the hybrid instrument was in excess of the proceeds received of $460,000, the Company recorded
a day one loss on convertible notes of $1,521,768. On September 30, 2023, the debt instruments were revalued at approximately $584,000
resulting in a gain of approximately $1,330,000 for the nine months ended September 30, 2023.
Other
Obligations
During
the year ending December 31, 2022, Michael Yurkowsky, CEO, advanced the Company approximately $40,000 as a non-interest-bearing note
with no established repayment terms. During the nine months ended September 30, 2023, approximately $13,000 in net additional advances
were made. The balance owed is approximately $53,000 as of September 30, 2023.
Note
6 - Equity Transactions
EQUITY TRANSACTIONS
In
January 2022, the Company offered certain warrant holders the opportunity to receive an additional warrant to purchase the Company’s
Common Stock at $14.00 per share, for a period of five (5) years from issuance for the exercise by March 31, 2022 of each existing warrant
originally issued in April 2020. As of December 31, 2022, the Company had eleven warrant holders exercise an aggregate of 83,579 warrants
at $14.00 per share resulting in cash proceeds of approximately $1,170,000 to the Company.
On
June 10, 2022, the Company amended (the “Amendment”) its Articles of Incorporation to effectuate a one-for-one thousand reverse
stock split (the “Reverse Split”) of its common stock. The Reverse Split was approved by FINRA on June 10, 2022, and effectuated
on June 13, 2022. Pursuant to the Amendment, the Company also reduced the authorized shares of common stock to 500,000,000. As a result
of the Reverse Split, the Company had approximately 618,506 shares of common stock outstanding and 438,776,170 shares of Series A Preferred
Stock outstanding as of December 31, 2022. As a result of the Reverse Stock Split, the Series A Preferred Stock is convertible at a ratio
of one thousand shares of Series A Preferred Stock into one share of common stock. Accordingly, the 438,776,170 outstanding shares of
Series A Preferred Stock are now convertible into an aggregate of 438,776 shares of common stock.
On
September 29, 2022, the Company entered into a securities purchase agreement with two related party accredited investors for the sale
of shares of Common Stock and warrants (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company sold an
aggregate of 112,500 shares of common stock and warrants to purchase 56,250 shares of Common Stock exercisable at $2.50 per share for
gross proceeds of approximately $225,000.
On
November 14, 2022, pursuant to the Purchase Agreement, the Company sold an aggregate of 15,000 shares of common stock and warrants to
purchase 7,250 shares of Common Stock exercisable at $2.50 per share for gross proceeds of $30,000.
On
March 17, 2023, the Company issued 9,615 shares of Common Stock to a convertible noteholder who, at the request of the noteholder, converted
$10,000 of convertible notes into the Company’s Common Stock.
On May 23, 2023, the Company issued 17,351 shares
of Common Stock to a convertible noteholder who, at the request of the noteholder, converted $14,000 of convertible notes into the Company’s
Common Stock.
On June 8, 2023, the Company issued 15,873 shares of Common Stock to a
convertible noteholder who, at the request of the noteholder, converted $20,000 of convertible notes into the Company’s Common Stock.
On July 10, 2023, the Company issued 21,530 shares
of Common Stock to a convertible noteholder who, at the request of the noteholder, converted $6,000 of convertible notes into the Company’s
Common Stock.
On July 20, 2023, the Company issued 29,834 shares
of Common Stock to a convertible noteholder who, at the request of the noteholder, converted $8,700 of convertible notes into the Company’s
Common Stock.
The
following table summarizes the Company’s common and preferred stock outstanding by class. The number of common stock shares has
been adjusted to reflect a one-for-one thousand reverse stock split that became effective on June 13, 2022.
SCHEDULE OF COMMON AND PREFERRED STOCK OUTSTANDING
| |
September 30,
2023 | | |
December 31,
2022 | |
Common Stock | |
| 712,710 | | |
| 618,506 | |
Series A Preferred Stock | |
| 438,776,170 | | |
| 438,776,170 | |
Series
A Preferred Stock
During
the nine months ended September 30, 2023, no shares of Series A Preferred Stock were converted to Common Stock.
Voting
Rights
Holders
of Series A Preferred Stock (“Series A Holders”) have the right to receive notice of any meeting of holders of common stock
and to vote upon any matter submitted to a vote of the holders of common stock. Each Series A Holder shall vote on each matter on an
as converted basis submitted to them with the holders of common stock.
Conversion
Series
A Preferred Stock converts to common stock at a 1000:1 ratio immediately upon request of the Series A Holder.
Liquidation,
Dissolution, or Winding Up
In
the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A Preferred
Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders and,
in the event of a Deemed Liquidation Event (as defined in the Second Amended and Restated Articles of Incorporation), the holders of
shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in
such Deemed Liquidation Event or out of the consideration received by the Company for such Deemed Liquidation Event (net of any retained
liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board of Directors of the Company),
together with any other assets of the Company available for distribution to its stockholders, all to the extent permitted by Nevada
law governing distributions to stockholders, as applicable, before any payment shall be made to the holders of Common Stock by reason
of their ownership thereof, an amount per share equal to one (1) times the Series A Original Issue Price for such share of Series A Preferred
Stock, plus any Series A Accruing Dividends accrued but unpaid thereon, whether or not declared. If upon any such liquidation, dissolution
or winding up of the Company or Deemed Liquidation Event, the assets of the Company available for distribution to its stockholders shall
be insufficient to pay the holders of shares of Series A Preferred Stock the full amount to which they shall be entitled under subsection
2.1 of the Second Amended and Restated Articles of Incorporation, the holders of shares of Series A Preferred Stock shall share ratably
in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable
in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.
In
the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment in full of all Series
A Liquidation Amounts (as defined in the Second Amended and Restated Articles of Incorporation) required to be paid to the holders of
shares of Series A Preferred Stock the remaining assets of the Company available for distribution to its stockholders or, in the case
of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Series A Preferred Stock shall be distributed
among the holders of the shares of Series A Preferred Stock and Common Stock, pro rata based on the number of shares held by each such
holder, treating for this purpose all shares of Series A Preferred Stock as if they had been converted to Common Stock pursuant to the
terms of the Second Amended and Restated Articles of Incorporation immediately prior to such liquidation, dissolution or winding up of
the Company.
Share-Based
Compensation Plan
The
Company utilizes the Black-Scholes valuation method to recognize share-based compensation expense over the vesting period. The expected
life represents the period that the share-based compensation awards are expected to be outstanding.
Stock
Option Activity
On
April 1, 2021, the Board of Directors of the Company approved and granted certain directors and officers of the Company an aggregate
of 54,750 stock options of which 4,750 were immediately vested on the date of grant. Each option granted has an exercise price of $70.00
per share and an expiration date of ten years from the date of grant. These options are not included in the Company’s current stock
option plan as they were granted outside of the plan.
On
June 10, 2022, the Company amended its Articles of Incorporation to effectuate a one-for-one thousand reverse stock split of its common
stock. The Reverse Split was approved by FINRA on June 10, 2022 and effectuated on June 13, 2022.
As
of September 30, 2023, 29,385 options were outstanding and 24,843 were vested. As of September 30, 2022, 29,635 options were outstanding
and 20,510 were vested. For the three and nine months ended September 30, 2023, the Company recognized an expense related to stock options
of approximately $26,000 and $101,000, respectively, which is included in share-based compensation. For the three months and nine months
ended September 30, 2022, the Company recognized approximately $61,000 and $246,000 in stock-based compensation expense, respectively,
which is included in share-based compensation. As of September 30, 2023, the Company has approximately $55,000 of unrecognized compensation
costs related to non-vested stock options, which is expected to be recognized over a weighted average period of approximately 1.35 years.
Inputs
used in the valuation models are as follows:
SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS
2021 Grants |
Option value | |
$ | 54.00 | | |
| to | | |
$ | 56.00 | |
Risk Free Rate | |
| 0.90 | % | |
| to | | |
| 1.37 | % |
Expected Dividend- yield | |
| - | | |
| to | | |
| - | |
Expected Volatility | |
| 173.99 | % | |
| to | | |
| 176.04 | % |
Expected term (years) | |
| 5 | | |
| to | | |
| 7 | |
The
following is a summary of stock option activity for the nine months ended September 30, 2022 and 2023:
SUMMARY OF STOCK OPTION ACTIVITY
| |
Shares | | |
Weighted Average Exercise Price | | |
Weighted Average
Remaining Term (Years) | |
Outstanding at December 31, 2021 | |
| 29,635 | | |
$ | 86.48 | | |
| 9.20 | |
Granted | |
| - | | |
| - | | |
| - | |
Exercised | |
| - | | |
| - | | |
| - | |
Outstanding at September 30, 2022 | |
| 29,635 | | |
$ | 86.48 | | |
| 8.71 | |
Exercisable at September 30, 2022 | |
| 20,510 | | |
$ | 93.81 | | |
| 8.44 | |
| |
| | | |
| | | |
| | |
Outstanding at December 31, 2022 | |
| 29,385 | | |
$ | 83.81 | | |
| 8.22 | |
Granted | |
| - | | |
| - | | |
| - | |
Exercised | |
| - | | |
| - | | |
| - | |
Outstanding at September 30, 2023 | |
| 29,385 | | |
$ | 83.81 | | |
| 7.48 | |
Exercisable at September 30, 2023 | |
| 24,843 | | |
$ | 86.33 | | |
| 7.47 | |
The
following is a summary of the Company’s non-vested shares for the nine months ended September 30, 2023:
SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED
| |
Shares | | |
Weighted Average Grant Date Fair Value | |
Non-vested at December 31, 2022 | |
| 7,979 | | |
$ | 55.70 | |
Vested | |
| (3,437 | ) | |
| 55.46 | |
Non-vested at September 30, 2023 | |
| 4,542 | | |
$ | 69.88 | |
Net
Loss Per Share
Basic
loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per
share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using
the treasury stock and if-converted methods, as applicable. Any potentially dilutive securities are antidilutive due to the Company’s
net losses.
The
Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been
antidilutive:
SCHEDULE OF ANTI-DILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE
| |
2023 | | |
2022 | |
| |
For the Nine Months Ended September 30, | |
| |
2023 | | |
2022 | |
Warrants to purchase common stock (in the money) | |
| - | | |
| 385,033 | |
Series A Preferred Stock convertible to common stock | |
| 438,776 | | |
| 515,874 | |
Total | |
| 438,776 | | |
| 900,907 | |
Excluded
from the above table are 493,180 warrants and 29,385 stock options for the nine months ended September 30, 2023 and 384,788 warrants and
29,635 stock options for the nine months ended September 30, 2022 as they are out of the money (exercise price greater than the stock
price). Inclusion of such would be anti-dilutive. As a result of the Reverse Stock Split, the Series A Preferred Stock is convertible
at a ratio of one thousand shares of Series A Preferred Stock into one share of common stock. Accordingly, the 438,776,170 outstanding
shares of Series A Preferred Stock are convertible into an aggregate of 438,776 shares of common stock at September 30, 2023.
Note
7 – Commitments & Contingencies
COMMITMENTS
& CONTINGENCIES
CEO
Compensation Agreement
On
December 23, 2021, the Company entered into an employment agreement (the “Employment Agreement”) with Michael Yurkowsky,
the Company’s Chief Executive Officer, to continue to serve as the Chief Executive Officer of the Company. Under the Employment
Agreement, which commenced on December 1, 2021 (the “Effective Date”) and has a term of one year from the Effective Date
(the “Employment Period”), Mr. Yurkowsky will receive a base salary of $180,000 per year. Upon the expiration of the Employment
Period, Mr. Yurkowsky’s employment with the Company will be on an at-will basis.
In
addition to his base salary, Mr. Yurkowsky may receive a one-time cash bonus in gross amount equal to $100,000 if (i) the Company’s
stock is listed and quoted on the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market, or the New York Stock
Exchange; or (ii) the Company secures and receives financing of at least $10,000,000.
As
additional compensation, Mr. Yurkowsky shall receive shares of common stock of the Company representing 1% of the Company’s fully
diluted equity as of the grant date if the Company achieves a market capitalization of at least $250 million for 60 consecutive days
during the Employment Period (the “Equity Award”). If the Company achieves a market capitalization of at least $500 million
for 60 consecutive days during the Employment Period, the executive shall receive an additional Equity Award of 1%, such that he has
in the aggregate received shares of common stock of the Company representing 2% of the Company’s fully diluted equity as of the
date of grant. These market conditions were reflected in the grant date fair value of the award as required under ASC 718 Compensation-Stock
Compensation.
The
Equity Award was measured at fair value on its grant date using a Monte Carlo simulation model. The Monte Carlo simulation model
includes assumptions for the expected term, volatility, and dividend yield, each of which are determined in reference to the
Company’s historical results. The Company will recognize aggregate share-based compensation expense of approximately $328,000
related to the Equity Award on a straight-line basis over the derived service period determined by the Monte Carlo simulation model,
which was 0.71
years. During the three and nine month period ending September 30, 2022, the Company recognized approximately $0 and $114,000
in compensation expense related to the Equity Award, respectively. If the market capitalization targets are met sooner than the derived service
period, the Company will adjust its stock-based compensation to reflect the cumulative expense associated with the vested Equity
Award. The Company will recognize expense if the requisite service is provided, regardless of whether the market conditions are
achieved.
Consulting
Agreements
The
Company entered into a consulting agreement with Tanya Rhodes of Rhodes & Associates, Inc, effective June 15, 2020, to serve as
the Chief Science Officer of the Company. The agreement has a minimum term of six months with an average fee of $21,000
per month plus expenses which increases 5%
per month on January 1 of each calendar year unless an alternative retainer amount is negotiated and agreed upon by both parties.
The Company extended the contract on January 1, 2021, resulting in monthly expenses of $22,500
plus expenses for services rendered. Due to lack of financial resources, the Company has been unable to pay Ms. Rhodes for her
services totaling approximately $220,000,
which has been accrued as part of accrued liabilities as of September 30, 2023.
Litigation
From
time to time, the Company may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise
in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate)
may materially and adversely affect the Company’s financial condition, results of operations, and liquidity. In addition, the ultimate
outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company
due to legal costs and expenses, diversion of management attention, and other factors. The Company expenses legal costs in the period
incurred. The Company cannot assure that additional contingencies of a legal nature or contingencies having legal aspects will not be
asserted against the Company in the future, and these matters could relate to prior, current or future transactions or events.
The
Company is involved in a lawsuit with Sinclair Broadcast Group, Inc. (“Sinclair”) which was filed on September 8, 2020, in
the Circuit Court for the Thirteenth Judicial Circuit in and for Hillsborough County, Florida. Sinclair has obtained a legal judgment
for breach of contract for advertising services in the amount of approximately $75,000 plus interest and costs. The Company has retained
legal counsel for guidance in this matter. The amount is recorded in accounts payable as of September 30, 2023.
The
Company is involved in a lawsuit with ITN Networks, LLC (“ITN”) which was filed on July 22, 2021, in the Circuit Court for
the Thirteenth Judicial Circuit in and for Hillsborough County, Florida. ITN has obtained a legal judgment for breach of contract for
advertising services in the amount of approximately $45,000 plus interest and costs. The Company has retained legal counsel for guidance
in this matter. The amount is recorded in accounts payable as of September 30, 2023.
Note
8 – Debt
DEBT
Notes
Payable
Notes
payable were assumed in the Merger (for further discussion, see Note 1 - “Overview” to the consolidated financial statements
in the Company’s 2020 Annual Report on Form 10-K) and are due in aggregate monthly installments of approximately $5,800 and carry
an interest rate of 5%. Each note originally had a maturity date of August 1, 2019. The Company finalized an eighteen-month extension
to March 1, 2021. The promissory notes have an aggregate outstanding balance of approximately $69,000 at September 30, 2023 and December
31, 2022. The Company has not made payments on these notes since February 10, 2020, due to the Company’s lack of working capital.
On April 19, 2022, the Company entered into a promissory note modification agreement with the Lender extending the maturity date of the
notes to April 1, 2024. The modification agreement also reduces the interest rate from 5% to 3% and requires a monthly payment of $1,000
per month with a balloon payment at the end of the modified term.
On
June 9, 2022, the Company entered into a securities purchase agreement for a total of $272,500 with two accredited investors. The notes
issued are convertible into common stock at a 65% discount to the lowest trading price in the 20-day period prior to conversion. The
notes bear interest at 10% and are due one year from issuance. For the first six months, the Company had the right to prepay the notes
at a premium of between 25% and 35% depending on when it is repaid.
The
Company also issued a promissory note for $100,000, on June 9, 2022, to another accredited investor. This note bears interest at 15%
(no matter when repaid) and converts at a discount of 25% of the price of a public offering or a 25% discount to the Volume Average Weighted
Price (“VWAP”) of the five (5) days prior to conversion.
On
August 8, 2022, the Company entered into a securities purchase agreement for a total of $65,000 with an accredited investor. The note
issued is convertible into common stock at a 65% discount to the lowest trading price in the 20-day period prior to conversion. The note
bears interest at 10% and is due one year from issuance. For the first six (6) months, the Company had the right to prepay the notes
at a premium of between 25% and 40% depending on when it is repaid.
On
February 28, 2023, the Company entered into a securities purchase agreement for a total of $150,000 with an accredited investor. The
note issued is convertible into common stock at a 65% discount to the lowest trading price in the 20-day period prior to conversion.
The note bears interest at 10% and is due one year from issuance. For the first six months, the Company has the right to prepay the note
at a premium of between 25% and 40% depending on when it is repaid.
The
embedded features in the June 2022, August 2022, and February 2023 convertible notes were analyzed under ASC 815 to determine if they
required bifurcation as derivative instruments. To be a derivative, one of the criteria is that the embedded component must be net-settleable.
While the Company’s Common Stock was traded on an exchange at the time of the transaction, the underlying shares are not readily
convertible into cash since there is insufficient daily trading volume for the holders to convert the convertible notes into Common Stock
without significantly affecting the share price. Accordingly, the embedded derivatives, including the embedded conversion feature, did
not meet the definition of a derivative, and therefore, did not require bifurcation from the host instrument. Certain default put provisions,
including a default put and default interest, were not considered to be clearly and closely related to the host instrument but the Company
concluded that the value of these provisions was de minimus at inception. The Company will reconsider the value of these provisions each
reporting period to determine if the value becomes material to the financial statements.
Note
9 – Acquisitions
ACQUISITIONS
The
Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted
for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value
of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is
met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether
or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business.
Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination
or an acquisition of assets.
If
an acquisition is determined to be a business combination as indicated in ASC 805, Business Combinations, the assets acquired,
and liabilities assumed are recorded at their respective estimated fair values at the date of the acquisition. The Company recognizes
and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the
identified net assets acquired.
If
an acquisition is determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the
cost of the asset acquisition, including transaction costs, to be allocated to identifiable assets acquired and liabilities assumed based
on a relative fair value basis. Assets acquired as part of an asset acquisition that are considered to be in-process research and development
(IPR&D) are immediately expensed unless there is an alternative future use in other research and development projects. Goodwill is
not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated
to the identifiable assets based on relative fair values (excluding non-qualifying assets). If the cost of the asset acquisition is less
than the fair value of the net assets acquired, no gain is recognized in earnings.
Contingent
consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes
payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis
in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired
asset or group of assets.
On
September 7, 2022, the Company acquired all of the membership interests, with Common Stock, of Jantibody LLC (“Jantibody”),
a Nevada limited liability company. Jantibody is focused on the development of novel proprietary immunotherapies targeted towards ovarian
cancer, pancreatic cancer, and mesothelioma. Prior to the acquisition, Michael Yurkowsky, CEO, had approximately 17.5% ownership interest
in Jantibody.
Pursuant
to the Jantibody Agreement, the Company issued the equity holders of Jantibody an aggregate of 52,023 shares of the Company’s common
stock which represented 15% of the Company’s common stock on a fully diluted basis at the time of the transaction. In addition,
for every share of the Company’s common stock issued as a result of the future conversion of the Company’s dilutive instruments,
including Series A preferred stock, warrants, stock options, and convertible notes, the Jantibody members will receive 15% of the aggregate
number of shares issued (the “Anti-Dilution” shares). The Anti-Dilution shares will be issued before the end of each fiscal
quarter.
The
Company has agreed to issue the Jantibody holders an additional 2.0% of the Company’s common stock then outstanding upon the enrollment
of the first patient in a Phase I FDA trial and additional 3.0% of the Company’s then outstanding common stock on a fully diluted
basis upon the enrollment of the first patient in a Phase [III] FDA trial. The Company determined the contingent consideration was not
subject to derivative accounting and will be recognized when the contingency is resolved, and the consideration is paid or becomes payable
as outlined in ASC 450, Contingencies.
The
Company determined this transaction represented an asset acquisition as defined by ASC 805, Business Combinations, as substantially
all of the value was in a single in-process research and development (“IPR&D”) group, which included the small molecule
drug CXCR4 inhibitor, AMD3100, and/or checkpoint inhibitors (CPI) for anti-cancer immune modulation. As a result, the consideration transferred
was allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their relative fair values
resulting in approximately $1,240,000 being assigned to the IPR&D asset and approximately $1,000,000 to assumed liabilities. The
liabilities assumed were current accounts payable and as such were recorded a book value.
The
purchase price of approximately $247,000 represented 52,023 shares of the Company’s common stock, 344,159 Anti-Dilution shares,
and direct transaction costs of $21,600. The purchase price was allocated, on a relative fair value basis, to the acquired intellectual
property, and the acquired net assets as follows:
SCHEDULE
OF NET IDENTIFIABLE ASSETS ACQUIRED
| |
|
| |
Consideration: | |
| | |
Common stock | |
$ | 29,557 | |
Common stock (anti-dilution shares, to be issued – included in other current liabilities) | |
| 195,532 | |
Direct transaction costs | |
| 21,600 | |
Total costs of the asset acquisition | |
$ | 246,689 | |
Assets acquired | |
| | |
Cash | |
$ | 469 | |
Liabilities assumed – legal and administrative costs | |
| (999,728 | ) |
Intangible assets: IPR&D | |
| 1,245,948 | |
Net identifiable assets acquired | |
$ | 246,689 | |
The
IPR&D had not yet reached technological feasibility and had no alternative future use; thus, the purchased IPR&D asset and related
costs were expensed immediately subsequent to the acquisition within the consolidated statements of operations.
On
December 22, 2022, the Company acquired a 100% interest, with Common Stock, in Scion Solutions, LLC (“Scion”). Scion is a
life sciences company that has developed a new technology in regenerative medicine specifically for limb salvage. Their proprietary product
SkinDisc (patent pending) is a combination of stem cells and several other molecular components that stimulate tissue regeneration. Prior
to the acquisition, Tanya Rhodes, CSO, had approximately 33.3% ownership interest in Scion.
Pursuant
to the terms of the Scion Agreement, the Company issued the equity holders of Scion an aggregate of 123,153 shares of the Company’s
common stock. In addition, for every share of the Company’s common stock issued within 18-months of the Effective Date of the transaction,
as a result of the future conversion of the Company’s dilutive instruments, including Series A preferred stock, warrants, stock
options, and convertible notes, the Scion members will receive 20% of the aggregate number of shares issued (the “Anti-Dilution”
shares). The Anti-Dilution shares will be issued before the end of each fiscal quarter.
In
addition, the former shareholders of Scion are eligible to receive Performance Payments consisting of the following:
SCHEDULE
OF PERFORMANCE PAYMENTS
Performance Milestone | |
Performance Payment | |
Qualified Funding/Uplisting of Innoveren Scientific | |
$ | 45,000 | |
1-Year Anniversary of Uplisting of Innoveren Scientific | |
$ | 75,000 | |
2-Year Anniversary of Uplisting of Innoveren Scientific | |
$ | 120,000 | |
Initiation of SkinDisc Study | |
$ | 50,000 | |
Receipt of De Novo or any other approval/clearance that would allow SkinDisc to go to market | |
$ | 100,000 | |
Submission for specific and individual reimbursement codes relating to SkinDisc | |
$ | 25,000 | |
Receipt of specific and individual reimbursement codes relating to SkinDisc | |
$ | 50,000 | |
Completion of SkinDisc Study | |
$ | 50,000 | |
Launch of any additional SkinDisc product line extension (e.g., SkinDisc Lite)* | |
$ | 100,000 | |
Annual net sales from SkinDisc (including SkinDisc extensions) (2023 and each subsequent calendar year)* | |
| Greater of (i) 4% of net revenues from SkinDisc (including SkinDisc line extensions) during such calendar year and (ii) $50,000 | |
Cumulative net sales from SkinDisc (including SkinDisc extensions) of $600,000 | |
$ | 200,000 | |
Cumulative net sales from SkinDisc (including SkinDisc extension) of $2,000,000 | |
$ | 150,000 | |
Cumulative net sales from SkinDisc (including SkinDisc extension) of $4,000,000 | |
$ | 300,000 | |
Net sales from SkinDisc (including SkinDisc extensions) of $6,000,000 during any single calendar year* | |
$ | 300,000 | |
Substantially
all of the value acquired was concentrated in a single in-process research and development (“IPRD”) asset, which included
license rights, clinical trial data, clinical trial development plans, research and development materials, formulations and intellectual
property related to SkinDisc. There was no workforce, and no outputs were present. Accordingly, the acquired set of assets and activities
did not meet the definition of a business as defined by ASC 805, Business Combinations and
was considered an asset acquisition. In an asset acquisition, the consideration transferred is allocated to identifiable tangible
and intangible assets acquired and liabilities assumed based on their relative fair values. In the Scion acquisition, the only asset
or liability acquired was IPR&D. As a result, the consideration transferred was recorded fully to the IPR&D asset.
In
an asset acquisition, cash-settled contingent consideration is measured when probable and estimable, unless the contingent consideration
falls under the guidance of ASC 815. The Company determined the contingent consideration was not subject to ASC 815 and thus, the performance
payments which were estimable and probable (i.e., more than 50% likely to occur) were recorded on the acquisition date. The fair value
was estimated based on a probability weighting of the present value of cash flows over the expected time period until payment, using
a credit-risk adjusted interest rate. Each reporting period, the Company will determine if the performance payments are estimable and
probable and will record them as a liability at that time.
The
purchase price was allocated, as follows:
SCHEDULE
OF NET IDENTIFIABLE ASSETS ACQUIRED AND LIABILITIES ASSUMED
| |
| | |
Consideration: | |
| | |
Common stock | |
$ | 54,070 | |
Anti-Dilution share liability | |
| 305,998 | |
Contingent Performance payment liability | |
| 417,850 | |
Direct transaction costs | |
| 14,338 | |
Total costs of the asset acquisition | |
$ | 792,256 | |
The
common stock value was recorded as equity. The remaining consideration was recorded as IPR&D, since the
SkinDisc technology was still in the research and development stage and had no alternative future use. The purchased IPR&D asset
of $792,256 was expensed immediately subsequent to the acquisition within our consolidated statements of operations.
Note
10- Redemption of Medovex, LLC Membership Interest and Sale of IP
REDEMPTION
OF MEDOVEX LLC MEMBERSHIP INTEREST AND SALE OF IP
Effective
April 2, 2021, and in conjunction with the Amended and Restated Limited Liability Company Agreement of Medovex, LLC (“JV”)
(the “LLC Agreement”), Innoveren, Scientific, Inc., through its wholly-owned subsidiary, Medovex Corp. (“Corp”),
entered into a Contribution Agreement with JV to pursue a joint venture regarding the continued development and commercialization of
the Company’s DenerveX Device. In connection with the Contribution Agreement, Corp and JV entered into an Intellectual Property (“IP”)
License Agreement (“License Agreement”) in part to permit Corp to license the IP to JV for use in commercializing the DenerveX
Device. The IP and related assets were previously deemed fully impaired by the Company in a prior year. Pursuant to the Contribution
Agreement, the JV issued certain membership interests in the JV to Corp in exchange for the contributed IP assets. The effects of the
Contribution Agreement on the Company’s consolidated financial statements were deemed immaterial.
Effective
September 21, 2023, Corp (as “Seller”) entered into a Membership Interest and LLCA Rights Redemption Agreement (“Redemption
Agreement”) with JV for the redemption (purchase) by JV of all of Corp’s membership interests outstanding with the JV, as
well as the purchase all of the rights of Corp under the Amended and Restated Limited Liability Company Agreement (“LLCA”)
dated April 2, 2021 (the “LLCA Rights”), for a purchase price of approximately $869,000. In addition, Corp and JV have agreed
in principle for the assignment and transfer of the DenerveX IP (the “2023 IP Agreement”) by Corp to JV for the rights to
IP under the DenerveX device and technology and all trade names, patents, trademarks, and other IP under the Medovex and Medovex Corp
names, for a purchase price of approximately $56,000. The Company and Corp will no longer be a party to any rights or obligations associated
with the DenerveX IP or associated assets.
The
sale of membership interests in the JV and the IP under the DenerveX device and technology was recorded as a deferred gain on
redemption of equity investment of approximately $869,000
and a deferred gain on sale of asset of approximately $56,000,
for the three and nine months ended September 30, 2023, on the accompanying consolidated statements of operations as the Company awaits the final transfer of IP to Medovex LLC. The IP that was
sold as part of the Redpemtion Agreement had a net book value of $0.
Note
11- Common Stock Warrants
COMMON STOCK WARRANTS
A
summary of the Company’s warrant issuance activity and related information for the nine months ended September, 2022 and 2023 is
as follows:
SUMMARY
OF ISSUANCE OF WARRANTS
| |
Shares | | |
Weighted
Average
Exercise Price | | |
Weighted
Average
Remaining
Contractual
Life | |
Outstanding at December 31, 2021 | |
| 406,301 | | |
$ | 34.88 | | |
| 8.17 | |
Expired | |
| (22,513 | ) | |
| 373.85 | | |
| - | |
Exercised | |
| (83,579 | ) | |
| 14.00 | | |
| - | |
Granted | |
| 140,829 | | |
| 9.41 | | |
| 4.63 | |
Outstanding and exercisable at September 30, 2022 | |
| 441,038 | | |
$ | 12.52 | | |
| 6.84 | |
| |
| | | |
| | | |
| | |
Outstanding at December 31, 2022 | |
| 447,967 | | |
$ | 10.90 | | |
| 6.65 | |
Expired | |
| (787 | ) | |
| (498.54 | ) | |
| - | |
Granted | |
| 46,000 | | |
| 2.00 | | |
| 4.44 | |
Outstanding and exercisable at September 30, 2023 | |
| 493,180 | | |
$ | 9.30 | | |
| 5.68 | |
The
fair value of all warrants issued are determined by using the Black-Scholes valuation technique. The inputs used in the Black-Scholes
valuation technique to value each of the warrants as of their respective issue dates are as follows:
SCHEDULE
OF ISSUANCE OF WARRANTS VALUATION TECHNIQUE
Event Description | |
Date | |
Number
of
Warrants | | |
Innoveren Scientific
Stock
Price | | |
Exercise
Price of
Warrant | | |
Grant
Date
Fair
Value | | |
Life of
Warrant | |
Risk
Free
Rate
of
Return
(%) | | |
Annualized
Volatility
Rate (%) | |
Granted for inducement agreement | |
1/19/2022 | |
| 3,732 | | |
$ | 63.25 | | |
$ | 14.00 | | |
$ | 62.00 | | |
5 years | |
|
1.62 | | |
| 187.79 | |
Granted for inducement agreement | |
1/20/2022 | |
| 372 | | |
$ | 64.50 | | |
$ | 14.00 | | |
$ | 64.00 | | |
5 years | |
|
1.62 | | |
| 187.85 | |
Granted for inducement agreement | |
1/20/2022 | |
| 187 | | |
$ | 64.50 | | |
$ | 14.00 | | |
$ | 64.00 | | |
5 years | |
|
1.62 | | |
| 187.85 | |
Granted for inducement agreement | |
1/24/2022 | |
| 374 | | |
$ | 48.00 | | |
$ | 14.00 | | |
$ | 47.00 | | |
5 years | |
|
1.53 | | |
| 188.01 | |
Granted for inducement agreement | |
1/25/2022 | |
| 3,744 | | |
$ | 49.10 | | |
$ | 14.00 | | |
$ | 48.00 | | |
5 years | |
|
1.56 | | |
| 188.00 | |
Granted for inducement agreement | |
2/02/2022 | |
| 3,741 | | |
$ | 44.55 | | |
$ | 14.00 | | |
$ | 44.00 | | |
5 years | |
|
1.60 | | |
| 188.25 | |
Granted for inducement agreement | |
2/04/2022 | |
| 6,935 | | |
$ | 44.38 | | |
$ | 14.00 | | |
$ | 43.00 | | |
5 years | |
|
1.78 | | |
| 188.33 | |
Granted for inducement agreement | |
2/04/2022 | |
| 13,870 | | |
$ | 44.38 | | |
$ | 14.00 | | |
$ | 43.00 | | |
5 years | |
|
1.78 | | |
| 188.33 | |
Granted for services provided | |
2/09/2022 | |
| 1,000 | | |
$ | 32.00 | | |
$ | 14.00 | | |
$ | 31.00 | | |
5 years | |
|
1.82 | | |
| 188.69 | |
Granted for inducement agreement | |
2/22/2022 | |
| 41,609 | | |
$ | 32.88 | | |
$ | 14.00 | | |
$ | 32.00 | | |
5 years | |
|
1.85 | | |
| 188.59 | |
Granted for inducement agreement | |
2/22/2022 | |
| 693 | | |
$ | 32.88 | | |
$ | 14.00 | | |
$ | 32.00 | | |
5 years | |
|
1.85 | | |
| 188.59 | |
Granted for inducement agreement | |
3/21/2022 | |
| 8,322 | | |
$ | 28.00 | | |
$ | 14.00 | | |
$ | 27.00 | | |
5 years | |
|
2.33 | | |
| 194.01 | |
Granted for securities purchase agreement | |
9/27/2022 | |
| 56,250 | | |
$ | 6.00 | | |
$ | 2.50 | | |
$ | 5.94 | | |
5 years | |
|
4.21 | | |
| 213.54 | |
Granted for securities purchase agreement | |
11/14/2022 | |
| 7,500 | | |
$ | 5.75 | | |
$ | 2.50 | | |
$ | 5.69 | | |
5 years | |
|
4.00 | | |
| 213.28 | |
Granted for convertible note agreement | |
2/21/2023 | |
| 30,000 | | |
$ | 1.60 | | |
$ | 2.00 | | |
$ | 1.57 | | |
5 years | |
|
4.16 | | |
| 211.43 | |
Granted for convertible note agreement | |
3/27/2023 | |
| 10,000 | | |
$ | 1.70 | | |
$ | 2.00 | | |
$ | 1.68 | | |
5 years | |
|
3.59 | | |
| 218.15 | |
Granted for convertible note agreement | |
3/28/2023 | |
| 2,500 | | |
$ | 1.60 | | |
$ | 2.00 | | |
$ | 1.58 | | |
5 years | |
|
3.63 | | |
| 218.17 | |
Granted for convertible note agreement | |
4/12/2023 | |
| 3,500 | | |
$ | 1.74 | | |
$ | 2.00 | | |
$ | 1.73 | | |
5 years | |
|
4.16 | | |
| 243.62 | |
The
fair value of warrants issued during the three and nine months ended September 30, 2023, totaled approximately $0 and $74,000, respectively. The methods
described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair
values. Furthermore, while the Company believes its valuation methods are appropriate and consistent with other market participants,
the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a
different fair value measurement at the reporting date.
Note
12 - Subsequent Events
SUBSEQUENT EVENTS
The Company recently received notice from Mass General Hospital (MGH)
that the Company was in default in its obligations to fund certain Jantibody activities and obligations and was terminating the license
agreement between Innoveren and The General Hopsital Corporation d/b/a MGH. The Company was sent an initial breach notice on February
24, 2023, following which Company met with MGH and negotiated a Second Amendment (MGH Agreement No. 2023-2413) effective April 24, 2023.
MGH notified the Company of breach for a second time on September 11, 2023, indicating grounds for termination of the Agreement unless
the breach was cured. To date, the breach has not been cured and MGH has not received payment. Consequently, the Agreement is hereby
terminated effective immediately as of November 6, 2023.
Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated
financial statements and the notes thereto appearing in Part I, Item 1 of this Quarterly Report. Historical results and trends that might
appear in this Quarterly Report should not be interpreted as being indicative of future operations.
Overview
Innoveren
Scientific, Inc (“the Company”) has evolved from focusing on treating chronic lung conditions after the closure of its lung
treatment clinics due to COVID-19. The Company is currently focusing on acquiring and developing early-stage companies or their technologies
in the areas of therapeutics, medical devices, and diagnostics. The goal is to develop these companies and incubate their technologies
to meaningful clinical inflection points.
On
June 3, 2022, the Company closed its clinic in Scottsdale, Arizona. The Company has now closed all of its clinical operations in the
autologous infusion therapy business which delivered treatments for patients with chronic respiratory and pulmonary disorders. The Company
will continue to pursue Food and Drug Administration (“FDA”) approval of the device that was utilized in the treatment provided
at the clinics. The Company also has a continued interest in the commercialization of the DenerveX device through a joint venture. The
Company has implemented the transition into a biologics and therapeutic device incubator company to bring new technologies to market.
The
consolidated results for Innoveren Scientific include the following wholly-owned subsidiaries: H-CYTE Management, LLC, Medovex Corp,
Cognitive Health Institute, LLC, and Lung Institute Tampa, LLC and the results include Lung Institute Dallas, LLC (“LI Dallas”),
Lung Institute Nashville, LLC (“LI Nashville”), Lung Institute Pittsburgh, LLC (“LI Pittsburgh”), and Lung Institute
Scottsdale, LLC (“LI Scottsdale”), as Variable Interest Entities (“VIEs”). Additionally, H-CYTE Management, LLC
was the operator and manager of the various Lung Health Institute (LHI) clinics: LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale.
The LI Dallas and LI Pittsburgh clinics did not reopen in 2020 after the temporary closure of all LI clinics due to COVID-19. During
the first quarter of 2022, the Company closed the LI Tampa and LI Nashville clinics. During the second quarter of 2022, the Company closed
the LI Scottsdale clinic. All LHI clinics are closed as of September 30, 2023.
As
of September 30, 2023, the Company has closed all of the LHI clinics and has moved away from the Infusion Division as part of its future
plans. The Company has transformed into a medical biosciences incubator focusing on bringing new biologics and therapeutic device technologies
to market for various health conditions.
Effective
September 21, 2023, Corp (as “Seller”) entered into a Membership Interest and LLCA Rights Redemption Agreement (“Redemption
Agreement”) with JV for the redemption (purchase) by JV of all of Corp’s membership interests outstanding with the JV, as
well as the purchase all of the rights of Corp under the Amended and Restated Limited Liability Company Agreement (“LLCA”)
dated April 2, 2021 (the “LLCA Rights”), for a purchase price of approximately $869,000. In addition, Corp and JV have agreed
in principle for the assignment and transfer of the DenerveX IP (the “2023 IP Agreement”) by Corp to JV for the rights to
IP under the DenerveX device and technology and all trade names, patents, trademarks, and other IP under the Medovex and Medovex Corp
names, for a purchase price of approximately $56,000. The Company and Corp will no longer be a party to any rights or obligations associated
with the DenerveX IP or associated assets.
The
sale of membership interests in the JV and the IP under the DenerveX device and technology was recorded as a deferred gain on redemption
of equity investment of approximately $869,000 and a deferred gain on sale of asset of approximately $56,000, for the three and nine
months ended September 30, 2023, on the accompanying consolidated statements of operations as the Company awaits the final transfer of
IP to Medovex LLC. The IP that was sold as part of the Redpemtion Agreement had a net book value of $0.
Critical
Accounting Policies and Estimates
The
Company’s discussion and analysis of its financial condition and results of operations are based on its consolidated financial
statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these
consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities
and the disclosure of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and
expenses during the reporting periods.
The
Company bases our estimates on historical experience and on various other factors that it believes are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Results
of Operations - Three and nine months ended September 30, 2023 and 2022
Revenue,
Cost of Sales and Gross Profit
The
Company recorded no revenue for the three and nine months ended September 30, 2023. The Company recorded revenue of
approximately $0 and $453,000 for the three and nine months ended September 30, 2022, respectively.
For
the three and nine months ended September 30, 2023 the Company generated a gross profit totaling approximately $0. For the three and
nine months ended September 30, 2022, the Company generated a gross profit totaling approximately $0 and $337,000, respectively. The
Company has closed all of the LHI Clinics, which was the Company’s only source of revenue. The Company has transformed itself into
a biologics and therapeutic device incubator company to bring new technologies to market.
Operating
Expenses
Salaries
and Related Costs
For
the three and nine months ended September 30, 2023 the Company incurred approximately $106,000 and $433,000 in salaries and related
costs, respectively. For the three and nine months ended September 30, 2022, the Company incurred approximately $221,000 and
$848,000 in salaries and related costs, respectively. The decrease in salaries and related costs for the three and nine months ended
September 30, 2023, as compared to the prior year, is due to the adjustments to the Company’s corporate structure by reducing
expenses as part of the transition into a biologics and therapeutic incubator company to bring new technologies to market. As of
September 30, 2023, due to lack of financial resources, the Company has incurred $513,000 in unpaid salaries and wages.
Other
General and Administrative
For
the three and nine months ended September 30, 2023 the Company incurred approximately, $290,000 and $718,000, in other general and administrative
costs, respectively. For the three and nine months ended September 30, 2022, the Company incurred approximately, $268,000 and $1,173,000,
in other general and administrative costs, respectively. The Company adjusted its corporate structure by reducing expenses as part of
the transition into a biologics and therapeutic incubator company to bring new technologies to market.
Other
Income/Expense
For
the three months and nine months ended September 30, 2023, the Company incurred approximately $0 and $1,527,000 in day one loss expense
related to the convertible notes payable carried at fair value.
For
the three and nine months ended September 30, 2023 interest expense was approximately $100,000 and $348,000 respectively. For the
three and nine months ended September, 2022 interest expense was approximately $91,000 and $279,000 respectively.
For the three and nine months ended September 30,
2023 the Company did not incur inducement expense. For the three and nine months ended June 30, 2022 inducement expense was approximately
$0 and $3,025,000 respectively.
Funding
Requirements
The
Company has historically incurred losses from operations and expects to continue to generate negative cash flows as the Company implements
its business plan to focus on acquiring and developing early-stage companies or their technologies in the areas of therapeutics, medical
devices, and diagnostics. The Company will need to raise cash from debt and equity offerings to continue its operations. There can be
no assurance that the Company will be successful in doing so.
Liquidity,
Going Concern, and Sources of Liquidity
The Company generated net income (loss) of approximately
$429,000 and $(841,000) for the nine months ended September 30, 2023 and 2022, respectively. The Company has historically incurred losses
from operations and expects to continue to generate negative cash flows as it implements the transition into a biologics and therapeutic
incubator company to bring new technologies to market. The consolidated financial statements are prepared using accounting principles
generally accepted in the United States (“U.S. GAAP”) as applicable to a going concern.
The Company had cash on hand of approximately $544,000
as of September 30, 2023 and approximately $150,000 as of November 9, 2023. The Company’s cash is insufficient to fund its operations
over the next year and the Company is currently working to obtain additional debt or equity financing to help support short-term working
capital needs.
There
can be no assurance that the Company will be able to raise additional funds or that the terms and conditions of any future financings
will be workable or acceptable to the Company or its shareholders. If the Company is unable to fund its operations from existing cash
on hand, operating cash flows, additional borrowings, or raising equity capital, the Company may be forced to discontinue operations.
The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset
amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going
concern.
On
February 24, 2023, the Company and certain investors entered into Securities Purchase Agreements (the “SPA”), whereby the
Company sold and issued to the certain investors an aggregate of three hundred thousand dollars ($300,000) of the Company’s convertible
promissory notes (the “Note” or “Notes”), which are convertible into the Company’s Common Stock, $0.001
par value (“Common Stock”). In connection with the aforementioned Notes, the Company also issued to the investors a warrant
to purchase (the “Purchase Warrant”) a certain number of shares of Common Stock, which are equal to 20% of the shares of
Common Stock issuable upon conversion of the Note, based on a price of $2.00 per share. These warrants have a term of five (5) years,
with an exercise price of $2.00 per share. Unless the Company chooses to terminate earlier, the offering and the sale of the Notes shall
terminate on the sooner of the sale of the maximum offering amount or April 30, 2023. However, the Company extended this offering to June 30, 2023.
The
Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering. Interest on
the Note shall accrue on the unpaid principal balance of this Note at the rate of eight percent (8%) per annum and will be calculated
on an actual/365-day basis. In the event that the Company moves forward with a qualified offering, as referenced in the SPA, the Holder
may convert the unpaid and outstanding principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock
at a conversion price equal to a 20% discount to the offering price.
Further,
in connection with the February 2023 SPA, the Company also issued Common Stock Purchase Warrants to certain investors, which are exercisable
on or prior to the close of business on the five (5) year anniversary of the initial issue date, to purchase up to a certain amount of
shares of Common Stock, with 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory Note purchased
by the Holder, pursuant to the SPA between the Holder and the Company, dated February 24, 2023. The Company issued Warrants to purchase
an aggregate of 30,000 shares of Common Stock. The exercise price per share of the Common Stock under this Warrant is $2.00.
On
February 28, 2023, the Company entered into a securities purchase agreement for a total of $150,000 with an accredited investor. The
note issued is convertible into common stock at a 65% discount to the lowest trading price in the 20-day period prior to conversion.
The note bears interest at 10% and is due one year from issuance. For the first six months, the Company has the right to prepay the note
at a premium of between 25% and 40% depending on when it is repaid.
On
March 27, 2023, the Company and three related party investors entered into Securities Purchase Agreements (the “SPA”), whereby,
the Company sold and issued to the certain investors, an aggregate of one hundred twenty five thousand dollars ($125,000) of the Company’s
convertible promissory notes (the “Note” or “Notes”), which are convertible into the Company’s Common Stock,
$0.001 par value (“Common Stock”). On April 12, 2023, the Company and an additional investor entered into the SPA, whereby,
the Company sold and issued an aggregate of thirty five thousand dollars ($35,000) of the Company’s Notes. In connection with the
aforementioned Notes, the Company also issued to the investors warrants to purchase (the “Purchase Warrant”) a certain number
of shares of Common Stock, which are equal to 20% of the shares of Common Stock issuable upon conversion of the Note, based on a price
of $2.00 per share. These warrants have a term of five (5) years, with an exercise price of $2.00 per share. Unless the Company chooses
to terminate earlier, the offering and the sale of the Notes shall terminate on the sooner of the sale of the maximum offering amount
or April 30, 2023. The Company entered into an agreement with the noteholders to extend the maturity of the outstanding notes until
July 31, 2024.
The
March 27, 2023 Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified
offering. The April 12, 2023 Note has a maturity date 60 days from issuance. Interest on the Note shall accrue on the unpaid
principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated on an actual/365-day basis. The
Company defaulted on this note on June 12, 2023 which triggered an increase in interest from 8% to 12%. In the event that the
Company moves forward with a qualified offering, as referenced in the SPA, the Holder may convert the unpaid and outstanding
principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock at a conversion price equal to a 20%
discount to the offering price.
Further,
in connection with the March 2023 and April 2023 SPA, the Company also issued Common Stock Purchase Warrants to certain investors, which
are exercisable on or prior to the close of business on the five (5) year anniversary of the initial issue date, to purchase up to a
certain amount of shares of Common Stock, with 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory
Note purchased by the Holder, pursuant to the SPA between the Holder and the Company. The Company issued Warrants to purchase an aggregate
of 12,500 shares of Common Stock. The exercise price per share of the Common Stock under this Warrant is $2.00.
Cash
activity for the nine months ended September 30, 2023 and December 31, 2022 is summarized as follows:
Working
Capital Deficit
| |
As Of | |
| |
September 30,
2023 | | |
December 31,
2022 | |
Current Assets | |
$ | 749,486 | | |
$ | 83,845 | |
Current Liabilities | |
| 9,661,036 | | |
| 7,476,893 | |
Working Capital Deficit | |
$ | (8,911,550 | ) | |
$ | (7,393,048 | ) |
Cash
Flows
Cash
activity for the nine months ended September 30, 2023 and 2022 is summarized as follows:
| |
Nine months Ended September 30, | |
| |
2023 | | |
2022 | |
Cash used in operating activities | |
$ | (826,371 | ) | |
$ | (1,822,004 | ) |
Cash used in investing activities | |
| 869,249 | | |
| | |
Cash provided by financing activities | |
| 501,004 | | |
| 1,763,086 | |
Net increase (decrease) in cash | |
$ | 543,882 | | |
$ | (58,449 | ) |
As
of September 30, 2023, the Company had approximately $544,000 of cash on hand.
Off-Balance
Sheet Arrangements
The
Company does not have any off-balance sheet arrangements as defined in Regulation S-K Item 303(a)(4) during the periods presented, investments
in special-purpose entities or undisclosed borrowings or debt. Additionally, we are not a party to any derivative contracts or synthetic
leases.
ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
Not
applicable to smaller reporting companies.
ITEM
4. CONTROLS AND PROCEDURES.
Evaluation
of Disclosure Controls and Procedures
We
maintain disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports
filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and
reported within the specified time periods and accumulated and communicated to our management, including our principal executive officer
and principal accounting officer, as appropriate to allow timely decisions regarding disclosure.
The
Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), evaluated the effectiveness
of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) as of September
30, 2023. In designing and evaluating the Company’s disclosure controls and procedures, management recognizes that disclosure controls
and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired objectives,
and the Company necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls
and procedures.
Based
on such evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2023, due to the
lack of working capital, the Company’s disclosure controls and procedures were not as effective as desired because of the material
weakness in our internal control over financial reporting as discussed below, and as a result, the Company engaged consultants, implemented
a number of new entity and process level controls and installed a new accounting software system to help mitigate this material weakness.
A
material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a
reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on
a timely basis. In our assessment of the effectiveness of internal control over financial reporting as of September 30, 2023, we determined
that internal control deficiencies relating to a lack of segregation of duties and knowledge related to more complex accounting transactions
still exist. Management believes these deficiencies mainly relate to the Company employing a limited number of accounting and finance
personnel. The aggregation of these deficiencies is considered to be a material weakness in internal control over financial reporting.
In
light of the conclusion that our disclosure controls and procedures were ineffective as of September 30, 2023, we have applied additional
procedures and processes as necessary to ensure the reliability of our financial reporting in regard to this quarterly report. Accordingly,
the Company believes, based on its knowledge, that: (i) this quarterly report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the circumstances under which they were made, not
misleading with respect to the period covered by this report; and (ii) the financial statements, and other financial information included
in this quarterly report, fairly present in all material respects our financial condition, results of operations and cash flows as of
and for the periods presented in this quarterly report.
PART
II – OTHER INFORMATION
ITEM
1. LEGAL PROCEEDINGS.
The
Company is involved in a lawsuit with Sinclair Broadcast Group, Inc. (“Sinclair”) which was filed on September 8, 2020, in
the Circuit Court for the Thirteenth Judicial Circuit in and for Hillsborough County, Florida. Sinclair has obtained a legal judgment
for breach of contract for advertising services in the amount of approximately $75,000 plus interest and costs. The Company has retained
legal counsel for guidance in this matter. The amount is recorded in accounts payable as of September 30, 2023.
The
Company is involved in a lawsuit with ITN Networks, LLC (“ITN”) which was filed on July 22, 2021, in the Circuit Court for
the Thirteenth Judicial Circuit in and for Hillsborough County, Florida. ITN has obtained a legal judgment for breach of contract for
advertising services in the amount of approximately $45,000 plus interest and costs. The Company has retained legal counsel for guidance
in this matter. The amount is recorded in accounts payable as of September 30, 2023.
ITEM
1A. RISK FACTORS.
We
are a smaller reporting company as defined by 17 CFR 229.10(f)(1). Thus, we are not required to provide information under this item.
ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
None.
ITEM
3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM
4. MINE SAFETY DISCLOSURES.
Not
applicable.
ITEM
5. OTHER INFORMATION.
Not
applicable.
ITEM
6. EXHIBITS.
The
exhibits listed in the accompanying Exhibit Index are filed, furnished or incorporated by reference as part of this Quarterly Report
on Form 10-Q.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
Date:
November 14, 2023
|
INNOVEREN
SCIENTIFIC, INC |
|
|
|
|
By: |
/s/
Michael Yurkowsky |
|
|
Michael
Yurkowsky |
|
|
Chief
Executive Officer
(Principal
Executive Officer) |
|
|
|
|
By: |
/s/
Jeremy Daniel |
|
|
Jeremy
Daniel |
|
|
Chief
Financial Officer
(Principal
Financial Officer and
Principal
Accounting Officer) |
EXHIBIT
INDEX
* |
Filed
herewith. |
|
|
** |
Pursuant
to Rule 406T of Regulation S-T adopted by the SEC, these interactive data files are deemed not filed or part of a registration statement
or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of
the Securities Exchange Act of 1934, and otherwise are not subject to liability under these sections. |
|
|
*** |
This
certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and it is not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing
of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
EXHIBIT
31.1
CERTIFICATION
OF CHIEF EXECUTIVE OFFICER
PURSUANT
TO RULE 13a-14(a) UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
I,
Michael Yurkowsky, certify that:
1. |
I
have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2023 of INNOVEREN SCIENTIFIC, Inc.; |
|
|
2. |
Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
the period covered by this report; |
|
|
3. |
Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
this report; |
|
|
4. |
The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
(a) |
Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
(b) |
Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
(c) |
Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and |
|
|
|
|
(d) |
Disclosed
in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. |
The
registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or
persons performing the equivalent functions): |
|
(a) |
All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
and |
|
|
|
|
(b) |
Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting. |
Date:
November 14, 2023 |
/s/
Michael Yurkowsky |
|
Michael
Yurkowsky |
|
Chief
Executive Officer |
EXHIBIT
31.2
CERTIFICATION
OF CHIEF FINANCIAL OFFICER
PURSUANT
TO RULE 13a-14(a) UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
I,
Jeremy Daniel, certify that:
1. |
I
have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2023 of INNOVEREN SCIENTIFIC, Inc.; |
|
|
2. |
Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
the period covered by this report; |
|
|
3. |
Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
this report; |
|
|
4. |
The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
(a) |
Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
(b) |
Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
(c) |
Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and |
|
|
|
|
(d) |
Disclosed
in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. |
The
registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or
persons performing the equivalent functions): |
|
(a) |
All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
and |
|
|
|
|
(b) |
Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting. |
Date:
November 14, 2023 |
/s/
Jeremy Daniel |
|
Jeremy
Daniel, |
|
Chief
Financial Officer |
EXHIBIT
32.1
CERTIFICATION
OF CHIEF EXECUTIVE OFFICER AND
CHIEF
FINANCIAL OFFICER PURSUANT TO RULE 13a-14(b) UNDER
THE
SECURITIES EXCHANGE ACT OF 1934 AND SECTION 1350 OF
CHAPTER
63 OF TITLE 18 OF THE UNITED STATES CODE
Each
of the undersigned, Michael Yurkowsky and Jeremy Daniel, certifies pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934
and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this quarterly report on Form 10-Q for the quarter ended
September 30, 2023, of INNOVEREN SCIENTIFIC, INC, Inc. (the “Company”) fully complies with the requirements of Section 13(a) of the Securities
Exchange Act of 1934, and (2) the information contained in this report fairly presents, in all material respects, the financial condition
and results of operations of the Company.
Date:
November 14, 2023
|
/s/
Michael Yurkowsky |
|
Michael
Yurkowsky |
|
Chief
Executive Officer |
|
|
|
/s/
Jeremy Daniel |
|
Jeremy
Daniel, |
|
Chief
Financial Officer |
v3.23.3
Cover - shares
|
9 Months Ended |
|
Sep. 30, 2023 |
Nov. 10, 2023 |
Cover [Abstract] |
|
|
Document Type |
10-Q
|
|
Amendment Flag |
false
|
|
Document Quarterly Report |
true
|
|
Document Transition Report |
false
|
|
Document Period End Date |
Sep. 30, 2023
|
|
Document Fiscal Period Focus |
Q3
|
|
Document Fiscal Year Focus |
2023
|
|
Current Fiscal Year End Date |
--12-31
|
|
Entity File Number |
001-36763
|
|
Entity Registrant Name |
INNOVEREN
SCIENTIFIC, INC
|
|
Entity Central Index Key |
0001591165
|
|
Entity Tax Identification Number |
46-3312262
|
|
Entity Incorporation, State or Country Code |
NV
|
|
Entity Address, Address Line One |
2202
N. West Shore Blvd
|
|
Entity Address, Address Line Two |
Ste 200
|
|
Entity Address, City or Town |
Tampa
|
|
Entity Address, State or Province |
FL
|
|
Entity Address, Postal Zip Code |
33607
|
|
City Area Code |
(844)
|
|
Local Phone Number |
633-6839
|
|
Title of 12(b) Security |
Common
Stock, par value $0.001 per share
|
|
Trading Symbol |
IVRN
|
|
Entity Current Reporting Status |
Yes
|
|
Entity Interactive Data Current |
Yes
|
|
Entity Filer Category |
Non-accelerated Filer
|
|
Entity Small Business |
true
|
|
Entity Emerging Growth Company |
false
|
|
Entity Shell Company |
false
|
|
Entity Common Stock, Shares Outstanding |
|
712,710
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as an quarterly report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a
+ Details
Name: |
dei_DocumentQuarterlyReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as a transition report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1
+ Details
Name: |
dei_DocumentTransitionReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405
+ Details
Name: |
dei_EntityInteractiveDataCurrent |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityShellCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Consolidated Balance Sheets - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Current Assets |
|
|
Cash |
$ 543,882
|
|
Patient financing receivable, current portion |
9,933
|
29,464
|
Other receivable |
55,751
|
|
Prepaid expenses |
139,920
|
54,381
|
Total Current Assets |
749,486
|
83,845
|
Property and equipment, net |
15,525
|
20,394
|
Patient financing receivable, net of current portion |
5,893
|
14,436
|
Other assets |
18,412
|
18,682
|
Total assets |
789,316
|
137,357
|
Current Liabilities |
|
|
Accounts payable |
1,259,050
|
971,492
|
Accrued liabilities |
1,507,859
|
1,418,368
|
Other current liabilities |
229,166
|
139,330
|
Notes payable, current portion |
110,471
|
104,468
|
Lease liability, current portion |
12,772
|
63,291
|
Anti-dilution share contingent consideration liability |
501,531
|
501,531
|
Deferred gain on redemption of equity method investment |
869,249
|
|
Deferred gain on sale of IP |
55,751
|
|
Total Current Liabilities |
9,661,036
|
7,476,893
|
Long-term Liabilities |
|
|
Royalty liability |
1,697,000
|
1,697,000
|
Milestone payment contingent consideration liability |
320,850
|
320,850
|
Total Long-term Liabilities |
2,017,850
|
2,017,850
|
Total Liabilities |
11,678,886
|
9,494,743
|
Stockholders’ Equity (Deficit) |
|
|
Preferred Stock - $.001 par value: 1,000,000,000 shares authorized; Series A Preferred Stock - $.001 par value: 800,000,000 shares authorized, 438,776,170 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively. |
438,773
|
438,773
|
Common stock - $.001 par value: 500,000,000 shares authorized, 712,170 and 618,506 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively. |
714
|
618
|
Additional paid-in capital |
49,764,451
|
49,531,216
|
Accumulated deficit |
(61,093,508)
|
(59,327,993)
|
Total Stockholders’ Deficit |
(10,889,570)
|
(9,357,386)
|
Total Liabilities and Stockholders’ Deficit |
789,316
|
137,357
|
Related Party [Member] |
|
|
Current Liabilities |
|
|
Convertible notes payable |
3,325,000
|
3,325,000
|
Convertible notes payable carried at fair value |
426,255
|
|
Interest payable |
563,990
|
400,042
|
Nonrelated Party [Member] |
|
|
Current Liabilities |
|
|
Convertible notes payable |
406,395
|
430,095
|
Convertible notes payable carried at fair value |
157,483
|
|
Interest payable |
$ 236,064
|
$ 123,276
|
X |
- DefinitionAntidilution share contingent consideration liability current.
+ References
+ Details
Name: |
IVRN_AntidilutionShareContingentConsiderationLiabilityCurrent |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionConvertible notes payable carried at fair value.
+ References
+ Details
Name: |
IVRN_ConvertibleNotesPayableCarriedAtFairValue |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionDeferred gain on redemption of equity investment.
+ References
+ Details
Name: |
IVRN_DeferredGainOnRedemptionOfEquityInvestment |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionDeferred gain on sale of IP.
+ References
+ Details
Name: |
IVRN_DeferredGainOnSale |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionMilestone payment contingent consideration liability net of current portion.
+ References
+ Details
Name: |
IVRN_MilestonePaymentContingentConsiderationLiabilityNetOfCurrentPortion |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_AccruedRoyaltiesCurrentAndNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20
+ Details
Name: |
us-gaap_Cash |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ConvertibleDebtCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InterestPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 201.5-02(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 201.5-02(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 201.5-02(26)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesNoncurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9
+ Details
Name: |
us-gaap_NotesAndLoansReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance for credit loss, of financing receivable, classified as noncurrent.
+ References
+ Details
Name: |
us-gaap_NotesAndLoansReceivableNetNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_NotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncurrent assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.
+ References
+ Details
Name: |
us-gaap_OtherReceivablesNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1
+ Details
Name: |
us-gaap_PrepaidExpenseCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Consolidated Balance Sheets (Parenthetical) - $ / shares
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Preferred stock, par value |
$ 0.001
|
$ 0.001
|
Preferred stock, shares authorized |
1,000,000,000
|
1,000,000,000
|
Common stock, par value |
$ 0.001
|
$ 0.001
|
Common stock, shares authorized |
500,000,000
|
500,000,000
|
Common stock, shares issued |
712,170
|
618,506
|
Common stock, shares outstanding |
712,170
|
618,506
|
Series A Preferred Stock [Member] |
|
|
Preferred stock, par value |
$ 0.001
|
$ 0.001
|
Preferred stock, shares authorized |
800,000,000
|
800,000,000
|
Preferred stock, shares issued |
438,776,170
|
438,776,170
|
Preferred stock, shares outstanding |
438,776,170
|
438,776,170
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Consolidated Statements of Operations (Unaudited) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Income Statement [Abstract] |
|
|
|
|
Revenues |
|
|
|
$ 453,460
|
Cost of Sales |
|
|
|
(116,602)
|
Gross Profit |
|
|
|
336,858
|
Operating Expenses |
|
|
|
|
Salaries and related costs |
105,534
|
221,304
|
432,510
|
848,036
|
Share based compensation |
26,232
|
120,448
|
100,759
|
535,481
|
Loss on disposal of property and equipment |
|
|
|
9,610
|
Acquired in process research and development |
|
1,245,948
|
|
1,245,948
|
Other general and administrative |
289,504
|
268,076
|
717,518
|
1,172,738
|
Total Operating Expenses |
421,270
|
1,855,776
|
1,250,787
|
3,811,813
|
Operating Loss |
(421,270)
|
(1,855,776)
|
(1,250,787)
|
(3,474,955)
|
Other Income (Expense) |
|
|
|
|
Warrant expense |
|
(334,238)
|
|
(334,238)
|
Inducement expense |
|
|
|
(3,024,872)
|
Day one loss on convertible notes carried at fair value |
|
|
(1,527,239)
|
|
Gain on convertible notes carried at fair value |
14,792
|
|
1,329,629
|
|
Loss on extinguishment of convertible notes payable |
|
|
|
(2,196,100)
|
Interest income |
446
|
1,756
|
1,941
|
506,795
|
Interest expense |
(99,587)
|
(91,186)
|
(348,447)
|
(278,665)
|
Other income (expense) |
9,844
|
|
29,388
|
(4,457)
|
Total Other Income (Expense) |
(74,505)
|
(423,668)
|
(514,728)
|
(5,331,537)
|
Net (Loss) |
(495,775)
|
(2,279,444)
|
(1,765,515)
|
(8,806,492)
|
Net (Loss) attributable to common stockholders |
$ (495,775)
|
$ (2,279,444)
|
$ (1,765,515)
|
$ (8,806,492)
|
(Loss) per share - basic |
$ (0.73)
|
$ (8.04)
|
$ (2.69)
|
$ (34.07)
|
(Loss) per share - diluted |
$ (0.73)
|
$ (8.04)
|
$ (2.69)
|
$ (34.07)
|
Weighted average outstanding shares - basic |
682,209
|
283,579
|
655,783
|
258,483
|
X |
- References
+ Details
Name: |
IVRN_GainOnConvertibleNotesCarriedAtFairValue |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
IVRN_LossOnConvertibleNotesCarriedAtFairValue |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_CostOfGoodsAndServicesSold |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_GainLossOnSaleOfPropertyPlantEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GrossProfit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net amount of operating interest income (expense).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.10) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_InterestIncomeExpenseNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(a),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_InvestmentIncomeNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
+ Details
Name: |
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of general and administrative expense classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OtherGeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of income (expense) related to nonoperating activities, classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OtherNonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Consolidated Statements of Stockholders' (Deficit) (Unaudited) - USD ($)
|
Series A Preferred Stock [Member]
Preferred Stock [Member]
|
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
Total |
Balance at Dec. 31, 2021 |
$ 501,887
|
$ 164,199
|
$ 43,700,084
|
$ (49,028,413)
|
$ (4,662,243)
|
Balance, shares at Dec. 31, 2021 |
501,887,534
|
166,394
|
|
|
|
Conversion of Series A Preferred Stock to Common Stock |
$ (63,114)
|
$ 7,364
|
55,750
|
|
|
Conversion of Series A Preferred Stock to Common Stock, shares |
(63,111,364)
|
63,114
|
|
|
|
Issuance of Common Stock pursuant to securities purchase agreement |
|
$ 113
|
224,888
|
|
225,001
|
Issuance of Common Stock pursuant to securities purchase agreement, shares |
|
112,500
|
|
|
|
Issuance of Common Stock pursuant to Jantibody acquisistion |
|
$ 52
|
29,505
|
|
29,557
|
Issuance of Common Stock pursuant to Jantibody acquisistion, shares |
|
52,023
|
|
|
|
Warrant expense |
|
|
334,238
|
|
334,238
|
Share based compensation |
|
|
535,481
|
|
535,481
|
Net loss |
|
|
|
(8,806,492)
|
(8,806,492)
|
Adjustment for 1-for-1,000 reverse stock split |
|
(254,831)
|
254,831
|
|
|
Inducement expense |
|
|
3,024,872
|
|
3,024,872
|
Conversion of warrants to Common Stock |
|
$ 83,580
|
1,086,530
|
|
1,170,110
|
Conversion of warrants to Common Stock, shares |
|
83,579
|
|
|
|
Balance at Sep. 30, 2022 |
$ 438,773
|
$ 477
|
49,246,179
|
(57,834,905)
|
(8,149,476)
|
Balance, shares at Sep. 30, 2022 |
438,776,170
|
477,610
|
|
|
|
Balance at Jun. 30, 2022 |
$ 494,578
|
$ 257
|
48,481,350
|
(55,555,461)
|
(6,579,276)
|
Balance, shares at Jun. 30, 2022 |
494,579,119
|
257,282
|
|
|
|
Conversion of Series A Preferred Stock to Common Stock |
$ (55,805)
|
$ 55
|
55,750
|
|
|
Conversion of Series A Preferred Stock to Common Stock, shares |
(55,802,949)
|
55,805
|
|
|
|
Issuance of Common Stock pursuant to securities purchase agreement |
|
$ 113
|
224,888
|
|
225,001
|
Issuance of Common Stock pursuant to securities purchase agreement, shares |
|
112,500
|
|
|
|
Issuance of Common Stock pursuant to Jantibody acquisistion |
|
$ 52
|
29,505
|
|
29,557
|
Issuance of Common Stock pursuant to Jantibody acquisistion, shares |
|
52,023
|
|
|
|
Warrant expense |
|
|
334,238
|
|
334,238
|
Share based compensation |
|
|
120,448
|
|
120,448
|
Net loss |
|
|
|
(2,279,444)
|
(2,279,444)
|
Balance at Sep. 30, 2022 |
$ 438,773
|
$ 477
|
49,246,179
|
(57,834,905)
|
(8,149,476)
|
Balance, shares at Sep. 30, 2022 |
438,776,170
|
477,610
|
|
|
|
Balance at Dec. 31, 2022 |
$ 438,773
|
$ 618
|
49,531,216
|
(59,327,993)
|
(9,357,386)
|
Balance, shares at Dec. 31, 2022 |
438,776,170
|
618,506
|
|
|
|
Share based compensation |
|
|
100,759
|
|
100,759
|
Net loss |
|
|
|
(1,765,515)
|
(1,765,515)
|
Conversion of convertible notes payable to Common Stock |
|
$ 96
|
58,604
|
|
58,700
|
Conversion of convertible notes payable to Common Stock, shares |
|
94,204
|
|
|
|
Issuance of warrants pursuant to convertible notes payable |
|
|
73,872
|
|
73,872
|
Balance at Sep. 30, 2023 |
$ 438,773
|
$ 714
|
49,764,451
|
(61,093,508)
|
(10,889,570)
|
Balance, shares at Sep. 30, 2023 |
438,776,170
|
712,710
|
|
|
|
Balance at Jun. 30, 2023 |
$ 438,773
|
$ 662
|
49,723,571
|
(60,597,733)
|
(10,434,727)
|
Balance, shares at Jun. 30, 2023 |
438,776,170
|
661,345
|
|
|
|
Share based compensation |
|
|
26,232
|
|
26,232
|
Net loss |
|
|
|
(495,775)
|
(495,775)
|
Conversion of convertible notes payable to Common Stock |
|
$ 52
|
14,648
|
|
14,700
|
Conversion of convertible notes payable to Common Stock, shares |
|
51,365
|
|
|
|
Balance at Sep. 30, 2023 |
$ 438,773
|
$ 714
|
$ 49,764,451
|
$ (61,093,508)
|
$ (10,889,570)
|
Balance, shares at Sep. 30, 2023 |
438,776,170
|
712,710
|
|
|
|
X |
- DefinitionAdjustments to additional paid in capital inducement expense.
+ References
+ Details
Name: |
IVRN_AdjustmentsToAdditionalPaidInCapitalInducementExpense |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of anti dilution common stock pursuant to acquisition.
+ References
+ Details
Name: |
IVRN_IssuanceOfAntiDilutionCommonStockPursuantToAcquisition |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of anti dilution common stock pursuant to acquisition shares.
+ References
+ Details
Name: |
IVRN_IssuanceOfAntiDilutionCommonStockPursuantToAcquisitionShares |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares conversion of convertible notes payable to common stock.
+ References
+ Details
Name: |
IVRN_StockIssuedDuringPeriodSharesConversionOfConvertibleNotesPayableToCommonStock |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionConversion of warrants to common stock, value
+ References
+ Details
Name: |
IVRN_StockIssuedDuringPeriodSharesProceedsFromConversionOfWarrants |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares purchase agreement.
+ References
+ Details
Name: |
IVRN_StockIssuedDuringPeriodSharesPurchaseAgreement |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value conversion of convertible notes payable to common stock.
+ References
+ Details
Name: |
IVRN_StockIssuedDuringPeriodValueConversionOfConvertibleNotesPayableToCommonStock |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionConversion of warrants to common stock
+ References
+ Details
Name: |
IVRN_StockIssuedDuringPeriodValueProceedsFromConversionOfWarrants |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value purchase agreement.
+ References
+ Details
Name: |
IVRN_StockIssuedDuringPeriodValuePurchaseAgreement |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
IVRN_StockIssuedDuringPeriodValueReverseStockSplits |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
X |
- References
+ Details
Name: |
us-gaap_StatementOfStockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4
+ Details
Name: |
us-gaap_StockholdersEquityReverseStockSplit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Cash Flows from Operating Activities |
|
|
|
|
|
Net loss |
$ (495,775)
|
$ (2,279,444)
|
$ (1,765,515)
|
$ (8,806,492)
|
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
Depreciation and amortization |
|
|
4,869
|
10,086
|
|
Amortization of debt premium |
|
|
|
(499,100)
|
|
Inducement expense |
|
|
|
3,024,872
|
|
Share based compensation expense |
26,232
|
120,448
|
100,759
|
535,481
|
|
Loss on debt extinguishment |
|
|
|
2,196,100
|
|
Warrant expense |
|
|
|
334,238
|
|
Bad debt expense |
|
|
20,301
|
59,820
|
|
Loss on disposal of property and equipment |
|
|
|
9,610
|
|
Expense of acquired IP, R&D |
|
|
|
1,245,948
|
|
Day one loss on derivative liabilities |
|
|
1,527,239
|
|
|
Gain on convertible notes payable carried at fair value |
(14,792)
|
|
(1,329,629)
|
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
Accounts receivable |
|
|
|
(46,320)
|
|
Patient financing receivable, current portion |
|
|
3,659
|
11,789
|
|
Patient financing receivable, net of current portion |
|
|
4,383
|
41,037
|
|
Other assets |
|
|
|
(2,981)
|
|
Prepaid expenses and other assets |
|
|
(85,539)
|
(57,304)
|
|
Interest payable |
|
|
112,788
|
120,677
|
|
Interest payable, related parties |
|
|
163,948
|
144,593
|
|
Accounts payable |
|
|
287,558
|
235,876
|
|
Accrued liabilities |
|
|
89,491
|
58,830
|
|
Other current liabilities |
|
|
39,317
|
(24,739)
|
|
Deferred revenue |
|
|
|
(414,025)
|
|
Net Cash Used in Operating Activities |
|
|
(826,371)
|
(1,822,004)
|
|
Cash Flows from Investing Activities |
|
|
|
|
|
Proceeds from redemption of equity method investment |
|
|
869,249
|
|
|
Cash acquired in asset acquisition |
|
|
|
469
|
|
Net Cash Provided By Investing Activities |
|
|
869,249
|
469
|
|
Cash Flows from Financing Activities |
|
|
|
|
|
Proceeds from notes payable |
|
|
18,004
|
67,500
|
|
Proceeds from convertible notes payable |
|
|
150,000
|
437,500
|
|
Payment on PPP Loan |
|
|
|
(66,275)
|
|
Payment on note payable |
|
|
(12,000)
|
(57,500)
|
|
Proceeds from warrants exercised |
|
|
|
1,170,110
|
|
Proceeds from issuance of common stock |
|
|
|
225,001
|
|
Payment on debt financing costs |
|
|
|
(13,250)
|
|
Payments on convertible notes |
|
|
(115,000)
|
|
|
Proceeds from convertible notes carried at fair value, related parties |
|
|
275,000
|
|
|
Proceeds from convertible notes carried at fair value |
|
|
185,000
|
|
|
Net Cash Provided by Financing Activities |
|
|
501,004
|
1,763,086
|
|
Net Change in Cash |
|
|
543,882
|
(58,449)
|
|
Cash - Beginning of period |
|
|
|
95,172
|
$ 95,172
|
Cash - End of period |
$ 543,882
|
$ 36,723
|
543,882
|
36,723
|
|
Supplementary Cash Flow Information |
|
|
|
|
|
Cash paid for interest |
|
|
80,710
|
9,916
|
|
Non Cash Investing & Financing Activity |
|
|
|
|
|
Conversion of Series A Preferred Stock to Common Stock |
|
|
|
63,114
|
|
Issuance of warrants pursuant to inducement agreements |
|
|
|
2,993,872
|
|
Issuance of warrants for services rendered |
|
|
|
31,000
|
|
Issuance of warrants pursuant to securities purchase agreement |
|
|
|
334,238
|
|
Issuance of Common Stock pursuant to SkinDisc acquisition |
|
|
|
29,557
|
|
Conversion of convertible notes payable to Common Stock |
|
|
58,700
|
|
|
Issuance of warrants pursuant to convertible notes payable - related parties |
|
|
44,255
|
|
|
Issuance of warrants pursuant to convertible notes payable |
|
|
$ 29,617
|
|
|
X |
- DefinitionConversion of convertible notes payable to common stock.
+ References
+ Details
Name: |
IVRN_ConversionOfConvertibleNotesPayableToCommonStock |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
IVRN_ExpenseOfAcquiredIpRd |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
IVRN_GainOnConvertibleNotesCarriedAtFairValue |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIncrease decrease in patient financing receivable current.
+ References
+ Details
Name: |
IVRN_IncreaseDecreaseInPatientFinancingReceivableCurrent |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIncrease decrease in patient financing receivable, net of current portion.
+ References
+ Details
Name: |
IVRN_IncreaseDecreaseInPatientFinancingReceivableNetOfCurrentPortion |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
IVRN_IssuanceOfCommonStockPursuantToSkindiscAcquisition |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of warrants for services rendered.
+ References
+ Details
Name: |
IVRN_IssuanceOfWarrantsForServicesRendered |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of warrants pursuant to convertible notes payable.
+ References
+ Details
Name: |
IVRN_IssuanceOfWarrantsPursuantToConvertibleNotesPayable |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of warrants pursuant to inducement agreements.
+ References
+ Details
Name: |
IVRN_IssuanceOfWarrantsPursuantToInducementAgreements |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
IVRN_IssuanceOfWarrantsPursuantToSecuritiesPurchaseAgreement |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
IVRN_LossOnConvertibleNotesCarriedAtFairValue |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
IVRN_WarrantExpenses |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_AmortizationOfDebtDiscountPremium |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12
+ Details
Name: |
us-gaap_CashAcquiredFromAcquisition |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_DepreciationAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_GainLossOnSaleOfPropertyPlantEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionChange in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayableTrade |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInDeferredRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInInterestPayableNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in current liabilities classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherCurrentLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in noncurrent assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherNoncurrentAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2
+ Details
Name: |
us-gaap_InterestPaidNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NoncashInvestingAndFinancingItemsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_PaymentOfFinancingAndStockIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.
+ References
+ Details
Name: |
us-gaap_ProceedsFromRepaymentsOfNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-19
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479567/321-10-45-1
+ Details
Name: |
us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromWarrantExercises |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_ProvisionForDoubtfulAccounts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfOtherShortTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe fair value of stock issued in noncash financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_StockIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.23.3
DESCRIPTION OF THE COMPANY
|
9 Months Ended |
Sep. 30, 2023 |
Accounting Policies [Abstract] |
|
DESCRIPTION OF THE COMPANY |
Note
1 - Description of the Company
DESCRIPTION
OF THE COMPANY
On
July 5, 2023, Innoveren Scientific, Inc. (the “Company formerly known as H-Cyte, Inc.”) filed with the Secretary of State
of the State of Nevada a Certificate of Amendment to Second Amended and Restated Article of Incorporation to change the corporate name
from H-Cyte, Inc. to Innoveren Scientific, Inc. The name change and Company’s new symbol, IVRN, became effective with FINRA on
July 10, 2023.
Innoveren
Scientific, Inc (“the Company”) has evolved from focusing on treating chronic lung conditions after the closure of its lung
treatment clinics due to COVID-19. The Company is currently focusing on acquiring and developing early-stage companies or their technologies
in the areas of therapeutics, medical devices, and diagnostics. The goal is to develop these companies and incubate their technologies
to meaningful clinical inflection points.
On
June 3, 2022, the Company closed its clinic in Scottsdale, Arizona. The Company has closed all of its clinical operations in the autologous
infusion therapy business which delivered treatments for patients with chronic respiratory and pulmonary disorders. The Company will
continue to pursue Food and Drug Administration (“FDA”) approval of the device that was utilized in the treatment provided
at the clinics. The
Company has implemented the transition into a biologics and therapeutic device incubator company to bring new technologies to market.
The
consolidated results for Innoveren Scientific, Inc include the following wholly-owned subsidiaries: H-CYTE Management, LLC, Medovex Corp,
Cognitive Health Institute, LLC, and Lung Institute Tampa, LLC and the results include Lung Institute Dallas, LLC (“LI Dallas”),
Lung Institute Nashville, LLC (“LI Nashville”), Lung Institute Pittsburgh, LLC (“LI Pittsburgh”), and Lung Institute
Scottsdale, LLC (“LI Scottsdale”), as Variable Interest Entities (“VIEs”). Additionally, H-CYTE Management, LLC
was the operator and manager of the various Lung Health Institute (LHI) clinics: LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale.
The LI Dallas and LI Pittsburgh clinics did not reopen in 2020 after the temporary closure of all LI clinics due to COVID-19. During
the first quarter of 2022, the Company closed the LI Tampa and LI Nashville clinics. During the second quarter of 2022, the Company closed
the LI Scottsdale clinic. All LHI clinics are closed as of September 30, 2023. The Company leases a shared office space for its corporate
address as the Company’s employees continue to work remotely.
On
June 10, 2022, the Company amended (the “Amendment”) its Articles of Incorporation to effectuate a one-for-one thousand reverse
stock split (the “Reverse Split”) of its common stock. The Reverse Split was approved by FINRA on June 10, 2022 and effectuated
on June 13, 2022. Pursuant to the Amendment, the Company also reduced the authorized shares of common stock to 500,000,000. As a result
of the Reverse Split, as of September 30, 2023, the Company has 712,710 shares of common stock outstanding and 438,776,170 shares of Series
A Preferred Stock outstanding. As a result of the Reverse Stock Split, the Series A Preferred Stock conversion ratio is now one thousand
shares of Series A Preferred Stock converts into one share of common stock. Accordingly, the 438,776,170 outstanding shares of Series
A Preferred Stock are now convertible into an aggregate of 438,776 shares of common stock.
On
September 7, 2022, the Company acquired all of the membership interests, with common stock, of Jantibody LLC (“Jantibody”),
a Nevada limited liability company. Jantibody is focused on the development of novel proprietary immunotherapies targeted towards ovarian
cancer, pancreatic cancer, and mesothelioma (see Note 9).
On
December 22, 2022, the Company acquired all the membership interests, with common stock, in Scion Solutions, LLC (“Scion”).
Scion is a life sciences company that has developed a new technology in regenerative medicine specifically for limb salvage. Their proprietary
product SkinDisc (patent pending) is a combination of stem cells and several other molecular components that stimulate tissue regeneration
(see Note 9).
Effective
September 21, 2023, Corp (as “Seller”) entered into a Membership Interest and LLCA Rights Redemption Agreement (“Redemption
Agreement”) with JV for the redemption (purchase) by JV of all of Corp’s membership interests outstanding with the JV, as
well as the purchase all of the rights of Corp under the Amended and Restated Limited Liability Company Agreement (“LLCA”)
dated April 2, 2021 (the “LLCA Rights”), for a purchase price of approximately $869,000. In addition, Corp and JV have agreed
in principle for the assignment and transfer of the DenerveX IP (the “2023 IP Agreement”) by Corp to JV for the rights to
IP under the DenerveX device and technology and all trade names, patents, trademarks, and other IP under the Medovex and Medovex Corp
names, for a purchase price of approximately $56,000. The Company and Corp will no longer be a party to any rights or obligations associated
with the DenerveX IP or associated assets.
The
sale of membership interests in the JV and the IP under the DenerveX device and technology was recorded as deferral on gain on
redemption of equity method investment of approximately $869,000
and deferral on gain on sale of IP of approximately $56,000,
for the three and nine months ended September 30, 2023, on the accompanying consolidated statements of operations.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//275/tableOfContent
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent
+ Details
Name: |
us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
BASIS OF PRESENTATION
|
9 Months Ended |
Sep. 30, 2023 |
Accounting Policies [Abstract] |
|
BASIS OF PRESENTATION |
Note
2 – Basis of presentation
BASIS
OF PRESENTATION
The
accompanying interim consolidated financial statements have been prepared based upon U.S. Securities and Exchange Commission rules that
permit reduced disclosure for interim periods. Therefore, they do not include all information and footnote disclosures necessary for
a complete presentation of the Company’s financial position, results of operations and cash flows, in conformity with generally
accepted accounting principles. The Company filed audited consolidated financial statements as of and for the fiscal years ended December
31, 2022 and 2021, which included all information and notes necessary for such complete presentation in conjunction with its 2022 Annual
Report on Form 10-K.
Certain
prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on
the reported results of operations.
The
results of operations for the interim period ended September 30, 2023, are not necessarily indicative of the results to be expected for
any future period or the entire fiscal year. These interim consolidated financial statements should be read in conjunction with the audited
consolidated financial statements for the year ended December 31, 2022, which are contained in the Company’s 2022 Annual Report
on Form 10-K. For further discussion refer to Note 2 – “Basis Of Presentation And Summary of Significant Accounting Policies”
to the consolidated financial statements and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations – Critical Accounting Policies and Estimates” in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2022.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
+ Details
Name: |
us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
LIQUIDITY, GOING CONCERN AND SOURCES OF LIQUIDITY
|
9 Months Ended |
Sep. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
LIQUIDITY, GOING CONCERN AND SOURCES OF LIQUIDITY |
Note
3 – Liquidity, Going Concern and Sources of Liquidity
LIQUIDITY,
GOING CONCERN AND SOURCES OF LIQUIDITY
The
Company incurred net losses of approximately $496,000
and $1,766,000 for
the three and nine months ended September 30, 2023. The Company has historically incurred losses from operations and expects to continue
to generate negative cash flows as it implements its plan around acquiring and developing early-stage companies or their technologies
in the areas of therapeutics, medical devices, and diagnostics. The consolidated financial statements are prepared using accounting principles
generally accepted in the United States (“U.S. GAAP”) as applicable to a going concern.
The
Company had cash on hand of approximately $544,000 as of September 30, 2023 and approximately $150,000, as of November 9, 2023. The Company’s
cash is insufficient to fund its operations over the next year and the Company is currently working to obtain additional debt or equity
financing to help support short-term working capital needs.
There
can be no assurance that the Company will be able to raise additional funds or that the terms and conditions of any future financings
will be workable or acceptable to the Company or its shareholders. If the Company is unable to fund its operations from existing cash
on hand, operating cash flows, additional borrowings, or raising equity capital, the Company may be forced to cease operations. The consolidated
financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
On
February 24, 2023, the Company and certain investors entered into Securities Purchase Agreements (the “SPA”), whereby the
Company sold and issued to the certain investors an aggregate of three hundred thousand dollars ($300,000) of the Company’s convertible
promissory notes (the “Note” or “Notes”), which are convertible into the Company’s Common Stock, $0.001
par value (“Common Stock”). In connection with the aforementioned Notes, the Company also issued to the investors a warrant
to purchase (the “Purchase Warrant”) a certain number of shares of Common Stock, which are equal to 20% of the shares of
Common Stock issuable upon conversion of the Note, based on a price of $2.00 per share. These warrants have a term of five (5) years,
with an exercise price of $2.00 per share. Unless the Company chooses to terminate earlier, the offering and the sale of the Notes shall
terminate on the sooner of the sale of the maximum offering amount or April 30, 2023. However, the Company extended this offering to June 30, 2023, per terms of agreement.
The
Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering. Interest on
the Note shall accrue on the unpaid principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated
on an actual/365-day basis. In the event that the Company moves forward with a qualified offering, as referenced in the SPA, the Holder
may convert the unpaid and outstanding principal plus any accrued and unpaid interest into shares of the Company’s Common Stock
at a conversion price equal to a 20% discount to the offering price.
Further,
in connection with the SPA, the Company also issued Common Stock Purchase Warrants to certain investors, which are exercisable on or
prior to the close of business on the five (5) year anniversary of the initial issue date, to purchase up to a certain amount of shares
of Common Stock, with 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory Note purchased by the
Holder, pursuant to the SPA between the Holder and the Company, dated February 24, 2023. The Company issued Warrants to purchase an aggregate
of 30,000 shares of Common Stock. The exercise price per share of the Common Stock under these Warrants is $2.00.
On
February 28, 2023, the Company entered into a securities purchase agreement for a total of $150,000 with an accredited investor. The
note issued is convertible into common stock at a 65% discount to the lowest trading price in the 20-day period prior to conversion.
The note bears interest at 10% and is due one year from issuance. For the first six months, the Company has the right to prepay the note
at a premium of between 25% and 40% depending on when it is repaid.
On
March 27, 2023, the Company and three related party investors entered into Securities Purchase Agreements (the “SPA”), whereby,
the Company sold and issued to the certain investors, an aggregate of one hundred twenty five thousand dollars ($125,000) of the Company’s
convertible promissory notes (the “Note” or “Notes”), which are convertible into the Company’s Common Stock,
$0.001 par value (“Common Stock”). On April 12, 2023, the Company and an additional investor entered into the SPA, whereby,
the Company sold and issued an aggregate of thirty five thousand dollars ($35,000) of the Company’s Notes. In connection with the
aforementioned Notes, the Company also issued to the investors a warrant to purchase (the “Purchase Warrant”) a certain number
of shares of Common Stock, which are equal to 20% of the shares of Common Stock issuable upon conversion of the Note, based on a price
of $2.00 per share. These warrants have a term of five (5) years, with an exercise price of $2.00 per share. Unless the Company chooses
to terminate earlier, the offering and the sale of the Notes shall terminate on the sooner of the sale of the maximum offering amount
or April 30, 2023. However, the Company extended this offering to June 30, 2023, per terms of agreement.
The
March 27, 2023 Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified
offering. The April 12, 2023 Note has a maturity date 60 days from issuance. Interest on the Note shall accrue on the unpaid
principal balance of this Note at the rate of eight percent (8%) per annum and will be calculated on an actual/365-day basis. The
Company defaulted on this note on June 12, 2023 which triggered an increase in interest from 8% to 12%. In the event that the
Company moves forward with a qualified offering, as referenced in the SPA, the Holder may convert the unpaid and outstanding
principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock at a conversion price equal to a 20%
discount to the offering price.
Further,
in connection with the SPA, the Company also issued Common Stock Purchase Warrants to certain investors, which are exercisable on or
prior to the close of business on the five (5) year anniversary of the initial issue date, to purchase up to a certain amount of shares
of Common Stock, with 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory Note purchased by the
Holder, pursuant to the SPA between the Holder and the Company. The Company issued Warrants to purchase an aggregate of 12,500 shares
of Common Stock. The exercise price per share of the Common Stock under these Warrants is $2.00.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205-40/tableOfContent
+ Details
Name: |
us-gaap_SubstantialDoubtAboutGoingConcernTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
FAIR VALUE OF FINANCIAL INSTRUMENTS
|
9 Months Ended |
Sep. 30, 2023 |
Fair Value Disclosures [Abstract] |
|
FAIR VALUE OF FINANCIAL INSTRUMENTS |
Note
4 – Fair Value of Financial Instruments
FAIR VALUE OF FINANCIAL INSTRUMENTS
The
Company measures certain financial instruments and certain financial instruments with related parties at fair value on a recurring basis.
The Company elected the fair value option of accounting for certain debt instruments. Under the fair value option, the financial instrument
is initially measured at its issue date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis
each reporting period with the resulting fair value adjustment recognized as other income (expense) in the consolidated statement of
operations. As of September 30, 2023, the fair value of these instruments was as follows:
SCHEDULE OF FAIR VALUE INSTRUMENT
| |
Total | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
| |
| | |
| | |
| | |
| |
Assets: | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Liabilities: | |
| | | |
| | | |
| | | |
| | |
Convertible Notes at fair value | |
$ | 583,738 | | |
$ | - | | |
$ | - | | |
$ | 583,738 | |
The
following is a reconciliation of the beginning and ending balances for the Convertible Notes measured at fair value on a recurring basis
using significant unobservable inputs (Level 3) during the nine months ended September 30, 2023:
SCHEDULE OF CONVERTIBLE NOTE MEASURED AT FAIR VALUE
| |
| | |
Balance at December 31, 2022 | |
$ | — | |
Fair value of Convertible Notes issued | |
| (1,913,367 | ) |
Gain on change in fair value of Convertible Notes | |
| 1,329,629 | |
| |
| | |
Balance at September 30, 2023 | |
$ | (583,738 | ) |
The
estimated fair values reported utilize the Company’s common stock price along with certain Level 3 inputs, as discussed below,
in the development of Monte Carlo simulation models. The estimated fair values are subjective and are affected by changes in inputs to
the valuation models /analyses, including the Company’s common stock price, the Company’s dividend yield, risk-free rates
based on U.S. Treasury security yields, and certain other Level-3 inputs including, assumptions regarding the estimated volatility in
the value of the Company’s common stock price, the probability of a Qualified Offering, the estimated price of a Qualified Offering,
and credit-risk adjusted discount rates. Changes in these assumptions can materially affect the estimated fair values.
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_FairValueDisclosuresTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
RELATED PARTY TRANSACTIONS
|
9 Months Ended |
Sep. 30, 2023 |
Related Party Transactions [Abstract] |
|
RELATED PARTY TRANSACTIONS |
Note
5 – Related Party Transactions
RELATED
PARTY TRANSACTIONS
Officers
and Board Members and Related Expenses
On
January 12, 2021, Mr. Raymond Monteleone was appointed as Chairman of the Board, Audit Committee Chair, and Compensation Committee Chair.
There are understandings between the Company and Mr. Monteleone for him to receive $7,500 per month to serve on the Board of Directors
and an additional $2,500 per quarter to serve as Chairman of the Board, Audit Committee Chair, and Compensation Committee Chair. Effective
July 1, 2022, due to lack of working capital, Mr. Monteleone receives $3,750 per month to serve on the Board of Directors and to serve
as Chairman of the Board, Audit Committee Chair, and Compensation Committee Chair. For the three months and nine months ended September
30, 2023 the Company expensed $11,250 and $33,750, respectively, for board of director fees to Mr. Monteleone. For the three months and
nine months ended September 30, 2022 the Company expensed $13,750 and $63,750, respectively, for board of director fees to Mr. Monteleone.
Due to lack of financial resources, the Company has been unable to pay Mr. Monteleone for his services totaling $57,500, which is included
in accounts payable as of September 30, 2023.
On
January 12, 2021, Mr. William Horne stepped down as Chairman of the Board. Mr. Horne will remain a member of the Board. Mr. Horne agreed
to continue to defer the $108,000 in base salary deferred by him in 2018 until such time as there is a positive cash flow to meet the
Company’s financial obligations and then the Company and Mr. Horne will work together in good faith to negotiate a payment plan
for such deferred salary. Effective December 1, 2021, Mr. Horne will receive $5,000 per month to serve on the Board of Directors. Effective
July 1, 2022, due to lack of working capital, Mr. Horne receives $2,500 per month to serve on the Board of Directors. For the three months
and nine months ended September 30, 2023, the Company expensed approximately $7,500 and $22,500, respectively, in compensation and board
of director fees to Mr. Horne. For the three months and nine months ended September 30, 2022 the Company expensed $7,500 and $42,500
respectively, for board of director fees to Mr. Horne. Due to lack of financial resources, the Company has been unable to pay Mr. Horne
for his services totaling $37,500, which is included in accounts payable as of September 30, 2023.
Mr.
Richard Rosenblum entered into an oral agreement with the Company effective January 17, 2022, in which Mr. Rosenblum will receive $5,000
per month to serve on the Board of Directors. Effective July 1, 2022, due to lack of working capital, Mr. Rosenblum receives $2,500 per
month to serve on the Board of Directors. For the three and nine months ended September 30, 2023 the Company expensed $7,500 and $22,500,
for board of director fees to Mr. Rosenblum. For the three months and nine months ended September 30, 2022 the Company expensed $7,500
and $35,000, respectively, for board of director fees to Mr. Rosenblum. Due to lack of financial resources, the Company has been unable
to pay Mr. Rosenblum for his services totaling $37,500, which is included in accounts payable as of September 30, 2023.
Mr.
Matthew Anderer entered into an oral agreement with the Company effective January 17, 2022, in which Mr. Anderer will receive $5,000
per month to serve on the Board of Directors. Effective July 1, 2022, due to lack of working capital, Mr. Anderer receives $2,500 per
month to serve on the Board of Directors. For the three month and nine months ended September 30, 2023 the Company expensed $7,500 and
$22,500, respectively, for board of director fees to Mr. Anderer. For the three months and nine months ended September 30, 2022 the Company
expensed $7,500 and $35,000, respectively, for board of director fees to Mr. Anderer. Due to lack of financial resources, the Company
has been unable to pay Mr. Anderer for his services totaling $37,500, which is included in accounts payable as of September 30, 2023.
Debt
and Other Obligations
Convertible
Notes Payable
On
April 1, 2021, the Company, entered into a Secured Convertible Note Purchase Agreement (the “April 2021 Note Purchase
Agreement”) with five (5) related party investors (the “Holders”). Pursuant to the terms of the April 2021 Note
Purchase Agreement, the Company sold promissory notes in the aggregate principal amount of $2,575,000 maturing
on June
17, 2022 with an annual interest rate of 8%.
The Notes are convertible into shares of Common Stock at a discount of 20%
to the price paid for such New Securities in the next round of financing that meets the definition of Qualified Financing as defined
in the April 2021 Note Purchase Agreement. The Notes are secured by the assets of the Company under a security agreement with the
Holders. The lead investor of the April 2021 Note Purchase Agreement, FWHC Bridge, LLC, advanced $1,500,000 of
the total amount to the Company. FWHC Bridge, LLC is an affiliated entity of FWHC, LLC, which is a principal stockholder and related
party of the Company. An additional affiliate of FWHC, LLC provided an additional $25,000 as
part of the April 2021 Note Purchase Agreement. The Company entered into an agreement with the noteholders to extend the
maturity of the outstanding notes until July 31, 2024.
On
October 14, 2021, the Company entered into the Second Closing Bring Down Agreement (the “October 2021 Note Purchase Agreement”)
whereby the five (5) related party investors who had entered into the April 2021 Note Purchase Agreement purchased new notes in the Company
in the aggregate principal amount of $750,000. The Notes are due and payable on June 17, 2022 and bear interest at an annual rate of
8%. The Notes are convertible into shares of Common Stock at a discount of 20% to the price paid for such New Securities in the next
financing that meets the definition of a Qualified Financing as defined in the Note Purchase Agreement. The Notes are secured by all
of the assets of the Company under a security agreement with the Holders. The lead investor of the October 2021 Note Purchase Agreement,
FWHC Bridge, LLC, advanced $437,000 of the total amount to the Company. FWHC Bridge, LLC is an affiliated entity of FWHC, LLC, which
is a principal stockholder and related party of the Company. An additional affiliate of FWHC, LLC provided an additional $7,000 as part
of the October 2021 Note Purchase Agreement. The Company entered into an agreement with the noteholders to extend the maturity of the outstanding notes until
July 31, 2024.
On
February 22, 2022, the Company entered into a Debt Conversion Agreement (the “Amendment Agreement”) which i) provided for
an additional round of convertible debt financing (“Tranche 2 Notes”) of up to $500,000 and ii) amended the conversion price
on the convertible notes issued April 1, 2021 and October 8, 2021 (“Tranche 1 Notes”) from 80% of the price paid in a Qualified
Financing (proceeds of at least $15 million), to the lesser of (x) $0.002 and (y) the price paid in a Qualified Financing (proceeds of
at least $10 million). The Amendment Agreement also provides the following Milestone Payments:
|
1) |
$1,000,000
after filing a premarket notification pursuant to Section 510(k) of the Food, Drug and Cosmetic Act, of its intent to market its
PRP cellular therapy |
|
2) |
Following
the closing of a Qualified Financing, 25% of all proceeds raised in excess of $10 million (not to exceed $1 million) |
The
Milestone Payments are not to exceed $2 million, and the Amendment Agreement also specifies that a Qualified Financing will not occur
prior to the closing of the acquisition of Jantibody, LLC.
The
Company evaluated the Amendment Agreement under ASC 470-50, “Debt – Modification and Extinguishment”, and concluded
that probability of having to pay a Milestone payment was minimal and the change in the fair value of the conversion feature was not
material. The Amendment did not cause a material change in cash flows so extinguishment accounting was not applicable.
On
April 29, 2022, the Company entered into an Amended and Restated Note Conversion Agreement (the “Note Conversion Agreement”)
with certain holders of its Tranche 1 Notes (i) providing for a conversion price equal to the lesser of (x) $0.002 per share (pre-split)
and (y) the price per share paid by the investors in a Qualified Financing for such New Securities purchased for cash and not through
conversion of Notes (as such terms are defined in the Note Conversion Agreement), in each case subject to appropriate adjustment in the
event of any stock dividend, stock split, combination or other similar recapitalization, (ii) automatic conversion upon the occurrence
of a Qualified Financing, and (iii) amendment of the maturity date from March 31, 2022 to June 17, 2022 (the “New Notes”).
Upon the effective date of the Company’s 1,000-1 reverse split, the conversion price adjusted to the lesser of (a) the price in
the Qualified Financing or (b) $2.00 per share. The New Notes also provided the investors with Royalty Payments equal to 15% of all net
sales generated by the Company with respect to the sale of products or services associated with the 510(k) Notification related to the
Company’s autologous cellular therapy (PRP-PBMC) to treat chronic lung disorder. The Royalty Payments are in lieu of the Milestone
Payments but are perpetual and there is no limit to the aggregate amount of Royalty Payments that may be paid. It is the intent of the Company to pay the royalty payments even though the required conditions were not met. The
Company entered into an agreement with the noteholders to extend the maturity of the outstanding notes until July 31, 2024.
Due
to changes in key provisions of the Tranche 1 Notes, the Company analyzed the before and after cash flows between the (i) fair value
of the New Notes and (ii) reacquisition price of the Tranche 1 Notes prior to the (A) change in the maturity date from March 31, 2022
to June 17, 2022, (B) change in the conversion price to the lesser of (x) $2.00 and (y) the price paid in a Qualified Financing, and
(C) the fair value of the potential Royalty Payments, to determine whether these changes resulted in a modification or extinguishment
of the Tranche 1 Notes. The Company entered into an agreement with the noteholders to extend the maturity of the outstanding notes until
July 31, 2024
The
Company used a discounted cash flow method with Monte Carlo Simulation to value the Royalty Payments. Future Royalty Payments were estimated
based on management’s best estimate of future cash flows under various scenarios which were discounted to present value using a
risk-adjusted rate of 70%.
Based
on the before and after cash flows of each note, the change was considered significantly different. Consequently, the New Notes were
accounted for as a debt extinguishment of the Tranche 1 Notes and a new debt issuance of the New Notes. The Company recorded a $2.2 million
loss upon extinguishment of debt in the year ended December 31, 2022, which was comprised of the following:
SCHEDULE OF LOSS UPON EXTINGUISHMENT
|
|
|
|
|
Carrying
value of Tranche 1 Notes |
|
$ |
3,580,738 |
|
Less:
Fair value of New Notes |
|
|
(4,079,838 |
) |
Less:
Fair value of Royalty Payments |
|
|
(1,697,000 |
) |
Loss
on Extinguishment |
|
$ |
(2,196,100 |
) |
The
Note Conversion Agreement also provided for the consummation of a Tranche 2 Financing (the “Tranche 2 Notes”) subject to
(i) the aggregate principal amount of indebtedness represented by the Tranche 2 Notes being capped at $500,000 and (ii) Tranche 2 Notes’
being an unsecured obligation of the Company and expressly subordinate in all respects to all indebtedness of the Company under the Notes
and including language in which the holders of such Tranche 2 Notes acknowledge, confirm and agree to the foregoing subordination terms.
Pursuant to the terms of the Note Conversion Agreement, the Investors have agreed not to sell any capital stock of the Company for a
period of 12 months following the Qualified Financing. For the year ended December 31, 2022, approximately $499,000 of amortization of
the debt premium is included in interest income. The Company entered into an agreement with the noteholders to extend the maturity of
the outstanding notes until July 31, 2024.
On
February 24, 2023, the Company and certain investors entered into Securities Purchase Agreements (the “SPA”), whereby the
Company sold and issued to the certain investors an aggregate of three hundred thousand dollars ($300,000) of the Company’s convertible
promissory notes (the “Note” or “Notes”), which are convertible into the Company’s Common Stock, $0.001
par value (“Common Stock”). In connection with the aforementioned Notes, the Company also issued to the investors a warrant
to purchase (the “Purchase Warrant”) a certain number of shares of Common Stock, which are equal to 20% of the shares of
Common Stock issuable upon conversion of the Note, based on a price of $2.00 per share. These warrants have a term of five (5) years,
with an exercise price of $2.00 per share. Unless the Company chooses to terminate earlier, the offering and the sale of the Notes shall
terminate on the sooner of the sale of the maximum offering amount or April 30, 2023. However, the Company extended this offering to June 30, 2023 per terms of agreement.
The
Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering. Interest on
the Note shall accrue on the unpaid principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated
on an actual/365-day basis. In the event that the Company moves forward with a qualified offering, as referenced in the SPA, the Holder
may convert the unpaid and outstanding principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock
at a conversion price equal to a 20% discount to the offering price.
Further,
in connection with the February 2023 SPA, the Company also issued Common Stock Purchase Warrants to certain investors, which are exercisable
on or prior to the close of business on the five (5) year anniversary of the initial issue date, to purchase up to a certain amount of
shares of Common Stock, with 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory Note purchased
by the Holder, pursuant to the SPA between the Holder and the Company, dated February 24, 2023. The Company issued Warrants to purchase
an aggregate of 30,000 shares of Common Stock. The exercise price per share of the Common Stock under these Warrants is $2.00.
On
March 27, 2023, the Company and three related party investors entered into Securities Purchase Agreements (the “SPA”), whereby,
the Company sold and issued to the certain investors, an aggregate of one hundred twenty five thousand dollars ($125,000) of the Company’s
convertible promissory notes (the “Note” or “Notes”), which are convertible into the Company’s Common Stock,
$0.001 par value (“Common Stock”).
On
April 12, 2023, the Company and an additional investor entered into the SPA, whereby the Company sold and issued thirty five thousand
dollars ($35,000) of the Company’s Notes. In connection with the aforementioned Notes, the Company also issued to the investors
a warrant to purchase (the “Purchase Warrant”) a certain number of shares of Common Stock, which are equal to 20% of the
shares of Common Stock issuable upon conversion of the Note, based on a price of $2.00 per share. These warrants have a term of five
(5) years, with an exercise price of $2.00 per share. Unless the Company chooses to terminate earlier, the offering and the sale of the
Notes shall terminate on the sooner of the sale of the maximum offering amount or April 30, 2023. However, the Company extended this
offering to June 30, 2023 per terms of the agreement.
The
March 27, 2023, Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified
offering. The April 12, 2023, Note has a maturity date 60 days from issuance. Interest on the Note shall accrue on the unpaid
principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated on an actual/365-day basis. The
Company defaulted on this note on June 12, 2023 which triggered an increase in interest from 8% to 12%. In the event that the
Company moves forward with a qualified offering, as referenced in the SPA, the Holder may convert the unpaid and outstanding
principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock at a conversion price equal to a 20%
discount to the offering price.
Further,
in connection with the March 2023 and April 2023 SPA, the Company also issued Common Stock Purchase Warrants to certain investors, which
are exercisable on or prior to the close of business on the five (5) year anniversary of the initial issue date, to purchase up to a
certain amount of shares of Common Stock, with 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory
Note purchased by the Holder, pursuant to the SPA between the Holder and the Company. The Company issued Warrants to purchase an aggregate
of 12,500 shares of Common Stock. The exercise price per share of the Common Stock under these Warrants is $2.00.
We
evaluated the February 2023, March 2023, and April 2023 SPA in accordance with ASC Topic 815, Derivatives and Hedging, and determined
that they contained a variable share settlement feature tied to the price of a future financing which functions as a redemption option.
FASB ASC 825-10-25 allows the Company to elect the fair value option for recording financial instruments when they are initially recognized
or if there is an event that requires re-measurement of the instruments at fair value, such as a significant modification of the debt.
The Company elected to initially and subsequently measure the Convertible Notes in their entirety at fair value, with changes in fair
value recognized in earnings. Management believes the fair value option best reflects the underlying economics of these Convertible Notes.
Because
these Convertible Notes are carried in their entirety at fair value, the value of the contingent conversion feature is embodied in that
fair value. The Company estimates the fair value based on a probability weighted analysis which considers the present value of the cash
flows using a credit risk adjusted rate enhanced by the conversion feature valued using a Monte Carlo model. This method was considered
by management to be the most appropriate method of encompassing the credit risk and exercise behavior that a market participant would
consider when valuing a hybrid financial instrument. Inputs used to value the Convertible Notes as of September 30, 2023 included, (i)
present value of future cash flows using a credit risk adjusted rate of 20.0%, (ii) remaining term of approximately five months, (iii)
volatility of 322%, (iv) closing stock price on the valuation date, and (v) the conversion price based on the estimated price of a Qualified
Offering, less a 20% discount, in accordance with the terms of the Note. Changes due to instrument-specific credit risk are recorded
in Other Comprehensive Income with all other changes in value being recorded in net income.
At
inception, the fair value of the Convertible Notes using the fair value option was $1,913,367, and the fair value of the related Warrants
issued was approximately $73,872. Because the fair value of the hybrid instrument was in excess of the proceeds received of $460,000, the Company recorded
a day one loss on convertible notes of $1,521,768. On September 30, 2023, the debt instruments were revalued at approximately $584,000
resulting in a gain of approximately $1,330,000 for the nine months ended September 30, 2023.
Other
Obligations
During
the year ending December 31, 2022, Michael Yurkowsky, CEO, advanced the Company approximately $40,000 as a non-interest-bearing note
with no established repayment terms. During the nine months ended September 30, 2023, approximately $13,000 in net additional advances
were made. The balance owed is approximately $53,000 as of September 30, 2023.
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//850/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
EQUITY TRANSACTIONS
|
9 Months Ended |
Sep. 30, 2023 |
Equity [Abstract] |
|
EQUITY TRANSACTIONS |
Note
6 - Equity Transactions
EQUITY TRANSACTIONS
In
January 2022, the Company offered certain warrant holders the opportunity to receive an additional warrant to purchase the Company’s
Common Stock at $14.00 per share, for a period of five (5) years from issuance for the exercise by March 31, 2022 of each existing warrant
originally issued in April 2020. As of December 31, 2022, the Company had eleven warrant holders exercise an aggregate of 83,579 warrants
at $14.00 per share resulting in cash proceeds of approximately $1,170,000 to the Company.
On
June 10, 2022, the Company amended (the “Amendment”) its Articles of Incorporation to effectuate a one-for-one thousand reverse
stock split (the “Reverse Split”) of its common stock. The Reverse Split was approved by FINRA on June 10, 2022, and effectuated
on June 13, 2022. Pursuant to the Amendment, the Company also reduced the authorized shares of common stock to 500,000,000. As a result
of the Reverse Split, the Company had approximately 618,506 shares of common stock outstanding and 438,776,170 shares of Series A Preferred
Stock outstanding as of December 31, 2022. As a result of the Reverse Stock Split, the Series A Preferred Stock is convertible at a ratio
of one thousand shares of Series A Preferred Stock into one share of common stock. Accordingly, the 438,776,170 outstanding shares of
Series A Preferred Stock are now convertible into an aggregate of 438,776 shares of common stock.
On
September 29, 2022, the Company entered into a securities purchase agreement with two related party accredited investors for the sale
of shares of Common Stock and warrants (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company sold an
aggregate of 112,500 shares of common stock and warrants to purchase 56,250 shares of Common Stock exercisable at $2.50 per share for
gross proceeds of approximately $225,000.
On
November 14, 2022, pursuant to the Purchase Agreement, the Company sold an aggregate of 15,000 shares of common stock and warrants to
purchase 7,250 shares of Common Stock exercisable at $2.50 per share for gross proceeds of $30,000.
On
March 17, 2023, the Company issued 9,615 shares of Common Stock to a convertible noteholder who, at the request of the noteholder, converted
$10,000 of convertible notes into the Company’s Common Stock.
On May 23, 2023, the Company issued 17,351 shares
of Common Stock to a convertible noteholder who, at the request of the noteholder, converted $14,000 of convertible notes into the Company’s
Common Stock.
On June 8, 2023, the Company issued 15,873 shares of Common Stock to a
convertible noteholder who, at the request of the noteholder, converted $20,000 of convertible notes into the Company’s Common Stock.
On July 10, 2023, the Company issued 21,530 shares
of Common Stock to a convertible noteholder who, at the request of the noteholder, converted $6,000 of convertible notes into the Company’s
Common Stock.
On July 20, 2023, the Company issued 29,834 shares
of Common Stock to a convertible noteholder who, at the request of the noteholder, converted $8,700 of convertible notes into the Company’s
Common Stock.
The
following table summarizes the Company’s common and preferred stock outstanding by class. The number of common stock shares has
been adjusted to reflect a one-for-one thousand reverse stock split that became effective on June 13, 2022.
SCHEDULE OF COMMON AND PREFERRED STOCK OUTSTANDING
| |
September 30,
2023 | | |
December 31,
2022 | |
Common Stock | |
| 712,710 | | |
| 618,506 | |
Series A Preferred Stock | |
| 438,776,170 | | |
| 438,776,170 | |
Series
A Preferred Stock
During
the nine months ended September 30, 2023, no shares of Series A Preferred Stock were converted to Common Stock.
Voting
Rights
Holders
of Series A Preferred Stock (“Series A Holders”) have the right to receive notice of any meeting of holders of common stock
and to vote upon any matter submitted to a vote of the holders of common stock. Each Series A Holder shall vote on each matter on an
as converted basis submitted to them with the holders of common stock.
Conversion
Series
A Preferred Stock converts to common stock at a 1000:1 ratio immediately upon request of the Series A Holder.
Liquidation,
Dissolution, or Winding Up
In
the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A Preferred
Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders and,
in the event of a Deemed Liquidation Event (as defined in the Second Amended and Restated Articles of Incorporation), the holders of
shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in
such Deemed Liquidation Event or out of the consideration received by the Company for such Deemed Liquidation Event (net of any retained
liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board of Directors of the Company),
together with any other assets of the Company available for distribution to its stockholders, all to the extent permitted by Nevada
law governing distributions to stockholders, as applicable, before any payment shall be made to the holders of Common Stock by reason
of their ownership thereof, an amount per share equal to one (1) times the Series A Original Issue Price for such share of Series A Preferred
Stock, plus any Series A Accruing Dividends accrued but unpaid thereon, whether or not declared. If upon any such liquidation, dissolution
or winding up of the Company or Deemed Liquidation Event, the assets of the Company available for distribution to its stockholders shall
be insufficient to pay the holders of shares of Series A Preferred Stock the full amount to which they shall be entitled under subsection
2.1 of the Second Amended and Restated Articles of Incorporation, the holders of shares of Series A Preferred Stock shall share ratably
in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable
in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.
In
the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment in full of all Series
A Liquidation Amounts (as defined in the Second Amended and Restated Articles of Incorporation) required to be paid to the holders of
shares of Series A Preferred Stock the remaining assets of the Company available for distribution to its stockholders or, in the case
of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Series A Preferred Stock shall be distributed
among the holders of the shares of Series A Preferred Stock and Common Stock, pro rata based on the number of shares held by each such
holder, treating for this purpose all shares of Series A Preferred Stock as if they had been converted to Common Stock pursuant to the
terms of the Second Amended and Restated Articles of Incorporation immediately prior to such liquidation, dissolution or winding up of
the Company.
Share-Based
Compensation Plan
The
Company utilizes the Black-Scholes valuation method to recognize share-based compensation expense over the vesting period. The expected
life represents the period that the share-based compensation awards are expected to be outstanding.
Stock
Option Activity
On
April 1, 2021, the Board of Directors of the Company approved and granted certain directors and officers of the Company an aggregate
of 54,750 stock options of which 4,750 were immediately vested on the date of grant. Each option granted has an exercise price of $70.00
per share and an expiration date of ten years from the date of grant. These options are not included in the Company’s current stock
option plan as they were granted outside of the plan.
On
June 10, 2022, the Company amended its Articles of Incorporation to effectuate a one-for-one thousand reverse stock split of its common
stock. The Reverse Split was approved by FINRA on June 10, 2022 and effectuated on June 13, 2022.
As
of September 30, 2023, 29,385 options were outstanding and 24,843 were vested. As of September 30, 2022, 29,635 options were outstanding
and 20,510 were vested. For the three and nine months ended September 30, 2023, the Company recognized an expense related to stock options
of approximately $26,000 and $101,000, respectively, which is included in share-based compensation. For the three months and nine months
ended September 30, 2022, the Company recognized approximately $61,000 and $246,000 in stock-based compensation expense, respectively,
which is included in share-based compensation. As of September 30, 2023, the Company has approximately $55,000 of unrecognized compensation
costs related to non-vested stock options, which is expected to be recognized over a weighted average period of approximately 1.35 years.
Inputs
used in the valuation models are as follows:
SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS
2021 Grants |
Option value | |
$ | 54.00 | | |
| to | | |
$ | 56.00 | |
Risk Free Rate | |
| 0.90 | % | |
| to | | |
| 1.37 | % |
Expected Dividend- yield | |
| - | | |
| to | | |
| - | |
Expected Volatility | |
| 173.99 | % | |
| to | | |
| 176.04 | % |
Expected term (years) | |
| 5 | | |
| to | | |
| 7 | |
The
following is a summary of stock option activity for the nine months ended September 30, 2022 and 2023:
SUMMARY OF STOCK OPTION ACTIVITY
| |
Shares | | |
Weighted Average Exercise Price | | |
Weighted Average
Remaining Term (Years) | |
Outstanding at December 31, 2021 | |
| 29,635 | | |
$ | 86.48 | | |
| 9.20 | |
Granted | |
| - | | |
| - | | |
| - | |
Exercised | |
| - | | |
| - | | |
| - | |
Outstanding at September 30, 2022 | |
| 29,635 | | |
$ | 86.48 | | |
| 8.71 | |
Exercisable at September 30, 2022 | |
| 20,510 | | |
$ | 93.81 | | |
| 8.44 | |
| |
| | | |
| | | |
| | |
Outstanding at December 31, 2022 | |
| 29,385 | | |
$ | 83.81 | | |
| 8.22 | |
Granted | |
| - | | |
| - | | |
| - | |
Exercised | |
| - | | |
| - | | |
| - | |
Outstanding at September 30, 2023 | |
| 29,385 | | |
$ | 83.81 | | |
| 7.48 | |
Exercisable at September 30, 2023 | |
| 24,843 | | |
$ | 86.33 | | |
| 7.47 | |
The
following is a summary of the Company’s non-vested shares for the nine months ended September 30, 2023:
SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED
| |
Shares | | |
Weighted Average Grant Date Fair Value | |
Non-vested at December 31, 2022 | |
| 7,979 | | |
$ | 55.70 | |
Vested | |
| (3,437 | ) | |
| 55.46 | |
Non-vested at September 30, 2023 | |
| 4,542 | | |
$ | 69.88 | |
Net
Loss Per Share
Basic
loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per
share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using
the treasury stock and if-converted methods, as applicable. Any potentially dilutive securities are antidilutive due to the Company’s
net losses.
The
Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been
antidilutive:
SCHEDULE OF ANTI-DILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE
| |
2023 | | |
2022 | |
| |
For the Nine Months Ended September 30, | |
| |
2023 | | |
2022 | |
Warrants to purchase common stock (in the money) | |
| - | | |
| 385,033 | |
Series A Preferred Stock convertible to common stock | |
| 438,776 | | |
| 515,874 | |
Total | |
| 438,776 | | |
| 900,907 | |
Excluded
from the above table are 493,180 warrants and 29,385 stock options for the nine months ended September 30, 2023 and 384,788 warrants and
29,635 stock options for the nine months ended September 30, 2022 as they are out of the money (exercise price greater than the stock
price). Inclusion of such would be anti-dilutive. As a result of the Reverse Stock Split, the Series A Preferred Stock is convertible
at a ratio of one thousand shares of Series A Preferred Stock into one share of common stock. Accordingly, the 438,776,170 outstanding
shares of Series A Preferred Stock are convertible into an aggregate of 438,776 shares of common stock at September 30, 2023.
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
COMMITMENTS & CONTINGENCIES
|
9 Months Ended |
Sep. 30, 2023 |
Commitments and Contingencies Disclosure [Abstract] |
|
COMMITMENTS & CONTINGENCIES |
Note
7 – Commitments & Contingencies
COMMITMENTS
& CONTINGENCIES
CEO
Compensation Agreement
On
December 23, 2021, the Company entered into an employment agreement (the “Employment Agreement”) with Michael Yurkowsky,
the Company’s Chief Executive Officer, to continue to serve as the Chief Executive Officer of the Company. Under the Employment
Agreement, which commenced on December 1, 2021 (the “Effective Date”) and has a term of one year from the Effective Date
(the “Employment Period”), Mr. Yurkowsky will receive a base salary of $180,000 per year. Upon the expiration of the Employment
Period, Mr. Yurkowsky’s employment with the Company will be on an at-will basis.
In
addition to his base salary, Mr. Yurkowsky may receive a one-time cash bonus in gross amount equal to $100,000 if (i) the Company’s
stock is listed and quoted on the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market, or the New York Stock
Exchange; or (ii) the Company secures and receives financing of at least $10,000,000.
As
additional compensation, Mr. Yurkowsky shall receive shares of common stock of the Company representing 1% of the Company’s fully
diluted equity as of the grant date if the Company achieves a market capitalization of at least $250 million for 60 consecutive days
during the Employment Period (the “Equity Award”). If the Company achieves a market capitalization of at least $500 million
for 60 consecutive days during the Employment Period, the executive shall receive an additional Equity Award of 1%, such that he has
in the aggregate received shares of common stock of the Company representing 2% of the Company’s fully diluted equity as of the
date of grant. These market conditions were reflected in the grant date fair value of the award as required under ASC 718 Compensation-Stock
Compensation.
The
Equity Award was measured at fair value on its grant date using a Monte Carlo simulation model. The Monte Carlo simulation model
includes assumptions for the expected term, volatility, and dividend yield, each of which are determined in reference to the
Company’s historical results. The Company will recognize aggregate share-based compensation expense of approximately $328,000
related to the Equity Award on a straight-line basis over the derived service period determined by the Monte Carlo simulation model,
which was 0.71
years. During the three and nine month period ending September 30, 2022, the Company recognized approximately $0 and $114,000
in compensation expense related to the Equity Award, respectively. If the market capitalization targets are met sooner than the derived service
period, the Company will adjust its stock-based compensation to reflect the cumulative expense associated with the vested Equity
Award. The Company will recognize expense if the requisite service is provided, regardless of whether the market conditions are
achieved.
Consulting
Agreements
The
Company entered into a consulting agreement with Tanya Rhodes of Rhodes & Associates, Inc, effective June 15, 2020, to serve as
the Chief Science Officer of the Company. The agreement has a minimum term of six months with an average fee of $21,000
per month plus expenses which increases 5%
per month on January 1 of each calendar year unless an alternative retainer amount is negotiated and agreed upon by both parties.
The Company extended the contract on January 1, 2021, resulting in monthly expenses of $22,500
plus expenses for services rendered. Due to lack of financial resources, the Company has been unable to pay Ms. Rhodes for her
services totaling approximately $220,000,
which has been accrued as part of accrued liabilities as of September 30, 2023.
Litigation
From
time to time, the Company may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise
in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate)
may materially and adversely affect the Company’s financial condition, results of operations, and liquidity. In addition, the ultimate
outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company
due to legal costs and expenses, diversion of management attention, and other factors. The Company expenses legal costs in the period
incurred. The Company cannot assure that additional contingencies of a legal nature or contingencies having legal aspects will not be
asserted against the Company in the future, and these matters could relate to prior, current or future transactions or events.
The
Company is involved in a lawsuit with Sinclair Broadcast Group, Inc. (“Sinclair”) which was filed on September 8, 2020, in
the Circuit Court for the Thirteenth Judicial Circuit in and for Hillsborough County, Florida. Sinclair has obtained a legal judgment
for breach of contract for advertising services in the amount of approximately $75,000 plus interest and costs. The Company has retained
legal counsel for guidance in this matter. The amount is recorded in accounts payable as of September 30, 2023.
The
Company is involved in a lawsuit with ITN Networks, LLC (“ITN”) which was filed on July 22, 2021, in the Circuit Court for
the Thirteenth Judicial Circuit in and for Hillsborough County, Florida. ITN has obtained a legal judgment for breach of contract for
advertising services in the amount of approximately $45,000 plus interest and costs. The Company has retained legal counsel for guidance
in this matter. The amount is recorded in accounts payable as of September 30, 2023.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//440/tableOfContent
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
DEBT
|
9 Months Ended |
Sep. 30, 2023 |
Debt Disclosure [Abstract] |
|
DEBT |
Note
8 – Debt
DEBT
Notes
Payable
Notes
payable were assumed in the Merger (for further discussion, see Note 1 - “Overview” to the consolidated financial statements
in the Company’s 2020 Annual Report on Form 10-K) and are due in aggregate monthly installments of approximately $5,800 and carry
an interest rate of 5%. Each note originally had a maturity date of August 1, 2019. The Company finalized an eighteen-month extension
to March 1, 2021. The promissory notes have an aggregate outstanding balance of approximately $69,000 at September 30, 2023 and December
31, 2022. The Company has not made payments on these notes since February 10, 2020, due to the Company’s lack of working capital.
On April 19, 2022, the Company entered into a promissory note modification agreement with the Lender extending the maturity date of the
notes to April 1, 2024. The modification agreement also reduces the interest rate from 5% to 3% and requires a monthly payment of $1,000
per month with a balloon payment at the end of the modified term.
On
June 9, 2022, the Company entered into a securities purchase agreement for a total of $272,500 with two accredited investors. The notes
issued are convertible into common stock at a 65% discount to the lowest trading price in the 20-day period prior to conversion. The
notes bear interest at 10% and are due one year from issuance. For the first six months, the Company had the right to prepay the notes
at a premium of between 25% and 35% depending on when it is repaid.
The
Company also issued a promissory note for $100,000, on June 9, 2022, to another accredited investor. This note bears interest at 15%
(no matter when repaid) and converts at a discount of 25% of the price of a public offering or a 25% discount to the Volume Average Weighted
Price (“VWAP”) of the five (5) days prior to conversion.
On
August 8, 2022, the Company entered into a securities purchase agreement for a total of $65,000 with an accredited investor. The note
issued is convertible into common stock at a 65% discount to the lowest trading price in the 20-day period prior to conversion. The note
bears interest at 10% and is due one year from issuance. For the first six (6) months, the Company had the right to prepay the notes
at a premium of between 25% and 40% depending on when it is repaid.
On
February 28, 2023, the Company entered into a securities purchase agreement for a total of $150,000 with an accredited investor. The
note issued is convertible into common stock at a 65% discount to the lowest trading price in the 20-day period prior to conversion.
The note bears interest at 10% and is due one year from issuance. For the first six months, the Company has the right to prepay the note
at a premium of between 25% and 40% depending on when it is repaid.
The
embedded features in the June 2022, August 2022, and February 2023 convertible notes were analyzed under ASC 815 to determine if they
required bifurcation as derivative instruments. To be a derivative, one of the criteria is that the embedded component must be net-settleable.
While the Company’s Common Stock was traded on an exchange at the time of the transaction, the underlying shares are not readily
convertible into cash since there is insufficient daily trading volume for the holders to convert the convertible notes into Common Stock
without significantly affecting the share price. Accordingly, the embedded derivatives, including the embedded conversion feature, did
not meet the definition of a derivative, and therefore, did not require bifurcation from the host instrument. Certain default put provisions,
including a default put and default interest, were not considered to be clearly and closely related to the host instrument but the Company
concluded that the value of these provisions was de minimus at inception. The Company will reconsider the value of these provisions each
reporting period to determine if the value becomes material to the financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
ACQUISITIONS
|
9 Months Ended |
Sep. 30, 2023 |
Business Combination and Asset Acquisition [Abstract] |
|
ACQUISITIONS |
Note
9 – Acquisitions
ACQUISITIONS
The
Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted
for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value
of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is
met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether
or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business.
Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination
or an acquisition of assets.
If
an acquisition is determined to be a business combination as indicated in ASC 805, Business Combinations, the assets acquired,
and liabilities assumed are recorded at their respective estimated fair values at the date of the acquisition. The Company recognizes
and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the
identified net assets acquired.
If
an acquisition is determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the
cost of the asset acquisition, including transaction costs, to be allocated to identifiable assets acquired and liabilities assumed based
on a relative fair value basis. Assets acquired as part of an asset acquisition that are considered to be in-process research and development
(IPR&D) are immediately expensed unless there is an alternative future use in other research and development projects. Goodwill is
not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated
to the identifiable assets based on relative fair values (excluding non-qualifying assets). If the cost of the asset acquisition is less
than the fair value of the net assets acquired, no gain is recognized in earnings.
Contingent
consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes
payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis
in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired
asset or group of assets.
On
September 7, 2022, the Company acquired all of the membership interests, with Common Stock, of Jantibody LLC (“Jantibody”),
a Nevada limited liability company. Jantibody is focused on the development of novel proprietary immunotherapies targeted towards ovarian
cancer, pancreatic cancer, and mesothelioma. Prior to the acquisition, Michael Yurkowsky, CEO, had approximately 17.5% ownership interest
in Jantibody.
Pursuant
to the Jantibody Agreement, the Company issued the equity holders of Jantibody an aggregate of 52,023 shares of the Company’s common
stock which represented 15% of the Company’s common stock on a fully diluted basis at the time of the transaction. In addition,
for every share of the Company’s common stock issued as a result of the future conversion of the Company’s dilutive instruments,
including Series A preferred stock, warrants, stock options, and convertible notes, the Jantibody members will receive 15% of the aggregate
number of shares issued (the “Anti-Dilution” shares). The Anti-Dilution shares will be issued before the end of each fiscal
quarter.
The
Company has agreed to issue the Jantibody holders an additional 2.0% of the Company’s common stock then outstanding upon the enrollment
of the first patient in a Phase I FDA trial and additional 3.0% of the Company’s then outstanding common stock on a fully diluted
basis upon the enrollment of the first patient in a Phase [III] FDA trial. The Company determined the contingent consideration was not
subject to derivative accounting and will be recognized when the contingency is resolved, and the consideration is paid or becomes payable
as outlined in ASC 450, Contingencies.
The
Company determined this transaction represented an asset acquisition as defined by ASC 805, Business Combinations, as substantially
all of the value was in a single in-process research and development (“IPR&D”) group, which included the small molecule
drug CXCR4 inhibitor, AMD3100, and/or checkpoint inhibitors (CPI) for anti-cancer immune modulation. As a result, the consideration transferred
was allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their relative fair values
resulting in approximately $1,240,000 being assigned to the IPR&D asset and approximately $1,000,000 to assumed liabilities. The
liabilities assumed were current accounts payable and as such were recorded a book value.
The
purchase price of approximately $247,000 represented 52,023 shares of the Company’s common stock, 344,159 Anti-Dilution shares,
and direct transaction costs of $21,600. The purchase price was allocated, on a relative fair value basis, to the acquired intellectual
property, and the acquired net assets as follows:
SCHEDULE
OF NET IDENTIFIABLE ASSETS ACQUIRED
| |
|
| |
Consideration: | |
| | |
Common stock | |
$ | 29,557 | |
Common stock (anti-dilution shares, to be issued – included in other current liabilities) | |
| 195,532 | |
Direct transaction costs | |
| 21,600 | |
Total costs of the asset acquisition | |
$ | 246,689 | |
Assets acquired | |
| | |
Cash | |
$ | 469 | |
Liabilities assumed – legal and administrative costs | |
| (999,728 | ) |
Intangible assets: IPR&D | |
| 1,245,948 | |
Net identifiable assets acquired | |
$ | 246,689 | |
The
IPR&D had not yet reached technological feasibility and had no alternative future use; thus, the purchased IPR&D asset and related
costs were expensed immediately subsequent to the acquisition within the consolidated statements of operations.
On
December 22, 2022, the Company acquired a 100% interest, with Common Stock, in Scion Solutions, LLC (“Scion”). Scion is a
life sciences company that has developed a new technology in regenerative medicine specifically for limb salvage. Their proprietary product
SkinDisc (patent pending) is a combination of stem cells and several other molecular components that stimulate tissue regeneration. Prior
to the acquisition, Tanya Rhodes, CSO, had approximately 33.3% ownership interest in Scion.
Pursuant
to the terms of the Scion Agreement, the Company issued the equity holders of Scion an aggregate of 123,153 shares of the Company’s
common stock. In addition, for every share of the Company’s common stock issued within 18-months of the Effective Date of the transaction,
as a result of the future conversion of the Company’s dilutive instruments, including Series A preferred stock, warrants, stock
options, and convertible notes, the Scion members will receive 20% of the aggregate number of shares issued (the “Anti-Dilution”
shares). The Anti-Dilution shares will be issued before the end of each fiscal quarter.
In
addition, the former shareholders of Scion are eligible to receive Performance Payments consisting of the following:
SCHEDULE
OF PERFORMANCE PAYMENTS
Performance Milestone | |
Performance Payment | |
Qualified Funding/Uplisting of Innoveren Scientific | |
$ | 45,000 | |
1-Year Anniversary of Uplisting of Innoveren Scientific | |
$ | 75,000 | |
2-Year Anniversary of Uplisting of Innoveren Scientific | |
$ | 120,000 | |
Initiation of SkinDisc Study | |
$ | 50,000 | |
Receipt of De Novo or any other approval/clearance that would allow SkinDisc to go to market | |
$ | 100,000 | |
Submission for specific and individual reimbursement codes relating to SkinDisc | |
$ | 25,000 | |
Receipt of specific and individual reimbursement codes relating to SkinDisc | |
$ | 50,000 | |
Completion of SkinDisc Study | |
$ | 50,000 | |
Launch of any additional SkinDisc product line extension (e.g., SkinDisc Lite)* | |
$ | 100,000 | |
Annual net sales from SkinDisc (including SkinDisc extensions) (2023 and each subsequent calendar year)* | |
| Greater of (i) 4% of net revenues from SkinDisc (including SkinDisc line extensions) during such calendar year and (ii) $50,000 | |
Cumulative net sales from SkinDisc (including SkinDisc extensions) of $600,000 | |
$ | 200,000 | |
Cumulative net sales from SkinDisc (including SkinDisc extension) of $2,000,000 | |
$ | 150,000 | |
Cumulative net sales from SkinDisc (including SkinDisc extension) of $4,000,000 | |
$ | 300,000 | |
Net sales from SkinDisc (including SkinDisc extensions) of $6,000,000 during any single calendar year* | |
$ | 300,000 | |
Substantially
all of the value acquired was concentrated in a single in-process research and development (“IPRD”) asset, which included
license rights, clinical trial data, clinical trial development plans, research and development materials, formulations and intellectual
property related to SkinDisc. There was no workforce, and no outputs were present. Accordingly, the acquired set of assets and activities
did not meet the definition of a business as defined by ASC 805, Business Combinations and
was considered an asset acquisition. In an asset acquisition, the consideration transferred is allocated to identifiable tangible
and intangible assets acquired and liabilities assumed based on their relative fair values. In the Scion acquisition, the only asset
or liability acquired was IPR&D. As a result, the consideration transferred was recorded fully to the IPR&D asset.
In
an asset acquisition, cash-settled contingent consideration is measured when probable and estimable, unless the contingent consideration
falls under the guidance of ASC 815. The Company determined the contingent consideration was not subject to ASC 815 and thus, the performance
payments which were estimable and probable (i.e., more than 50% likely to occur) were recorded on the acquisition date. The fair value
was estimated based on a probability weighting of the present value of cash flows over the expected time period until payment, using
a credit-risk adjusted interest rate. Each reporting period, the Company will determine if the performance payments are estimable and
probable and will record them as a liability at that time.
The
purchase price was allocated, as follows:
SCHEDULE
OF NET IDENTIFIABLE ASSETS ACQUIRED AND LIABILITIES ASSUMED
| |
| | |
Consideration: | |
| | |
Common stock | |
$ | 54,070 | |
Anti-Dilution share liability | |
| 305,998 | |
Contingent Performance payment liability | |
| 417,850 | |
Direct transaction costs | |
| 14,338 | |
Total costs of the asset acquisition | |
$ | 792,256 | |
The
common stock value was recorded as equity. The remaining consideration was recorded as IPR&D, since the
SkinDisc technology was still in the research and development stage and had no alternative future use. The purchased IPR&D asset
of $792,256 was expensed immediately subsequent to the acquisition within our consolidated statements of operations.
|
X |
- References
+ Details
Name: |
us-gaap_BusinessCombinationAndAssetAcquisitionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//805/tableOfContent
+ Details
Name: |
us-gaap_BusinessCombinationDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
REDEMPTION OF MEDOVEX LLC MEMBERSHIP INTEREST AND SALE OF IP
|
9 Months Ended |
Sep. 30, 2023 |
Redemption Of Medovex Llc Membership Interest And Sale Of Ip |
|
REDEMPTION OF MEDOVEX LLC MEMBERSHIP INTEREST AND SALE OF IP |
Note
10- Redemption of Medovex, LLC Membership Interest and Sale of IP
REDEMPTION
OF MEDOVEX LLC MEMBERSHIP INTEREST AND SALE OF IP
Effective
April 2, 2021, and in conjunction with the Amended and Restated Limited Liability Company Agreement of Medovex, LLC (“JV”)
(the “LLC Agreement”), Innoveren, Scientific, Inc., through its wholly-owned subsidiary, Medovex Corp. (“Corp”),
entered into a Contribution Agreement with JV to pursue a joint venture regarding the continued development and commercialization of
the Company’s DenerveX Device. In connection with the Contribution Agreement, Corp and JV entered into an Intellectual Property (“IP”)
License Agreement (“License Agreement”) in part to permit Corp to license the IP to JV for use in commercializing the DenerveX
Device. The IP and related assets were previously deemed fully impaired by the Company in a prior year. Pursuant to the Contribution
Agreement, the JV issued certain membership interests in the JV to Corp in exchange for the contributed IP assets. The effects of the
Contribution Agreement on the Company’s consolidated financial statements were deemed immaterial.
Effective
September 21, 2023, Corp (as “Seller”) entered into a Membership Interest and LLCA Rights Redemption Agreement (“Redemption
Agreement”) with JV for the redemption (purchase) by JV of all of Corp’s membership interests outstanding with the JV, as
well as the purchase all of the rights of Corp under the Amended and Restated Limited Liability Company Agreement (“LLCA”)
dated April 2, 2021 (the “LLCA Rights”), for a purchase price of approximately $869,000. In addition, Corp and JV have agreed
in principle for the assignment and transfer of the DenerveX IP (the “2023 IP Agreement”) by Corp to JV for the rights to
IP under the DenerveX device and technology and all trade names, patents, trademarks, and other IP under the Medovex and Medovex Corp
names, for a purchase price of approximately $56,000. The Company and Corp will no longer be a party to any rights or obligations associated
with the DenerveX IP or associated assets.
The
sale of membership interests in the JV and the IP under the DenerveX device and technology was recorded as a deferred gain on
redemption of equity investment of approximately $869,000
and a deferred gain on sale of asset of approximately $56,000,
for the three and nine months ended September 30, 2023, on the accompanying consolidated statements of operations as the Company awaits the final transfer of IP to Medovex LLC. The IP that was
sold as part of the Redpemtion Agreement had a net book value of $0.
|
X |
- References
+ Details
Name: |
IVRN_DisclosureRedemptionOfMedovexLlcMembershipInterestAndSaleOfIpAbstract |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
IVRN_RedemptionOfMedovexLLCMembershipInterestAndSaleOfIpTextBlock |
Namespace Prefix: |
IVRN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
COMMON STOCK WARRANTS
|
9 Months Ended |
Sep. 30, 2023 |
Common Stock Warrants |
|
COMMON STOCK WARRANTS |
Note
11- Common Stock Warrants
COMMON STOCK WARRANTS
A
summary of the Company’s warrant issuance activity and related information for the nine months ended September, 2022 and 2023 is
as follows:
SUMMARY
OF ISSUANCE OF WARRANTS
| |
Shares | | |
Weighted
Average
Exercise Price | | |
Weighted
Average
Remaining
Contractual
Life | |
Outstanding at December 31, 2021 | |
| 406,301 | | |
$ | 34.88 | | |
| 8.17 | |
Expired | |
| (22,513 | ) | |
| 373.85 | | |
| - | |
Exercised | |
| (83,579 | ) | |
| 14.00 | | |
| - | |
Granted | |
| 140,829 | | |
| 9.41 | | |
| 4.63 | |
Outstanding and exercisable at September 30, 2022 | |
| 441,038 | | |
$ | 12.52 | | |
| 6.84 | |
| |
| | | |
| | | |
| | |
Outstanding at December 31, 2022 | |
| 447,967 | | |
$ | 10.90 | | |
| 6.65 | |
Expired | |
| (787 | ) | |
| (498.54 | ) | |
| - | |
Granted | |
| 46,000 | | |
| 2.00 | | |
| 4.44 | |
Outstanding and exercisable at September 30, 2023 | |
| 493,180 | | |
$ | 9.30 | | |
| 5.68 | |
The
fair value of all warrants issued are determined by using the Black-Scholes valuation technique. The inputs used in the Black-Scholes
valuation technique to value each of the warrants as of their respective issue dates are as follows:
SCHEDULE
OF ISSUANCE OF WARRANTS VALUATION TECHNIQUE
Event Description | |
Date | |
Number
of
Warrants | | |
Innoveren Scientific
Stock
Price | | |
Exercise
Price of
Warrant | | |
Grant
Date
Fair
Value | | |
Life of
Warrant | |
Risk
Free
Rate
of
Return
(%) | | |
Annualized
Volatility
Rate (%) | |
Granted for inducement agreement | |
1/19/2022 | |
| 3,732 | | |
$ | 63.25 | | |
$ | 14.00 | | |
$ | 62.00 | | |
5 years | |
|
1.62 | | |
| 187.79 | |
Granted for inducement agreement | |
1/20/2022 | |
| 372 | | |
$ | 64.50 | | |
$ | 14.00 | | |
$ | 64.00 | | |
5 years | |
|
1.62 | | |
| 187.85 | |
Granted for inducement agreement | |
1/20/2022 | |
| 187 | | |
$ | 64.50 | | |
$ | 14.00 | | |
$ | 64.00 | | |
5 years | |
|
1.62 | | |
| 187.85 | |
Granted for inducement agreement | |
1/24/2022 | |
| 374 | | |
$ | 48.00 | | |
$ | 14.00 | | |
$ | 47.00 | | |
5 years | |
|
1.53 | | |
| 188.01 | |
Granted for inducement agreement | |
1/25/2022 | |
| 3,744 | | |
$ | 49.10 | | |
$ | 14.00 | | |
$ | 48.00 | | |
5 years | |
|
1.56 | | |
| 188.00 | |
Granted for inducement agreement | |
2/02/2022 | |
| 3,741 | | |
$ | 44.55 | | |
$ | 14.00 | | |
$ | 44.00 | | |
5 years | |
|
1.60 | | |
| 188.25 | |
Granted for inducement agreement | |
2/04/2022 | |
| 6,935 | | |
$ | 44.38 | | |
$ | 14.00 | | |
$ | 43.00 | | |
5 years | |
|
1.78 | | |
| 188.33 | |
Granted for inducement agreement | |
2/04/2022 | |
| 13,870 | | |
$ | 44.38 | | |
$ | 14.00 | | |
$ | 43.00 | | |
5 years | |
|
1.78 | | |
| 188.33 | |
Granted for services provided | |
2/09/2022 | |
| 1,000 | | |
$ | 32.00 | | |
$ | 14.00 | | |
$ | 31.00 | | |
5 years | |
|
1.82 | | |
| 188.69 | |
Granted for inducement agreement | |
2/22/2022 | |
| 41,609 | | |
$ | 32.88 | | |
$ | 14.00 | | |
$ | 32.00 | | |
5 years | |
|
1.85 | | |
| 188.59 | |
Granted for inducement agreement | |
2/22/2022 | |
| 693 | | |
$ | 32.88 | | |
$ | 14.00 | | |
$ | 32.00 | | |
5 years | |
|
1.85 | | |
| 188.59 | |
Granted for inducement agreement | |
3/21/2022 | |
| 8,322 | | |
$ | 28.00 | | |
$ | 14.00 | | |
$ | 27.00 | | |
5 years | |
|
2.33 | | |
| 194.01 | |
Granted for securities purchase agreement | |
9/27/2022 | |
| 56,250 | | |
$ | 6.00 | | |
$ | 2.50 | | |
$ | 5.94 | | |
5 years | |
|
4.21 | | |
| 213.54 | |
Granted for securities purchase agreement | |
11/14/2022 | |
| 7,500 | | |
$ | 5.75 | | |
$ | 2.50 | | |
$ | 5.69 | | |
5 years | |
|
4.00 | | |
| 213.28 | |
Granted for convertible note agreement | |
2/21/2023 | |
| 30,000 | | |
$ | 1.60 | | |
$ | 2.00 | | |
$ | 1.57 | | |
5 years | |
|
4.16 | | |
| 211.43 | |
Granted for convertible note agreement | |
3/27/2023 | |
| 10,000 | | |
$ | 1.70 | | |
$ | 2.00 | | |
$ | 1.68 | | |
5 years | |
|
3.59 | | |
| 218.15 | |
Granted for convertible note agreement | |
3/28/2023 | |
| 2,500 | | |
$ | 1.60 | | |
$ | 2.00 | | |
$ | 1.58 | | |
5 years | |
|
3.63 | | |
| 218.17 | |
Granted for convertible note agreement | |
4/12/2023 | |
| 3,500 | | |
$ | 1.74 | | |
$ | 2.00 | | |
$ | 1.73 | | |
5 years | |
|
4.16 | | |
| 243.62 | |
The
fair value of warrants issued during the three and nine months ended September 30, 2023, totaled approximately $0 and $74,000, respectively. The methods
described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair
values. Furthermore, while the Company believes its valuation methods are appropriate and consistent with other market participants,
the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a
different fair value measurement at the reporting date.
|
X |
- DefinitionCommon Stock Warrants [TextBlock]
+ References
+ Details
Name: |
IVRN_CommonStockWarrantsTextBlock |
Namespace Prefix: |
IVRN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
IVRN_DisclosureCommonStockWarrantsAbstract |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
SUBSEQUENT EVENTS
|
9 Months Ended |
Sep. 30, 2023 |
Subsequent Events [Abstract] |
|
SUBSEQUENT EVENTS |
Note
12 - Subsequent Events
SUBSEQUENT EVENTS
The Company recently received notice from Mass General Hospital (MGH)
that the Company was in default in its obligations to fund certain Jantibody activities and obligations and was terminating the license
agreement between Innoveren and The General Hopsital Corporation d/b/a MGH. The Company was sent an initial breach notice on February
24, 2023, following which Company met with MGH and negotiated a Second Amendment (MGH Agreement No. 2023-2413) effective April 24, 2023.
MGH notified the Company of breach for a second time on September 11, 2023, indicating grounds for termination of the Agreement unless
the breach was cured. To date, the breach has not been cured and MGH has not received payment. Consequently, the Agreement is hereby
terminated effective immediately as of November 6, 2023.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Fair Value Disclosures [Abstract] |
|
SCHEDULE OF FAIR VALUE INSTRUMENT |
SCHEDULE OF FAIR VALUE INSTRUMENT
| |
Total | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
| |
| | |
| | |
| | |
| |
Assets: | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Liabilities: | |
| | | |
| | | |
| | | |
| | |
Convertible Notes at fair value | |
$ | 583,738 | | |
$ | - | | |
$ | - | | |
$ | 583,738 | |
|
SCHEDULE OF CONVERTIBLE NOTE MEASURED AT FAIR VALUE |
The
following is a reconciliation of the beginning and ending balances for the Convertible Notes measured at fair value on a recurring basis
using significant unobservable inputs (Level 3) during the nine months ended September 30, 2023:
SCHEDULE OF CONVERTIBLE NOTE MEASURED AT FAIR VALUE
| |
| | |
Balance at December 31, 2022 | |
$ | — | |
Fair value of Convertible Notes issued | |
| (1,913,367 | ) |
Gain on change in fair value of Convertible Notes | |
| 1,329,629 | |
| |
| | |
Balance at September 30, 2023 | |
$ | (583,738 | ) |
|
X |
- DefinitionTabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.
+ References
+ Details
Name: |
us-gaap_ConvertibleDebtTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2C -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
X |
- DefinitionTabular disclosure of debt extinguished which may include, amount of gain (loss), the income tax effect and the per share amount of the aggregate gain (loss), net of the related income tax.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481244/470-50-50-1
+ Details
Name: |
us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
EQUITY TRANSACTIONS (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Equity [Abstract] |
|
SCHEDULE OF COMMON AND PREFERRED STOCK OUTSTANDING |
The
following table summarizes the Company’s common and preferred stock outstanding by class. The number of common stock shares has
been adjusted to reflect a one-for-one thousand reverse stock split that became effective on June 13, 2022.
SCHEDULE OF COMMON AND PREFERRED STOCK OUTSTANDING
| |
September 30,
2023 | | |
December 31,
2022 | |
Common Stock | |
| 712,710 | | |
| 618,506 | |
Series A Preferred Stock | |
| 438,776,170 | | |
| 438,776,170 | |
|
SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS |
Inputs
used in the valuation models are as follows:
SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS
2021 Grants |
Option value | |
$ | 54.00 | | |
| to | | |
$ | 56.00 | |
Risk Free Rate | |
| 0.90 | % | |
| to | | |
| 1.37 | % |
Expected Dividend- yield | |
| - | | |
| to | | |
| - | |
Expected Volatility | |
| 173.99 | % | |
| to | | |
| 176.04 | % |
Expected term (years) | |
| 5 | | |
| to | | |
| 7 | |
|
SUMMARY OF STOCK OPTION ACTIVITY |
The
following is a summary of stock option activity for the nine months ended September 30, 2022 and 2023:
SUMMARY OF STOCK OPTION ACTIVITY
| |
Shares | | |
Weighted Average Exercise Price | | |
Weighted Average
Remaining Term (Years) | |
Outstanding at December 31, 2021 | |
| 29,635 | | |
$ | 86.48 | | |
| 9.20 | |
Granted | |
| - | | |
| - | | |
| - | |
Exercised | |
| - | | |
| - | | |
| - | |
Outstanding at September 30, 2022 | |
| 29,635 | | |
$ | 86.48 | | |
| 8.71 | |
Exercisable at September 30, 2022 | |
| 20,510 | | |
$ | 93.81 | | |
| 8.44 | |
| |
| | | |
| | | |
| | |
Outstanding at December 31, 2022 | |
| 29,385 | | |
$ | 83.81 | | |
| 8.22 | |
Granted | |
| - | | |
| - | | |
| - | |
Exercised | |
| - | | |
| - | | |
| - | |
Outstanding at September 30, 2023 | |
| 29,385 | | |
$ | 83.81 | | |
| 7.48 | |
Exercisable at September 30, 2023 | |
| 24,843 | | |
$ | 86.33 | | |
| 7.47 | |
|
SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED |
The
following is a summary of the Company’s non-vested shares for the nine months ended September 30, 2023:
SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED
| |
Shares | | |
Weighted Average Grant Date Fair Value | |
Non-vested at December 31, 2022 | |
| 7,979 | | |
$ | 55.70 | |
Vested | |
| (3,437 | ) | |
| 55.46 | |
Non-vested at September 30, 2023 | |
| 4,542 | | |
$ | 69.88 | |
|
SCHEDULE OF ANTI-DILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE |
The
Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been
antidilutive:
SCHEDULE OF ANTI-DILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE
| |
2023 | | |
2022 | |
| |
For the Nine Months Ended September 30, | |
| |
2023 | | |
2022 | |
Warrants to purchase common stock (in the money) | |
| - | | |
| 385,033 | |
Series A Preferred Stock convertible to common stock | |
| 438,776 | | |
| 515,874 | |
Total | |
| 438,776 | | |
| 900,907 | |
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock shares.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-10
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7
+ Details
Name: |
us-gaap_ScheduleOfStockByClassTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
ACQUISITIONS (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
SCHEDULE OF PERFORMANCE PAYMENTS |
SCHEDULE
OF PERFORMANCE PAYMENTS
Performance Milestone | |
Performance Payment | |
Qualified Funding/Uplisting of Innoveren Scientific | |
$ | 45,000 | |
1-Year Anniversary of Uplisting of Innoveren Scientific | |
$ | 75,000 | |
2-Year Anniversary of Uplisting of Innoveren Scientific | |
$ | 120,000 | |
Initiation of SkinDisc Study | |
$ | 50,000 | |
Receipt of De Novo or any other approval/clearance that would allow SkinDisc to go to market | |
$ | 100,000 | |
Submission for specific and individual reimbursement codes relating to SkinDisc | |
$ | 25,000 | |
Receipt of specific and individual reimbursement codes relating to SkinDisc | |
$ | 50,000 | |
Completion of SkinDisc Study | |
$ | 50,000 | |
Launch of any additional SkinDisc product line extension (e.g., SkinDisc Lite)* | |
$ | 100,000 | |
Annual net sales from SkinDisc (including SkinDisc extensions) (2023 and each subsequent calendar year)* | |
| Greater of (i) 4% of net revenues from SkinDisc (including SkinDisc line extensions) during such calendar year and (ii) $50,000 | |
Cumulative net sales from SkinDisc (including SkinDisc extensions) of $600,000 | |
$ | 200,000 | |
Cumulative net sales from SkinDisc (including SkinDisc extension) of $2,000,000 | |
$ | 150,000 | |
Cumulative net sales from SkinDisc (including SkinDisc extension) of $4,000,000 | |
$ | 300,000 | |
Net sales from SkinDisc (including SkinDisc extensions) of $6,000,000 during any single calendar year* | |
$ | 300,000 | |
|
Jantibody LLC [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
SCHEDULE OF NET IDENTIFIABLE ASSETS ACQUIRED AND LIABILITIES ASSUMED |
SCHEDULE
OF NET IDENTIFIABLE ASSETS ACQUIRED
| |
|
| |
Consideration: | |
| | |
Common stock | |
$ | 29,557 | |
Common stock (anti-dilution shares, to be issued – included in other current liabilities) | |
| 195,532 | |
Direct transaction costs | |
| 21,600 | |
Total costs of the asset acquisition | |
$ | 246,689 | |
Assets acquired | |
| | |
Cash | |
$ | 469 | |
Liabilities assumed – legal and administrative costs | |
| (999,728 | ) |
Intangible assets: IPR&D | |
| 1,245,948 | |
Net identifiable assets acquired | |
$ | 246,689 | |
|
Scion Agreement [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
SCHEDULE OF NET IDENTIFIABLE ASSETS ACQUIRED AND LIABILITIES ASSUMED |
SCHEDULE
OF NET IDENTIFIABLE ASSETS ACQUIRED AND LIABILITIES ASSUMED
| |
| | |
Consideration: | |
| | |
Common stock | |
$ | 54,070 | |
Anti-Dilution share liability | |
| 305,998 | |
Contingent Performance payment liability | |
| 417,850 | |
Direct transaction costs | |
| 14,338 | |
Total costs of the asset acquisition | |
$ | 792,256 | |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_JantibodyLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_ScionAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
COMMON STOCK WARRANTS (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Common Stock Warrants |
|
SUMMARY OF ISSUANCE OF WARRANTS |
A
summary of the Company’s warrant issuance activity and related information for the nine months ended September, 2022 and 2023 is
as follows:
SUMMARY
OF ISSUANCE OF WARRANTS
| |
Shares | | |
Weighted
Average
Exercise Price | | |
Weighted
Average
Remaining
Contractual
Life | |
Outstanding at December 31, 2021 | |
| 406,301 | | |
$ | 34.88 | | |
| 8.17 | |
Expired | |
| (22,513 | ) | |
| 373.85 | | |
| - | |
Exercised | |
| (83,579 | ) | |
| 14.00 | | |
| - | |
Granted | |
| 140,829 | | |
| 9.41 | | |
| 4.63 | |
Outstanding and exercisable at September 30, 2022 | |
| 441,038 | | |
$ | 12.52 | | |
| 6.84 | |
| |
| | | |
| | | |
| | |
Outstanding at December 31, 2022 | |
| 447,967 | | |
$ | 10.90 | | |
| 6.65 | |
Expired | |
| (787 | ) | |
| (498.54 | ) | |
| - | |
Granted | |
| 46,000 | | |
| 2.00 | | |
| 4.44 | |
Outstanding and exercisable at September 30, 2023 | |
| 493,180 | | |
$ | 9.30 | | |
| 5.68 | |
|
SCHEDULE OF ISSUANCE OF WARRANTS VALUATION TECHNIQUE |
The
fair value of all warrants issued are determined by using the Black-Scholes valuation technique. The inputs used in the Black-Scholes
valuation technique to value each of the warrants as of their respective issue dates are as follows:
SCHEDULE
OF ISSUANCE OF WARRANTS VALUATION TECHNIQUE
Event Description | |
Date | |
Number
of
Warrants | | |
Innoveren Scientific
Stock
Price | | |
Exercise
Price of
Warrant | | |
Grant
Date
Fair
Value | | |
Life of
Warrant | |
Risk
Free
Rate
of
Return
(%) | | |
Annualized
Volatility
Rate (%) | |
Granted for inducement agreement | |
1/19/2022 | |
| 3,732 | | |
$ | 63.25 | | |
$ | 14.00 | | |
$ | 62.00 | | |
5 years | |
|
1.62 | | |
| 187.79 | |
Granted for inducement agreement | |
1/20/2022 | |
| 372 | | |
$ | 64.50 | | |
$ | 14.00 | | |
$ | 64.00 | | |
5 years | |
|
1.62 | | |
| 187.85 | |
Granted for inducement agreement | |
1/20/2022 | |
| 187 | | |
$ | 64.50 | | |
$ | 14.00 | | |
$ | 64.00 | | |
5 years | |
|
1.62 | | |
| 187.85 | |
Granted for inducement agreement | |
1/24/2022 | |
| 374 | | |
$ | 48.00 | | |
$ | 14.00 | | |
$ | 47.00 | | |
5 years | |
|
1.53 | | |
| 188.01 | |
Granted for inducement agreement | |
1/25/2022 | |
| 3,744 | | |
$ | 49.10 | | |
$ | 14.00 | | |
$ | 48.00 | | |
5 years | |
|
1.56 | | |
| 188.00 | |
Granted for inducement agreement | |
2/02/2022 | |
| 3,741 | | |
$ | 44.55 | | |
$ | 14.00 | | |
$ | 44.00 | | |
5 years | |
|
1.60 | | |
| 188.25 | |
Granted for inducement agreement | |
2/04/2022 | |
| 6,935 | | |
$ | 44.38 | | |
$ | 14.00 | | |
$ | 43.00 | | |
5 years | |
|
1.78 | | |
| 188.33 | |
Granted for inducement agreement | |
2/04/2022 | |
| 13,870 | | |
$ | 44.38 | | |
$ | 14.00 | | |
$ | 43.00 | | |
5 years | |
|
1.78 | | |
| 188.33 | |
Granted for services provided | |
2/09/2022 | |
| 1,000 | | |
$ | 32.00 | | |
$ | 14.00 | | |
$ | 31.00 | | |
5 years | |
|
1.82 | | |
| 188.69 | |
Granted for inducement agreement | |
2/22/2022 | |
| 41,609 | | |
$ | 32.88 | | |
$ | 14.00 | | |
$ | 32.00 | | |
5 years | |
|
1.85 | | |
| 188.59 | |
Granted for inducement agreement | |
2/22/2022 | |
| 693 | | |
$ | 32.88 | | |
$ | 14.00 | | |
$ | 32.00 | | |
5 years | |
|
1.85 | | |
| 188.59 | |
Granted for inducement agreement | |
3/21/2022 | |
| 8,322 | | |
$ | 28.00 | | |
$ | 14.00 | | |
$ | 27.00 | | |
5 years | |
|
2.33 | | |
| 194.01 | |
Granted for securities purchase agreement | |
9/27/2022 | |
| 56,250 | | |
$ | 6.00 | | |
$ | 2.50 | | |
$ | 5.94 | | |
5 years | |
|
4.21 | | |
| 213.54 | |
Granted for securities purchase agreement | |
11/14/2022 | |
| 7,500 | | |
$ | 5.75 | | |
$ | 2.50 | | |
$ | 5.69 | | |
5 years | |
|
4.00 | | |
| 213.28 | |
Granted for convertible note agreement | |
2/21/2023 | |
| 30,000 | | |
$ | 1.60 | | |
$ | 2.00 | | |
$ | 1.57 | | |
5 years | |
|
4.16 | | |
| 211.43 | |
Granted for convertible note agreement | |
3/27/2023 | |
| 10,000 | | |
$ | 1.70 | | |
$ | 2.00 | | |
$ | 1.68 | | |
5 years | |
|
3.59 | | |
| 218.15 | |
Granted for convertible note agreement | |
3/28/2023 | |
| 2,500 | | |
$ | 1.60 | | |
$ | 2.00 | | |
$ | 1.58 | | |
5 years | |
|
3.63 | | |
| 218.17 | |
Granted for convertible note agreement | |
4/12/2023 | |
| 3,500 | | |
$ | 1.74 | | |
$ | 2.00 | | |
$ | 1.73 | | |
5 years | |
|
4.16 | | |
| 243.62 | |
|
X |
- References
+ Details
Name: |
IVRN_DisclosureCommonStockWarrantsAbstract |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1
+ Details
Name: |
us-gaap_ScheduleOfAssumptionsUsedTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
DESCRIPTION OF THE COMPANY (Details Narrative) - USD ($)
|
|
|
9 Months Ended |
|
|
Sep. 21, 2023 |
Jun. 10, 2022 |
Sep. 30, 2023 |
Dec. 31, 2022 |
Sep. 10, 2022 |
Common stock, shares authorized |
|
500,000,000
|
500,000,000
|
500,000,000
|
|
Common stock, shares, outstanding |
|
|
712,170
|
618,506
|
|
Conversion of stock, shares converted |
|
438,776
|
|
|
|
Limited Liability Company Agreement [Member] |
|
|
|
|
|
Purchase price |
$ 869,000
|
|
|
|
|
Redemption Agreement [Member] |
|
|
|
|
|
Purchase price |
$ 56,000
|
|
|
|
|
Redemption of equity investment |
|
|
$ 869,000
|
|
|
Sale of assets |
|
|
$ 56,000
|
|
|
Series A Preferred Stock [Member] |
|
|
|
|
|
Preferred stock, shares outstanding |
|
|
438,776,170
|
438,776,170
|
438,776,170
|
Common Stock [Member] |
|
|
|
|
|
Common stock, shares, outstanding |
|
|
712,710
|
618,506
|
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockSharesConverted1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of gain (loss) on sale or disposal of other assets.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_GainLossOnSaleOfOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquireEquityMethodInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_LimitedLiabilityCompanyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_RedemptionAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
LIQUIDITY, GOING CONCERN AND SOURCES OF LIQUIDITY (Details Narrative)
|
|
|
|
3 Months Ended |
9 Months Ended |
|
|
|
Mar. 27, 2023
USD ($)
$ / shares
shares
|
Mar. 27, 2023
USD ($)
$ / shares
shares
|
Feb. 28, 2023
USD ($)
|
Feb. 24, 2023
USD ($)
$ / shares
shares
|
Feb. 24, 2023
USD ($)
$ / shares
shares
|
Sep. 30, 2023
USD ($)
$ / shares
|
Sep. 30, 2022
USD ($)
|
Sep. 30, 2023
USD ($)
$ / shares
|
Sep. 30, 2022
USD ($)
|
Nov. 09, 2023
USD ($)
|
Apr. 12, 2023
USD ($)
$ / shares
|
Dec. 31, 2022
$ / shares
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
$ 495,775
|
$ 2,279,444
|
$ 1,765,515
|
$ 8,806,492
|
|
|
|
Cash on hand |
|
|
|
|
|
$ 544,000
|
|
$ 544,000
|
|
$ 150,000
|
|
|
Common stock par value | $ / shares |
|
|
|
|
|
$ 0.001
|
|
$ 0.001
|
|
|
|
$ 0.001
|
Debt instrument description |
The
March 27, 2023, Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified
offering. The April 12, 2023, Note has a maturity date 60 days from issuance. Interest on the Note shall accrue on the unpaid
principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated on an actual/365-day basis. The
Company defaulted on this note on June 12, 2023 which triggered an increase in interest from 8% to 12%. In the event that the
Company moves forward with a qualified offering, as referenced in the SPA, the Holder may convert the unpaid and outstanding
principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock at a conversion price equal to a 20%
discount to the offering price.
|
|
|
|
|
|
|
The
Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering. Interest on
the Note shall accrue on the unpaid principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated
on an actual/365-day basis. In the event that the Company moves forward with a qualified offering, as referenced in the SPA, the Holder
may convert the unpaid and outstanding principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock
at a conversion price equal to a 20% discount to the offering price.
|
|
|
|
|
Convertible shares percentage |
|
20.00%
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock |
|
|
|
|
|
|
|
|
$ 225,001
|
|
|
|
Securities purchase agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, face amount |
$ 125,000
|
$ 125,000
|
|
$ 300,000
|
$ 300,000
|
|
|
|
|
|
$ 35,000
|
|
Common stock par value | $ / shares |
$ 0.001
|
$ 0.001
|
|
$ 0.001
|
$ 0.001
|
|
|
|
|
|
|
|
Debt Instrument Convertible Conversion Price | $ / shares |
|
|
|
$ 2.00
|
$ 2.00
|
|
|
|
|
|
|
|
Warrant term |
|
|
|
5 years
|
5 years
|
|
|
|
|
|
5 years
|
|
Warrant exercise price | $ / shares |
$ 2.00
|
$ 2.00
|
|
$ 2.00
|
$ 2.00
|
|
|
|
|
|
$ 2.00
|
|
Debt instrument description |
The
March 27, 2023 Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified
offering. The April 12, 2023 Note has a maturity date 60 days from issuance. Interest on the Note shall accrue on the unpaid
principal balance of this Note at the rate of eight percent (8%) per annum and will be calculated on an actual/365-day basis. The
Company defaulted on this note on June 12, 2023 which triggered an increase in interest from 8% to 12%. In the event that the
Company moves forward with a qualified offering, as referenced in the SPA, the Holder may convert the unpaid and outstanding
principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock at a conversion price equal to a 20%
discount to the offering price.
|
|
|
The
Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering. Interest on
the Note shall accrue on the unpaid principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated
on an actual/365-day basis. In the event that the Company moves forward with a qualified offering, as referenced in the SPA, the Holder
may convert the unpaid and outstanding principal plus any accrued and unpaid interest into shares of the Company’s Common Stock
at a conversion price equal to a 20% discount to the offering price.
|
|
|
|
|
|
|
|
|
Convertible shares percentage |
|
|
|
|
20.00%
|
|
|
|
|
|
|
|
Exercise on aggregate of warrants | shares |
12,500
|
12,500
|
|
30,000
|
30,000
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock |
|
|
$ 150,000
|
|
|
|
|
|
|
|
|
|
Common stock discount percentage |
|
|
65
|
|
|
|
|
|
|
|
|
|
Debt instrument, convertible description |
|
|
The note bears interest at 10% and is due one year from issuance. For the first six months, the Company has the right to prepay the note
at a premium of between 25% and 40% depending on when it is repaid
|
|
|
|
|
|
|
|
|
|
X |
- DefinitionConvertible shares percentage.
+ References
+ Details
Name: |
IVRN_ConvertibleSharesPercentage |
Namespace Prefix: |
IVRN_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionRatio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionRatio1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:pureItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of conversion terms for debt instrument.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIdentification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3
+ Details
Name: |
us-gaap_DebtInstrumentDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_SecuritiesPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
SCHEDULE OF FAIR VALUE INSTRUMENT (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
Assets: |
|
|
Convertible Notes at fair value |
583,738
|
|
Fair Value, Inputs, Level 1 [Member] |
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
Assets: |
|
|
Convertible Notes at fair value |
|
|
Fair Value, Inputs, Level 2 [Member] |
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
Assets: |
|
|
Convertible Notes at fair value |
|
|
Fair Value, Inputs, Level 3 [Member] |
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
Assets: |
|
|
Convertible Notes at fair value |
$ 583,738
|
|
X |
- DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_AssetsFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.
+ References
+ Details
Name: |
us-gaap_FinancialLiabilitiesFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
SCHEDULE OF CONVERTIBLE NOTE MEASURED AT FAIR VALUE (Details)
|
9 Months Ended |
Sep. 30, 2023
USD ($)
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
Fair value of Convertible Notes issued |
$ 1,913,367
|
Gain on change in fair value of Convertible Notes |
1,330,000
|
Balance at September 30, 2023 |
(583,738)
|
Fair Value, Inputs, Level 3 [Member] |
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
Balance at December 31, 2022 |
|
Fair value of Convertible Notes issued |
(1,913,367)
|
Gain on change in fair value of Convertible Notes |
1,329,629
|
Balance at September 30, 2023 |
$ (583,738)
|
X |
- DefinitionFair value of convertible notes issued.
+ References
+ Details
Name: |
IVRN_FairValueOfConvertibleNotesIssued |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionGain on convertible notes at fair value.
+ References
+ Details
Name: |
IVRN_GainOnConvertibleNotesAtFairValue |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.
+ References
+ Details
Name: |
us-gaap_FinancialLiabilitiesFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
SCHEDULE OF LOSS UPON EXTINGUISHMENT (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
Loss on Extinguishment |
|
|
|
$ (2,196,100)
|
|
Note Conversion Agreement [Member] |
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
Carrying value of Tranche 1 Notes |
|
|
|
|
$ 3,580,738
|
Less: Fair value of New Notes |
|
|
|
|
(4,079,838)
|
Less: Fair value of Royalty Payments |
|
|
|
|
(1,697,000)
|
Loss on Extinguishment |
|
|
|
|
$ (2,196,100)
|
X |
- DefinitionCarrying value of tranche notes.
+ References
+ Details
Name: |
IVRN_CarryingValueOfTrancheNotes |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFair value of new notes payable.
+ References
+ Details
Name: |
IVRN_FairValueOfNewNotesPayable |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFair value of royalty payments.
+ References
+ Details
Name: |
IVRN_FairValueOfRoyaltyPayments |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_NoteConversionAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
3 Months Ended |
6 Months Ended |
9 Months Ended |
12 Months Ended |
Apr. 12, 2023 |
Mar. 27, 2023 |
Feb. 24, 2023 |
Apr. 29, 2022 |
Feb. 22, 2022 |
Jan. 17, 2022 |
Oct. 14, 2021 |
Apr. 02, 2021 |
Jan. 12, 2021 |
Jan. 02, 2021 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Jul. 02, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Jul. 02, 2022 |
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Professional fees |
|
|
|
|
|
|
|
|
|
$ 22,500
|
|
|
|
|
|
|
|
Reverse stock split |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1-for-1,000
|
|
|
Loss extinguishment of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,200,000
|
|
Debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ (499,100)
|
|
|
Common stock par value |
|
|
|
|
|
|
|
|
|
|
$ 0.001
|
|
|
$ 0.001
|
|
$ 0.001
|
|
Debt instrument description |
|
The
March 27, 2023, Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified
offering. The April 12, 2023, Note has a maturity date 60 days from issuance. Interest on the Note shall accrue on the unpaid
principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated on an actual/365-day basis. The
Company defaulted on this note on June 12, 2023 which triggered an increase in interest from 8% to 12%. In the event that the
Company moves forward with a qualified offering, as referenced in the SPA, the Holder may convert the unpaid and outstanding
principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock at a conversion price equal to a 20%
discount to the offering price.
|
|
|
|
|
|
|
|
|
|
|
|
The
Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering. Interest on
the Note shall accrue on the unpaid principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated
on an actual/365-day basis. In the event that the Company moves forward with a qualified offering, as referenced in the SPA, the Holder
may convert the unpaid and outstanding principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock
at a conversion price equal to a 20% discount to the offering price.
|
|
|
|
Related party transaction description of transaction |
|
|
|
|
|
|
|
|
|
|
|
|
|
(i)
present value of future cash flows using a credit risk adjusted rate of 20.0%, (ii) remaining term of approximately five months, (iii)
volatility of 322%, (iv) closing stock price on the valuation date, and (v) the conversion price based on the estimated price of a Qualified
Offering, less a 20% discount, in accordance with the terms of the Note. Changes due to instrument-specific credit risk are recorded
in Other Comprehensive Income with all other changes in value being recorded in net income.
|
|
|
|
Fair value of convertible notes issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,913,367
|
|
|
|
Warrants issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
73,872
|
|
|
|
Investment owned at fair value |
|
|
|
|
|
|
|
|
|
|
$ 460,000
|
|
|
460,000
|
|
|
|
Loss on convertible notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,521,768
|
|
|
|
Financial liabilities fair value disclosure |
|
|
|
|
|
|
|
|
|
|
583,738
|
|
|
583,738
|
|
|
|
Gain on convertible notes at fair value |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,330,000
|
|
|
|
Related Party [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other liabilities |
|
|
|
|
|
|
|
|
|
|
13,000
|
|
|
13,000
|
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Secured Convertible Note Agreement [Member] | FWHC Bridge LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from convertible debt |
|
|
|
|
|
|
|
$ 1,500,000
|
|
|
|
|
|
|
|
|
|
Secured Convertible Note Agreement [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt effective rate |
|
|
|
|
|
|
|
20.00%
|
|
|
|
|
|
|
|
|
|
Second Closing Bring Down Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, face amount |
|
|
|
|
|
|
$ 750,000
|
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
8.00%
|
|
|
|
|
|
|
|
|
|
|
Debt effective rate |
|
|
|
|
|
|
20.00%
|
|
|
|
|
|
|
|
|
|
|
Proceeds from convertible debt |
|
|
|
|
|
|
$ 437,000
|
|
|
|
|
|
|
|
|
|
|
Debt Conversion Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from convertible debt |
|
|
|
|
$ 10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible debt |
|
|
|
|
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion price percentage |
|
|
|
|
25.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument convertible conversion price |
|
|
|
|
$ 0.002
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payments |
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Conversion Agreement [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from convertible debt |
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Conversion Agreement [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payments |
|
|
|
|
2,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Conversion Agreement [Member] | Share-Based Payment Arrangement, Tranche One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from convertible debt |
|
|
|
|
$ 15,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion price percentage |
|
|
|
|
80.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
Note Conversion Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument convertible conversion price |
|
|
|
$ 2.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Risk adjusted percentage |
|
|
|
70.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, decrease, forgiveness |
|
|
|
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 499,000
|
|
Note Conversion Agreement [Member] | New Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument convertible conversion price |
|
|
|
$ 2.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reverse stock split |
|
|
|
Upon the effective date of the Company’s 1,000-1 reverse split, the conversion price adjusted to the lesser of (a) the price in
the Qualified Financing or (b) $2.00 per share.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalty percentage |
|
|
|
15.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities purchase agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, face amount |
$ 35,000
|
$ 125,000
|
$ 300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument convertible conversion price |
|
|
$ 2.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable current |
|
|
$ 300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock par value |
|
$ 0.001
|
$ 0.001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares isuued and outstanding percentage |
|
|
20.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant term |
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise price per share |
$ 2.00
|
$ 2.00
|
$ 2.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument description |
|
The
March 27, 2023 Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified
offering. The April 12, 2023 Note has a maturity date 60 days from issuance. Interest on the Note shall accrue on the unpaid
principal balance of this Note at the rate of eight percent (8%) per annum and will be calculated on an actual/365-day basis. The
Company defaulted on this note on June 12, 2023 which triggered an increase in interest from 8% to 12%. In the event that the
Company moves forward with a qualified offering, as referenced in the SPA, the Holder may convert the unpaid and outstanding
principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock at a conversion price equal to a 20%
discount to the offering price.
|
The
Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering. Interest on
the Note shall accrue on the unpaid principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated
on an actual/365-day basis. In the event that the Company moves forward with a qualified offering, as referenced in the SPA, the Holder
may convert the unpaid and outstanding principal plus any accrued and unpaid interest into shares of the Company’s Common Stock
at a conversion price equal to a 20% discount to the offering price.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants to purchase aggregate |
|
12,500
|
30,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Raymond Monteleone [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Professional fees |
|
|
|
|
|
|
|
|
$ 7,500
|
|
|
|
|
|
|
|
|
Additional fees |
|
|
|
|
|
|
|
|
2,500
|
|
|
|
|
|
|
|
|
Debt instrument periodic payment |
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,750
|
|
|
|
|
Officers compensation |
|
|
|
|
|
|
|
|
|
|
11,250
|
$ 13,750
|
|
33,750
|
63,750
|
|
|
Accrued salaries |
|
|
|
|
|
|
|
|
|
|
57,500
|
|
|
57,500
|
|
|
|
William Horne [Member] | Oral Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Professional fees |
|
|
|
|
|
|
|
|
5,000
|
|
|
|
|
|
|
|
$ 2,500
|
Officers compensation |
|
|
|
|
|
|
|
|
|
|
7,500
|
7,500
|
|
22,500
|
42,500
|
|
|
Accrued salaries |
|
|
|
|
|
|
|
|
|
|
37,500
|
|
|
37,500
|
|
|
|
Deferred salary and compensation |
|
|
|
|
|
|
|
|
$ 108,000
|
|
|
|
|
|
|
|
|
Richard Rosenblum [Member] | Oral Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Professional fees |
|
|
|
|
|
$ 5,000
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument periodic payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,500
|
Officers compensation |
|
|
|
|
|
|
|
|
|
|
7,500
|
7,500
|
|
22,500
|
35,000
|
|
|
Accrued salaries |
|
|
|
|
|
|
|
|
|
|
37,500
|
|
|
37,500
|
|
|
|
Matthew Anderer [Member] | Oral Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Professional fees |
|
|
|
|
|
$ 5,000
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument periodic payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,500
|
Officers compensation |
|
|
|
|
|
|
|
|
|
|
7,500
|
$ 7,500
|
|
22,500
|
$ 35,000
|
|
|
Accrued salaries |
|
|
|
|
|
|
|
|
|
|
$ 37,500
|
|
|
$ 37,500
|
|
|
|
Investor [Member] | Secured Convertible Note Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, face amount |
|
|
|
|
|
|
|
$ 2,575,000
|
|
|
|
|
|
|
|
|
|
Debt Instrument, Maturity Date |
|
|
|
|
|
|
|
Jun. 17, 2022
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
|
8.00%
|
|
|
|
|
|
|
|
|
|
Investor [Member] | Secured Convertible Note Agreement [Member] | FWHC Bridge LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from convertible debt |
|
|
|
|
|
|
|
$ 25,000
|
|
|
|
|
|
|
|
|
|
Investor [Member] | Second Closing Bring Down Agreement [Member] | FWHC Bridge LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from convertible debt |
|
|
|
|
|
|
$ 7,000
|
|
|
|
|
|
|
|
|
|
|
Investor [Member] | Securities purchase agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument convertible conversion price |
$ 2.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable current |
$ 35,000
|
$ 125,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock par value |
|
$ 0.001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares isuued and outstanding percentage |
20.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant term |
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise price per share |
$ 2.00
|
$ 2.00
|
|
|
|
|
|
|
|
|
$ 2.00
|
|
|
$ 2.00
|
|
|
|
Debt instrument description |
|
Further,
in connection with the March 2023 and April 2023 SPA, the Company also issued Common Stock Purchase Warrants to certain investors, which
are exercisable on or prior to the close of business on the five (5) year anniversary of the initial issue date, to purchase up to a
certain amount of shares of Common Stock, with 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory
Note purchased by the Holder, pursuant to the SPA between the Holder and the Company.
|
|
|
|
|
|
|
|
|
|
|
|
Further,
in connection with the February 2023 SPA, the Company also issued Common Stock Purchase Warrants to certain investors, which are exercisable
on or prior to the close of business on the five (5) year anniversary of the initial issue date, to purchase up to a certain amount of
shares of Common Stock, with 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory Note purchased
by the Holder, pursuant to the SPA between the Holder and the Company, dated February 24, 2023.
|
|
|
|
Number of warrants to purchase aggregate |
|
12,500
|
|
|
|
|
|
|
|
|
30,000
|
|
|
30,000
|
|
|
|
Chief Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Repayments of related party debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 53,000
|
|
$ 40,000
|
|
X |
- DefinitionDeferred salary and compensation.
+ References
+ Details
Name: |
IVRN_DeferredSalaryAndCompensation |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDiscount present value risk percentage.
+ References
+ Details
Name: |
IVRN_DiscountPresentValueRiskPercentage |
Namespace Prefix: |
IVRN_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFair value of convertible notes issued.
+ References
+ Details
Name: |
IVRN_FairValueOfConvertibleNotesIssued |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionGain on convertible notes at fair value.
+ References
+ Details
Name: |
IVRN_GainOnConvertibleNotesAtFairValue |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLoss on convertible notes.
+ References
+ Details
Name: |
IVRN_LossOnConvertibleNotes |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued and outstanding percentage.
+ References
+ Details
Name: |
IVRN_NumberOfSharesIsuuedAndOutstandingPercentage |
Namespace Prefix: |
IVRN_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRoyalty payment percentage.
+ References
+ Details
Name: |
IVRN_RoyaltyPaymentPercentage |
Namespace Prefix: |
IVRN_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedSalariesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_AmortizationOfDebtDiscountPremium |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_ConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ConvertibleNotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionMinimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDecrease for amounts of indebtedness forgiven by the holder of the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentDecreaseForgiveness |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIdentification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3
+ Details
Name: |
us-gaap_DebtInstrumentDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateEffectivePercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of the required periodic payments including both interest and principal payments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3
+ Details
Name: |
us-gaap_DebtInstrumentPeriodicPayment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.
+ References
+ Details
Name: |
us-gaap_FinancialLiabilitiesFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionReflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFair value of investment in security owned.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-2
Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
+ Details
Name: |
us-gaap_InvestmentOwnedAtFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OfficersCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of liabilities classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_OtherLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
+ Details
Name: |
us-gaap_ProfessionalFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4
+ Details
Name: |
us-gaap_StockholdersEquityReverseStockSplit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_SecuredConvertibleNoteAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IVRN_FWHCBridgeLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_SecondClosingBringDownAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_DebtConversionAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_NoteConversionAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=IVRN_NewNotesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_SecuritiesPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=IVRN_RaymondMonteleoneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=IVRN_WilliamHorneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_OralAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=IVRN_RichardRosenblumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=IVRN_MatthewAndererMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=us-gaap_InvestorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
SCHEDULE OF COMMON AND PREFERRED STOCK OUTSTANDING (Details) - shares
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Sep. 10, 2022 |
Class of Stock [Line Items] |
|
|
|
Common stock, shares outstanding |
712,170
|
618,506
|
|
Series A Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, shares outstanding |
438,776,170
|
438,776,170
|
438,776,170
|
One for Thousand Reverse Stock Split [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Common stock, shares outstanding |
712,710
|
618,506
|
|
One for Thousand Reverse Stock Split [Member] | Series A Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, shares outstanding |
438,776,170
|
438,776,170
|
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_OneForOneThousandReverseStockSplitMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=IVRN_TwoThousandTwentyOneGrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
SUMMARY OF STOCK OPTION ACTIVITY (Details) - $ / shares
|
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Equity [Abstract] |
|
|
Shares, Outstanding Balance |
29,385
|
29,635
|
Weighted Average Exercise Price, Outstanding Balance |
$ 83.81
|
$ 86.48
|
Weighted Average Remaining Term (Years), Outstanding |
8 years 2 months 19 days
|
9 years 2 months 12 days
|
Shares, Exercised |
|
|
Weighted Average Exercise Price, Granted |
|
|
Shares, Exercised |
|
|
Weighted Average Exercise Price, Exercised |
|
|
Shares, Outstanding Balance |
29,385
|
29,635
|
Weighted Average Exercise Price, Outstanding Balance |
$ 83.81
|
$ 86.48
|
Weighted Average Remaining Term (Years), Outstanding |
7 years 5 months 23 days
|
8 years 8 months 15 days
|
Shares, Exercisable Balance |
24,843
|
20,510
|
Weighted Average Exercise Price, Exercisable Balance |
$ 86.33
|
$ 93.81
|
Weighted Average Remaining Term (Years), Exercisable |
7 years 5 months 19 days
|
8 years 5 months 8 days
|
X |
- DefinitionShare based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.
+ References
+ Details
Name: |
IVRN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNet number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED (Details)
|
9 Months Ended |
Sep. 30, 2023
$ / shares
shares
|
Equity [Abstract] |
|
Shares Non-vested, Balance | shares |
7,979
|
Weighted Average Grant Date Fair Value Non-vested, Balance | $ / shares |
$ 55.70
|
Shares Non-vested, Vested | shares |
(3,437)
|
Weighted Average Grant Date Fair Value Non-vested, Vested | $ / shares |
$ 55.46
|
Shares Non-vested, Balance | shares |
4,542
|
Weighted Average Grant Date Fair Value Non-vested, Balance | $ / shares |
$ 69.88
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of non-vested options outstanding.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average grant-date fair value of non-vested options outstanding.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of options vested.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average grant-date fair value of options vested.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=IVRN_WarrantsToPurchaseCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=IVRN_SeriesAPreferredStockConvertibleToCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
EQUITY TRANSACTIONS (Details Narrative) - USD ($)
|
|
|
|
|
|
|
|
|
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
|
|
|
Jul. 20, 2023 |
Jul. 10, 2023 |
Jun. 08, 2023 |
May 23, 2023 |
Mar. 17, 2023 |
Nov. 14, 2022 |
Sep. 29, 2022 |
Jun. 10, 2022 |
Apr. 02, 2021 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Sep. 10, 2022 |
Mar. 31, 2022 |
Dec. 31, 2021 |
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, shares authorized |
|
|
|
|
|
|
|
500,000,000
|
|
500,000,000
|
|
500,000,000
|
|
500,000,000
|
|
|
|
Common stock, shares outstanding |
|
|
|
|
|
|
|
|
|
712,170
|
|
712,170
|
|
618,506
|
|
|
|
Conversion of stock shares |
|
|
|
|
|
|
|
438,776
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock |
|
|
|
|
|
|
|
|
|
|
|
|
$ 225,001
|
|
|
|
|
Conversion of stock, description |
|
|
|
|
|
|
|
|
|
|
|
As a result of the Reverse Stock Split, the Series A Preferred Stock is convertible
at a ratio of one thousand shares of Series A Preferred Stock into one share of common stock.
|
|
|
|
|
|
Share granted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share based compensation, stock option vested |
|
|
|
|
|
|
|
|
|
|
|
3,437
|
|
|
|
|
|
Share based compensation, stock option exercise price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation arrangement by share-based payment award, options,outstanding number |
|
|
|
|
|
|
|
|
|
29,385
|
29,635
|
29,385
|
29,635
|
29,385
|
|
|
29,635
|
Share-based compensation arrangement by share-based payment award, vested ,outstanding number |
|
|
|
|
|
|
|
|
|
24,843
|
20,510
|
24,843
|
20,510
|
|
|
|
|
Employee benefits and share based compensation |
|
|
|
|
|
|
|
|
|
$ 26,000
|
$ 61,000
|
$ 101,000
|
$ 246,000
|
|
|
|
|
Aggregate intrinsic value |
|
|
|
|
|
|
|
|
|
$ 55,000
|
|
$ 55,000
|
|
|
|
|
|
Weighted average remaining contractual term |
|
|
|
|
|
|
|
|
|
|
|
1 year 4 months 6 days
|
|
|
|
|
|
Antidilutive securities excluded from computation |
|
|
|
|
|
|
|
|
|
|
|
438,776
|
900,907
|
|
|
|
|
Reverse Stock Split [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of stock shares |
|
|
|
|
|
|
|
|
|
|
|
438,776
|
|
|
|
|
|
Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Antidilutive securities excluded from computation |
|
|
|
|
|
|
|
|
|
|
|
493,180
|
384,788
|
|
|
|
|
Stock Options [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Antidilutive securities excluded from computation |
|
|
|
|
|
|
|
|
|
|
|
29,385
|
29,635
|
|
|
|
|
Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrant |
|
|
|
|
|
$ 2.50
|
$ 2.50
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock |
|
|
|
|
|
$ 30,000
|
$ 225,000
|
|
|
|
|
|
|
|
|
|
|
Series A Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, shares outstanding |
|
|
|
|
|
|
|
|
|
438,776,170
|
|
438,776,170
|
|
438,776,170
|
438,776,170
|
|
|
Conversion of stock, shares |
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
Preferred stock, voting rights |
|
|
|
|
|
|
|
|
|
|
|
Holders
of Series A Preferred Stock (“Series A Holders”) have the right to receive notice of any meeting of holders of common stock
and to vote upon any matter submitted to a vote of the holders of common stock. Each Series A Holder shall vote on each matter on an
as converted basis submitted to them with the holders of common stock.
|
|
|
|
|
|
Conversion of stock, description |
|
|
|
|
|
|
|
|
|
|
|
converts to common stock at a 1000:1 ratio immediately upon request of the Series A Holder.
|
|
|
|
|
|
Series A Preferred Stock [Member] | Reverse Stock Split [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, shares outstanding |
|
|
|
|
|
|
|
|
|
438,776,170
|
|
438,776,170
|
|
|
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, shares outstanding |
|
|
|
|
|
|
|
|
|
712,710
|
|
712,710
|
|
618,506
|
|
|
|
Convertible shares issued |
29,834
|
21,530
|
15,873
|
17,351
|
9,615
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible value |
$ 8,700
|
$ 6,000
|
$ 20,000
|
$ 14,000
|
$ 10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock [Member] | Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sale of new shares |
|
|
|
|
|
15,000
|
112,500
|
|
|
|
|
|
|
|
|
|
|
Warrant [Member] | Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock and warrants purchase |
|
|
|
|
|
7,250
|
56,250
|
|
|
|
|
|
|
|
|
|
|
Warrant Holders [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 14.00
|
|
$ 14.00
|
|
Warrant term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
Common stock and warrants purchase |
|
|
|
|
|
|
|
|
|
|
|
|
|
83,579
|
|
|
|
Proceeds from warrant exercises |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,170,000
|
|
|
|
Directors and Officers [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share granted |
|
|
|
|
|
|
|
|
54,750
|
|
|
|
|
|
|
|
|
Share based compensation, stock option vested |
|
|
|
|
|
|
|
|
4,750
|
|
|
|
|
|
|
|
|
Share based compensation, stock option exercise price |
|
|
|
|
|
|
|
|
$ 70.00
|
|
|
|
|
|
|
|
|
X |
- DefinitionProceeds from warrant exercise.
+ References
+ Details
Name: |
IVRN_ProceedsFromWarrantExercise |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionA unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockSharesConverted1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockSharesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for employee benefit and equity-based compensation.
+ References
+ Details
Name: |
us-gaap_EmployeeBenefitsAndShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDescription of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_PreferredStockVotingRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNet number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options vested.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_ReverseStockSplitMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=IVRN_WarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=IVRN_StockOptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_PurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=IVRN_WarrantHoldersMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=IVRN_DirectorsAndOfficersMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
COMMITMENTS & CONTINGENCIES (Details Narrative) - USD ($)
|
|
|
|
3 Months Ended |
9 Months Ended |
Dec. 23, 2021 |
Jan. 02, 2021 |
Jun. 15, 2020 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
Employment bonus |
|
|
|
$ 105,534
|
$ 221,304
|
$ 432,510
|
$ 848,036
|
Share-based compensation arrangement by share-based payment |
As
additional compensation, Mr. Yurkowsky shall receive shares of common stock of the Company representing 1% of the Company’s fully
diluted equity as of the grant date if the Company achieves a market capitalization of at least $250 million for 60 consecutive days
during the Employment Period (the “Equity Award”). If the Company achieves a market capitalization of at least $500 million
for 60 consecutive days during the Employment Period, the executive shall receive an additional Equity Award of 1%, such that he has
in the aggregate received shares of common stock of the Company representing 2% of the Company’s fully diluted equity as of the
date of grant.
|
|
|
|
|
|
|
Employee benefits and share-based compensation |
|
|
|
26,000
|
61,000
|
101,000
|
246,000
|
Equity award based compensation expense |
|
|
|
|
$ 0
|
|
$ 114,000
|
Professional fees |
|
$ 22,500
|
|
|
|
|
|
Sinclair Broadcast Group Inc [Member] |
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
Advertising expense |
|
|
|
|
|
75,000
|
|
ITN Network, LLC [Member] |
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
Advertising expense |
|
|
|
|
|
45,000
|
|
Employment Agreement [Member] | Chief Executive Officer [Member] | Yurkowsky [Member] |
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
Base salary |
$ 180,000
|
|
|
|
|
|
|
Employment bonus |
100,000
|
|
|
|
|
|
|
Secures and financing receivable |
10,000,000
|
|
|
|
|
|
|
Equity Award [Member] |
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
Share based compensation expense |
$ 328,000
|
|
|
|
|
|
|
Straight line basis derived service period |
8 months 15 days
|
|
|
|
|
|
|
Equity Award [Member] | Chief Executive Officer [Member] | Minimum [Member] |
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
Employee benefits and share-based compensation |
$ 250,000,000
|
|
|
|
|
|
|
Equity Award [Member] | Chief Executive Officer [Member] | Maximum [Member] |
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
Employee benefits and share-based compensation |
$ 500,000,000
|
|
|
|
|
|
|
Consulting Agreement [Member] | Tanya Rhodes of Rhodes & Associates, Inc [Member] |
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
Professional average fee |
|
|
$ 21,000
|
|
|
|
|
Increase in professional average fee percentage |
|
|
5.00%
|
|
|
|
|
Accrued liabilities |
|
|
|
$ 220,000
|
|
$ 220,000
|
|
X |
- DefinitionEquity award based compensation expense.
+ References
+ Details
Name: |
IVRN_EquityAwardBasedCompensationExpense |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIncrease in professional average fee percentage.
+ References
+ Details
Name: |
IVRN_IncreaseInProfessionalAverageFeePercentage |
Namespace Prefix: |
IVRN_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionProfessional average fee.
+ References
+ Details
Name: |
IVRN_ProfessionalAverageFee |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionSecures and financing receivable.
+ References
+ Details
Name: |
IVRN_SecuresAndFinancingReceivable |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionStraight Line Basis Derived Service Period.
+ References
+ Details
Name: |
IVRN_StraightLineBasisDerivedServicePeriod |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_AccruedLiabilitiesCurrentAndNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1
+ Details
Name: |
us-gaap_AdvertisingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_AllocatedShareBasedCompensationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for employee benefit and equity-based compensation.
+ References
+ Details
Name: |
us-gaap_EmployeeBenefitsAndShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9
+ Details
Name: |
us-gaap_LossContingenciesLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
+ Details
Name: |
us-gaap_ProfessionalFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ References
+ Details
Name: |
us-gaap_SalariesWagesAndOfficersCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDescription of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
dei_LegalEntityAxis=IVRN_SinclairBroadcastGroupIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IVRN_ITNNetworkLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_EmploymentAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_EquityAwardMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_ConsultingAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IVRN_TanyaRhodesOfRhodesAndAssociatesIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
DEBT (Details Narrative) - USD ($)
|
|
|
|
|
|
9 Months Ended |
|
|
|
Mar. 27, 2023 |
Feb. 28, 2023 |
Feb. 24, 2023 |
Aug. 08, 2022 |
Jun. 09, 2022 |
Jun. 09, 2022 |
Sep. 30, 2023 |
Apr. 12, 2023 |
Feb. 02, 2023 |
Dec. 31, 2022 |
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
Debt instrument description |
The
March 27, 2023, Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified
offering. The April 12, 2023, Note has a maturity date 60 days from issuance. Interest on the Note shall accrue on the unpaid
principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated on an actual/365-day basis. The
Company defaulted on this note on June 12, 2023 which triggered an increase in interest from 8% to 12%. In the event that the
Company moves forward with a qualified offering, as referenced in the SPA, the Holder may convert the unpaid and outstanding
principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock at a conversion price equal to a 20%
discount to the offering price.
|
|
|
|
|
|
The
Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering. Interest on
the Note shall accrue on the unpaid principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated
on an actual/365-day basis. In the event that the Company moves forward with a qualified offering, as referenced in the SPA, the Holder
may convert the unpaid and outstanding principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock
at a conversion price equal to a 20% discount to the offering price.
|
|
|
|
Securities purchase agreement [Member] |
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
Debt instrument description |
The
March 27, 2023 Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified
offering. The April 12, 2023 Note has a maturity date 60 days from issuance. Interest on the Note shall accrue on the unpaid
principal balance of this Note at the rate of eight percent (8%) per annum and will be calculated on an actual/365-day basis. The
Company defaulted on this note on June 12, 2023 which triggered an increase in interest from 8% to 12%. In the event that the
Company moves forward with a qualified offering, as referenced in the SPA, the Holder may convert the unpaid and outstanding
principal plus any accrued and unpaid Interest into shares of the Company’s Common Stock at a conversion price equal to a 20%
discount to the offering price.
|
|
The
Notes have a maturity date of the earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering. Interest on
the Note shall accrue on the unpaid principal balance of this Note at the rate of eight percent (8%) per annum, and will be calculated
on an actual/365-day basis. In the event that the Company moves forward with a qualified offering, as referenced in the SPA, the Holder
may convert the unpaid and outstanding principal plus any accrued and unpaid interest into shares of the Company’s Common Stock
at a conversion price equal to a 20% discount to the offering price.
|
|
|
|
|
|
|
|
Debt instrument, face amount |
$ 125,000
|
|
$ 300,000
|
|
|
|
|
$ 35,000
|
|
|
Two accredited investors [Member] | Securities purchase agreement [Member] |
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
10.00%
|
10.00%
|
|
|
|
|
Debt instrument, face amount |
|
|
|
|
$ 272,500
|
$ 272,500
|
|
|
|
|
Debt effective rate |
|
|
|
|
65.00%
|
65.00%
|
|
|
|
|
Accredited investors [Member] | Securities purchase agreement [Member] |
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
Debt instrument description |
|
|
|
|
This note bears interest at 15%
(no matter when repaid) and converts at a discount of 25% of the price of a public offering or a 25% discount to the Volume Average Weighted
Price (“VWAP”) of the five (5) days prior to conversion.
|
For the first six months, the Company had the right to prepay the notes
at a premium of between 25% and 35% depending on when it is repaid.
|
|
|
|
|
Debt instrument, face amount |
|
|
|
|
$ 100,000
|
$ 100,000
|
|
|
|
|
Accredited investor [Member] | Securities purchase agreement [Member] |
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
10.00%
|
|
|
|
|
10.00%
|
|
Debt instrument description |
|
For the first six months, the Company has the right to prepay the note
at a premium of between 25% and 40% depending on when it is repaid
|
|
For the first six (6) months, the Company had the right to prepay the notes
at a premium of between 25% and 40% depending on when it is repaid.
|
|
|
|
|
|
|
Debt instrument, face amount |
|
$ 150,000
|
|
$ 65,000
|
|
|
|
|
|
|
Debt effective rate |
|
65.00%
|
|
65.00%
|
|
|
|
|
|
|
Notes Payable [Member] |
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
Debt instrument periodic payment |
|
|
|
|
|
|
$ 5,800
|
|
|
|
Interest rate |
|
|
|
|
|
|
5.00%
|
|
|
|
Debt instrument description |
|
|
|
|
|
|
The Company finalized an eighteen-month extension
to March 1, 2021.
|
|
|
|
Debt instrument periodic payment |
|
|
|
|
|
|
$ 1,000
|
|
|
|
Notes Payable [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
5.00%
|
|
|
|
Notes Payable [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
3.00%
|
|
|
|
Notes Payable [Member] | Merger [Member] |
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
|
|
Aug. 01, 2019
|
|
|
|
Promissory Note [Member] |
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
$ 69,000
|
|
|
$ 69,000
|
X |
- DefinitionIdentification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3
+ Details
Name: |
us-gaap_DebtInstrumentDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateEffectivePercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of the required periodic payments including both interest and principal payments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3
+ Details
Name: |
us-gaap_DebtInstrumentPeriodicPayment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of payment greater than the preceding installment payments to be paid at final maturity date of debt.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_NotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_SecuritiesPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=IVRN_TwoAccreditedInvestorsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=IVRN_AccreditedInvestorsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=IVRN_AccreditedInvestorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=IVRN_NotesPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=IVRN_MergerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=IVRN_PromissoryNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
SCHEDULE OF NET IDENTIFIABLE ASSETS ACQUIRED (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 22, 2022 |
Sep. 07, 2022 |
Acquired Finite-Lived Intangible Assets [Line Items] |
|
|
|
Total costs of the asset acquisition |
$ 792,256
|
|
|
Intellectual Property [Member] |
|
|
|
Acquired Finite-Lived Intangible Assets [Line Items] |
|
|
|
Common stock |
|
$ 54,070
|
$ 29,557
|
Common stock (anti-dilution shares, to be issued – included in other current liabilities) |
|
305,998
|
195,532
|
Direct transaction costs |
|
14,338
|
21,600
|
Total costs of the asset acquisition |
|
$ 792,256
|
246,689
|
Cash |
|
|
469
|
Liabilities assumed – legal and administrative costs |
|
|
(999,728)
|
Intangible assets: IPR&D |
|
|
1,245,948
|
Net identifiable assets acquired |
|
|
$ 246,689
|
X |
- DefinitionBusiness combination recognized identifiable assets acquired and liabilities assumed anti dilution shares.
+ References
+ Details
Name: |
IVRN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAntiDilutionShares |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionBusiness combination recognized identifiable assets acquired and liabilities assumed common stock.
+ References
+ Details
Name: |
IVRN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCommonStock |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionBusiness combination recognized identifiable assets acquired and liabilities assumed direct transaction costs.
+ References
+ Details
Name: |
IVRN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDirectTransactionCosts |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of assets acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
SCHEDULE OF PERFORMANCE PAYMENTS (Details) - Scion Agreement [Member]
|
Dec. 22, 2022
USD ($)
|
Qualified Funding/Uplifting [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
$ 45,000
|
1-Year Anniversary of Uplifting [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
75,000
|
2-Year Anniversary of Uplifting [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
120,000
|
Initiation of SkinDisc Study [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
50,000
|
Receipt of Approval/Clearance that would Allow SkinDisc to go to Market [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
100,000
|
Submission for Specific and Individual Reimbursement Codes Relating to SkinDisc [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
25,000
|
Receipt of Specific and Individual Reimbursement Codes Relating to SkinDisc [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
50,000
|
Completion of SkinDisc Study [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
50,000
|
Launch of Any Additional SkinDisc Product Line Extension [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
$ 100,000
|
Sales [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment description |
Greater of (i) 4% of net revenues from SkinDisc (including SkinDisc line extensions) during such calendar year and (ii) $50,000
|
Cumulative Net Sales from SkinDisc of $600,000 [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
$ 200,000
|
Cumulative Net Sales from SkinDisc of $2,000,000 [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
150,000
|
Cumulative Net Sales from SkinDisc of $4,000,000 [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
300,000
|
Net Sales from SkinDisc of $6,000,000 [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Performance payment |
$ 300,000
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_ScionAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_QualifiedFundingOrUpliftingMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_AnniversaryOfUpliftingYearOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_AnniversaryOfUpliftingYearTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_InitiationOfSkinDiscStudyMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_ReceiptOfApprovalClearanceThatAllowSkinDiscToGoToMarketMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_SubmissionForSpecificAndIndividualReimbursementCodesRelatingToSkindiscMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_ReceiptOfSpecificAndIndividualReimbursementCodesRelatingToSkindiscMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_CompletionOfSkindiscStudyMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_LaunchOfAnyAdditionalSkindiscProductLineExtensionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_SalesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_SalesFromSkinDiscOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_SalesFromSkinDiscTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_SalesFromSkinDiscThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_SalesFromSkinDiscFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
SCHEDULE OF PERFORMANCE PAYMENTS (Details) (Parenthetical) - Scion Agreement [Member]
|
Dec. 22, 2022
USD ($)
|
Cumulative Net Sales from SkinDisc of $600,000 [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Net sales |
$ 600,000
|
Cumulative Net Sales from SkinDisc of $2,000,000 [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Net sales |
2,000,000
|
Cumulative Net Sales from SkinDisc of $4,000,000 [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Net sales |
4,000,000
|
Net Sales from SkinDisc of $6,000,000 [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Net sales |
$ 6,000,000
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
+ Details
Name: |
us-gaap_Revenues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_ScionAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_SalesFromSkinDiscOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_SalesFromSkinDiscTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_SalesFromSkinDiscThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=IVRN_SalesFromSkinDiscFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
SCHEDULE OF NET IDENTIFIABLE ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 22, 2022 |
Sep. 07, 2022 |
Acquired Finite-Lived Intangible Assets [Line Items] |
|
|
|
Total costs of the asset acquisition |
$ 792,256
|
|
|
Intellectual Property [Member] |
|
|
|
Acquired Finite-Lived Intangible Assets [Line Items] |
|
|
|
Common stock |
|
$ 54,070
|
$ 29,557
|
Anti-Dilution share liability |
|
305,998
|
195,532
|
Contingent Performance payment liability |
|
417,850
|
|
Direct transaction costs |
|
14,338
|
21,600
|
Total costs of the asset acquisition |
|
$ 792,256
|
$ 246,689
|
X |
- DefinitionBusiness combination recognized identifiable assets acquired and liabilities assumed anti dilution shares.
+ References
+ Details
Name: |
IVRN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAntiDilutionShares |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionBusiness combination recognized identifiable assets acquired and liabilities assumed common stock.
+ References
+ Details
Name: |
IVRN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCommonStock |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionBusiness combination recognized identifiable assets acquired and liabilities assumed direct transaction costs.
+ References
+ Details
Name: |
IVRN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDirectTransactionCosts |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of assets acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
ACQUISITIONS (Details Narrative) - USD ($)
|
|
|
12 Months Ended |
|
Dec. 22, 2022 |
Sep. 07, 2022 |
Dec. 31, 2022 |
Sep. 30, 2023 |
Business Acquisition [Line Items] |
|
|
|
|
Business combination, recognized identifiable assets acquired |
|
$ 1,240,000
|
|
|
Assumed liabilities |
|
1,000,000
|
|
|
Purchase price |
|
247,000
|
|
|
Transaction costs |
|
$ 21,600
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets |
|
|
|
$ 792,256
|
Scion Agreement [Member] |
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
Voting right percentage |
100.00%
|
|
|
|
Common Stock [Member] |
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
Number of shares issued |
|
52,023
|
|
|
Anti Dilution Shares [Member] |
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
Number of shares issued |
|
|
344,159
|
|
Jantibody Agreement [Member] | Common Stock [Member] |
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
Shares issued, acquisition |
|
52,023
|
|
|
Scion Agreement [Member] |
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
Shares issued, acquisition |
123,153
|
|
|
|
Jantibody LLC [Member] |
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
Ownership percentage |
|
17.50%
|
|
|
Scion Solutions LLC [Member] |
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
Ownership percentage |
|
|
|
33.30%
|
X |
- DefinitionBusiness acquisition number of shares issued.
+ References
+ Details
Name: |
IVRN_BusinessAcquisitionNumberOfSharesIssued |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.
+ References
+ Details
Name: |
us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5
+ Details
Name: |
us-gaap_BusinessAcquisitionLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2
+ Details
Name: |
us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of assets acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of identifiable intangible assets recognized as of the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities assumed at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
+ Details
Name: |
us-gaap_EquityMethodInvestmentOwnershipPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued during the period pursuant to acquisitions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=IVRN_ScionAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=IVRN_AntiDilutionSharesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_JantibodyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_ScionAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=IVRN_JantibodyLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=IVRN_ScionSolutionsLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of gain (loss) on sale or disposal of other assets.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_GainLossOnSaleOfOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquireEquityMethodInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_LimitedLiabilityCompanyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_RedemptionAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
SUMMARY OF ISSUANCE OF WARRANTS (Details) - $ / shares
|
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Common Stock Warrants |
|
|
Number of Shares, Warrants Outstanding and Exercisable, Beginning |
447,967
|
406,301
|
Weighted Average Exercise Price Outstanding and Exercisable, Beginning |
$ 10.90
|
$ 34.88
|
Weighted Average Remaining Contractual Life Warrants Outstanding and Exercisable, Beginning |
6 years 7 months 24 days
|
8 years 2 months 1 day
|
Number of shares , Expired |
(787)
|
(22,513)
|
Weighted Average Exercise Price, Expired |
$ (498.54)
|
$ 373.85
|
Number of Shares, Exercised |
|
(83,579)
|
Weighted Average Exercise Price, Exercised |
|
$ 14.00
|
Number of Shares, Warrants Granted |
46,000
|
140,829
|
Weighted Average Exercise Price, Granted |
$ 2.00
|
$ 9.41
|
Weighted Average Remaining Contractual Life Warrants Granted |
4 years 5 months 8 days
|
4 years 7 months 17 days
|
Number of Shares, Warrants Outstanding and Exercisable, Ending |
493,180
|
441,038
|
Weighted Average Exercise Price, Outstanding and Exercisable, Balance |
$ 9.30
|
$ 12.52
|
Weighted Average Remaining Contractual Life Outstanding and Exercisable |
5 years 8 months 4 days
|
6 years 10 months 2 days
|
X |
- References
+ Details
Name: |
IVRN_DisclosureCommonStockWarrantsAbstract |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments granted weighted average remaining contractual term.
+ References
+ Details
Name: |
IVRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageRemainingContractualTerm |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non-option equity instruments grants in period weighted average exercise price exercised.
+ References
+ Details
Name: |
IVRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePriceExercised |
Namespace Prefix: |
IVRN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non-option equity instruments grants in period weighted average exercise price expired.
+ References
+ Details
Name: |
IVRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePriceExpired |
Namespace Prefix: |
IVRN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments grants in period weighted average exercise price granted.
+ References
+ Details
Name: |
IVRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePriceGranted |
Namespace Prefix: |
IVRN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.
+ References
+ Details
Name: |
IVRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
IVRN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by remaining contractual term.
+ References
+ Details
Name: |
IVRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageRemainingContractualTerm |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEquity instruments outstanding weighted average remaining contractual term ending.
+ References
+ Details
Name: |
IVRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of non-option equity instruments exercised by participants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares under non-option equity instrument agreements for which rights to exercise lapsed.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(4) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNet number of non-option equity instruments granted to participants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(1) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.23.3
SCHEDULE OF ISSUANCE OF WARRANTS VALUATION TECHNIQUE (Details)
|
9 Months Ended |
Sep. 30, 2023
$ / shares
shares
|
2/09/2022 Granted For Services Provided [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
1,000
|
Stock Price |
$ 32.00
|
Warrant exercise price |
14.00
|
Warrant Grant Date Fair Value |
$ 31.00
|
Life of Warrant |
5 years
|
Measurement Input, Risk Free Interest Rate [Member] | 2/09/2022 Granted For Services Provided [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
1.82
|
Measurement Input, Price Volatility [Member] | 2/09/2022 Granted For Services Provided [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
188.69
|
1/19/2022 Granted For Inducement Agreement [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
3,732
|
Stock Price |
$ 63.25
|
Warrant exercise price |
14.00
|
Warrant Grant Date Fair Value |
$ 62.00
|
Life of Warrant |
5 years
|
1/19/2022 Granted For Inducement Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
1.62
|
1/19/2022 Granted For Inducement Agreement [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
187.79
|
1/20/2022 Granted For Inducement Agreement [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
372
|
Stock Price |
$ 64.50
|
Warrant exercise price |
14.00
|
Warrant Grant Date Fair Value |
$ 64.00
|
Life of Warrant |
5 years
|
1/20/2022 Granted For Inducement Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
1.62
|
1/20/2022 Granted For Inducement Agreement [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
187.85
|
Granted For Inducement Agreement Two [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
187
|
Stock Price |
$ 64.50
|
Warrant exercise price |
14.00
|
Warrant Grant Date Fair Value |
$ 64.00
|
Life of Warrant |
5 years
|
Granted For Inducement Agreement Two [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
1.62
|
Granted For Inducement Agreement Two [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
187.85
|
1/24/2022 Granted For Inducement Agreement Three [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
374
|
Stock Price |
$ 48.00
|
Warrant exercise price |
14.00
|
Warrant Grant Date Fair Value |
$ 47.00
|
Life of Warrant |
5 years
|
1/24/2022 Granted For Inducement Agreement Three [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
1.53
|
1/24/2022 Granted For Inducement Agreement Three [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
188.01
|
1/25/2022 Granted For Inducement Agreement Four [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
3,744
|
Stock Price |
$ 49.10
|
Warrant exercise price |
14.00
|
Warrant Grant Date Fair Value |
$ 48.00
|
Life of Warrant |
5 years
|
1/25/2022 Granted For Inducement Agreement Four [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
1.56
|
1/25/2022 Granted For Inducement Agreement Four [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
188.00
|
2/02/2022 Granted For Inducement Agreement Five [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
3,741
|
Stock Price |
$ 44.55
|
Warrant exercise price |
14.00
|
Warrant Grant Date Fair Value |
$ 44.00
|
Life of Warrant |
5 years
|
2/02/2022 Granted For Inducement Agreement Five [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
1.60
|
2/02/2022 Granted For Inducement Agreement Five [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
188.25
|
2/04/2022 Granted For Inducement Agreement Six [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
6,935
|
Stock Price |
$ 44.38
|
Warrant exercise price |
14.00
|
Warrant Grant Date Fair Value |
$ 43.00
|
Life of Warrant |
5 years
|
2/04/2022 Granted For Inducement Agreement Six [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
1.78
|
2/04/2022 Granted For Inducement Agreement Six [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
188.33
|
2/04/2022 Granted For Inducement Agreement Seven [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
13,870
|
Stock Price |
$ 44.38
|
Warrant exercise price |
14.00
|
Warrant Grant Date Fair Value |
$ 43.00
|
Life of Warrant |
5 years
|
2/04/2022 Granted For Inducement Agreement Seven [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
1.78
|
2/04/2022 Granted For Inducement Agreement Seven [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
188.33
|
2/22/2022 Granted For Inducement Agreement Eight [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
41,609
|
Stock Price |
$ 32.88
|
Warrant exercise price |
14.00
|
Warrant Grant Date Fair Value |
$ 32.00
|
Life of Warrant |
5 years
|
2/22/2022 Granted For Inducement Agreement Eight [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
1.85
|
2/22/2022 Granted For Inducement Agreement Eight [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
188.59
|
2/22/2022 Granted For Inducement Agreement Nine [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
693
|
Stock Price |
$ 32.88
|
Warrant exercise price |
14.00
|
Warrant Grant Date Fair Value |
$ 32.00
|
Life of Warrant |
5 years
|
2/22/2022 Granted For Inducement Agreement Nine [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
1.85
|
2/22/2022 Granted For Inducement Agreement Nine [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
188.59
|
Granted For Inducement Agreement Ten [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
8,322
|
Stock Price |
$ 28.00
|
Warrant exercise price |
14.00
|
Warrant Grant Date Fair Value |
$ 27.00
|
Life of Warrant |
5 years
|
Granted For Inducement Agreement Ten [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
2.33
|
Granted For Inducement Agreement Ten [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
194.01
|
9/27/2022 Granted for Securities Purchase Agreement [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
56,250
|
Stock Price |
$ 6.00
|
Warrant exercise price |
2.50
|
Warrant Grant Date Fair Value |
$ 5.94
|
Life of Warrant |
5 years
|
9/27/2022 Granted for Securities Purchase Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
4.21
|
9/27/2022 Granted for Securities Purchase Agreement [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
213.54
|
11/14/2022 Granted for Securities Purchase Agreement One [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
7,500
|
Stock Price |
$ 5.75
|
Warrant exercise price |
2.50
|
Warrant Grant Date Fair Value |
$ 5.69
|
Life of Warrant |
5 years
|
11/14/2022 Granted for Securities Purchase Agreement One [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
4.00
|
11/14/2022 Granted for Securities Purchase Agreement One [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
213.28
|
Granted For Convertible Note Agreement [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
30,000
|
Stock Price |
$ 1.60
|
Warrant exercise price |
2.00
|
Warrant Grant Date Fair Value |
$ 1.57
|
Life of Warrant |
5 years
|
Granted For Convertible Note Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
4.16
|
Granted For Convertible Note Agreement [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
211.43
|
Granted For Convertible Note Agreement One [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
10,000
|
Stock Price |
$ 1.70
|
Warrant exercise price |
2.00
|
Warrant Grant Date Fair Value |
$ 1.68
|
Life of Warrant |
5 years
|
Granted For Convertible Note Agreement One [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
3.59
|
Granted For Convertible Note Agreement One [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
218.15
|
Granted For Convertible Note Agreement Two [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
2,500
|
Stock Price |
$ 1.60
|
Warrant exercise price |
2.00
|
Warrant Grant Date Fair Value |
$ 1.58
|
Life of Warrant |
5 years
|
Granted For Convertible Note Agreement Two [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
3.63
|
Granted For Convertible Note Agreement Two [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
218.17
|
Granted For Convertible Note Agreement Three [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Exercise on aggregate of warrants | shares |
3,500
|
Stock Price |
$ 1.74
|
Warrant exercise price |
2.00
|
Warrant Grant Date Fair Value |
$ 1.73
|
Life of Warrant |
5 years
|
Granted For Convertible Note Agreement Three [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
4.16
|
Granted For Convertible Note Agreement Three [Member] | Measurement Input, Price Volatility [Member] |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
Warrant Input, Percentage |
243.62
|
X |
- DefinitionWarrant grant date fair value.
+ References
+ Details
Name: |
IVRN_WarrantGrantDateFairValue |
Namespace Prefix: |
IVRN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_ClassOfWarrantOrRightAxis=IVRN_GrantedForServicesProvidedMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForInducementAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForInducementAgreementOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForInducementAgreementTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForInducementAgreementThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForInducementAgreementFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForInducementAgreementFiveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForInducementAgreementSixMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForInducementAgreementSevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForInducementAgreementEightMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForInducementAgreementNineMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForInducementAgreementTenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForSecuritiesPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForSecuritiesPurchaseAgreementOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForConvertibleNoteAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForConvertibleNoteAgreementOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForConvertibleNoteAgreementTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IVRN_GrantedForConvertibleNoteAgreementThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- References
+ Details
Name: |
IVRN_DisclosureCommonStockWarrantsAbstract |
Namespace Prefix: |
IVRN_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of preferred stock and warrants for common stock issued.
+ References
+ Details
Name: |
us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
H CYTE (QB) (USOTC:HCYT)
過去 株価チャート
から 5 2024 まで 6 2024
H CYTE (QB) (USOTC:HCYT)
過去 株価チャート
から 6 2023 まで 6 2024